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Antibiotic resistance is an increasing concern for global health care, with some estimates 
suggesting that 10 million people will die from antibiotic resistant infections in the year 2050. 
Fueling this prospect, few antimicrobials are being actively developed and recently commercial 
entities have fled from the development of new anti-infectives. New antimicrobials and drug 
development strategies are urgently needed to revitalize this critical pipeline. While many 
putative antibiotics demonstrate promising in vitro potency, they routinely fail in vivo due to 
poor drug-like properties (e.g. oral bioavailability, serum-half life, toxicity) resulting in overly 
expensive drug development pipelines. Fortunately, drug-like properties can be modified through 
the addition of chemical protecting groups to create “prodrugs”. Lipophilic prodrugging 
strategies have been primarily deployed to remedy poor oral absorption but have also been 
utilized as a means of specifically delivering active drug to specific cells and tissue types. Here 
we demonstrate that lipophilic prodrugging of phosphonate antibiotics through a carboxy ester 
modification increases membrane permeability and enhances antimicrobial potency. 
Unfortunately, many lipophilic prodrugging strategies are rapidly cleaved in vivo by serum 
esterases rendering these potency and transport gains useless during clinical settings. Using three 
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species of staphylococci, we identify and biochemically characterize two esterases, GloB and 
FrmB responsible for the activation of carboxy ester prodrugs. Additionally, we solve the three-
dimensional structures of both GloB and FrmB, facilitating additional structure-guided design of 
promoieties. Finally, we characterize the substrate specificity of human and mouse sera, enabling 
the development of promoieties which are selectively activated by microbial species. These 
findings not only allow the development of novel anti-staphylococcals but lay the framework for 
identification of microbial-specific prodrug design and design of long-lasting serum prodrugs. As 
lipophilic prodrugging expands the number of compounds that are membrane permeable, we 
expect that this approach will facilitate an expansion of the number of potential drugs. 
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Chapter 1: Introduction 
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1.1 Antibiotic resistance threatens modern medicine 
1.1.1 The rise of antibiotics 
The history of humans is strongly intertwined with microorganisms. Microbes are integral to the 
production of fermented foods and beverages such as bread, yogurt, and beer, they contribute to 
the production of several modern medical therapies such as insulin and the antibiotic, 
tetracycline, and remain with us through our life aiding in the digestion of complex 
carbohydrates as members of our “microbiome”. While microbes have contributed many 
positives to humans, some contribute a significant disease burden. The microbial parasite, 
Plasmodium falciparum, has been estimated as having killed as much as 4-5% of all humans who 
have ever lived. In 2019, an estimated 1.4 million humans died due to infection with the bacteria, 
Mycobacterium tuberculosis (1). While most parasitic and bacterial infections are now relatively 
easy to treat, this has not always been the case. 
In the late 19th and early 20th century, chemotherapeutics as we now know them began to 
develop. Paul Ehrlich developed the anti-syphilitic compound, arsphenamine, and cemented the 
idea that pure chemical compounds could be used to fight disease (2). In 1928 Alexander 
Fleming discovered the antibiotic penicillin, when the fungal contaminate, Penicillium rubens, 
prevented growth of his desired organism, Staphylococcus aureus (3). As was common at the 
time, Fleming was able to culture the fungal contaminant and isolate the growth inhibitory 
compound to demonstrate that the compound itself, rather than P. rubens was responsible for 
growth inhibition of S. aureus. The most striking observation, however, was that that the isolated 
compound was a potent inhibitor of many bacterial cultures and had no notable toxicity against 
mammals (3). While many chemicals can kill microbes, penicillin (penicillin G) was the first 
compound isolated that did so without also hurting humans. 
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Naturally, the identification of penicillin meant that individuals with otherwise life-threatening 
infections could be safely cured. Indeed, shortly after it’s discovery, penicillin was utilized 
several times to cure bacterial infections (4–6). Unfortunately, as with many chemotherapeutics, 
transitioning from performance in laboratory models to humans was difficult. Penicillin G is 
rapidly excreted from humans, necessitating multiple doses of penicillin to effectively treat 
infections. Further, initial penicillin G production strategies yielded miniscule amounts of 
compound limiting the application of penicillin G in the clinic to only a few cases. Large scale 
production was eventually achieved in the early 1940s and penicillin became a common 
mechanism for curing bacterial infections. 
1.1.2 Antibiotic resistance and new antimicrobials 
The discovery of penicillin G was heralded as a promising success, yet even before mass 
administration was feasible, bacterial resistance to penicillin G existed (7). “Penicillinase”, an 
enzyme found both intracellularly and extracellularly depending on the species of bacteria 
producing it, was first documented in 1940 and noted to rapidly degrade penicillin (Figure 1). 
Penicillin G resistance was, perhaps, to be expected. Penicillin G was isolated as a natural 
product of bacteria and its production was likely selected for as a mechanism of reducing 
competition for the Penicillium mold. If Penicillium had been producing penicillin G for a long 
time, bacteria were also dying from penicillin for a long time. Many experiments in laboratory 
settings have demonstrated the ease of resistance to chemical compounds within short time 
periods (8, 9). Long-term exposure of microbes to penicillin production, as would be expected 
through the co-evolution of microbes with Penicillium, thus would be more than sufficient time 
for resistance to arise in certain microbial species. 
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As penicillin treatment became common, so too did bacterial resistance to penicillin G. The first 
case of clinical resistance to penicillin was documented in 1942 when 4 strains of 
Staphylococcus aureus were isolated following penicillin treatment (10). By the late 1960s, over 
80% of S. aureus strains were resistant to penicillin (11). Penicillin G resistance was also rapidly 
observed among S. pneumoniae, and E. coli (12). 
Fortunately, following the discovery of penicillin G was an era of antimicrobial discovery where 
new antibiotics were rapidly discovered. Streptomycin was discovered in 1944 (13). 
Cephalosporins were discovered the following year and entered clinical use in the 1960s (14). 
While natural antibiotic scaffolds were expanding, developments in the field of medicinal 
chemistry enabled the scalable production of semi-synthetic antibiotics. Semi-synthetic 
antibiotics are produced through a combination of fermentation by an existing antimicrobial 
producing strain, and synthetic chemistry approaches to modify specific attributes of a 
developing compound. Semi-synthetic antibiotics have proven immensely valuable. In 1959, 
Beecham modified the benzyl group of penicillin G to an ortho-dimethoxyphenyl group, creating 
the β-lactamase resistant compound, methicillin (Figure 2) (15). While β-lactamases capable of 
hydrolyzing methicillin soon became commonplace, the principle that an antibiotic can be 
chemically modified to exhibit more favorable properties took hold. A total of four generations 
of penicillin modified compounds now exist. Penicillin G was among the first generation of β-
lactamase sensitive compounds and methicillin and other β-lactamase resistant derivatives came 
with the second generation. Subsequent generations focused on extending the antibiotic 
spectrum, or number of bacteria that the antibiotic works upon, and altering the uptake, 
distribution, and stability of compounds within the human (also known as the pharmacokinetic 
and pharmacodynamic properties) (Figure 1). Similar semi-synthetic approaches have occurred 
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for the cephalosporin compounds with great success. In sum, semi-synthetic approaches are an 
efficient combination of synthetic chemistry and microbial fermentation that allow for the cheap 
production of a variety of antibiotics.  
While humans have continued to race against expanding bacterial β-lactamase specificity, it is 
worth noting that penicillin resistance occurs via several additional mechanisms which highlight 
the flexibility of microbes. It was originally observed that different species of bacteria were 
naturally resistant to penicillin independent of any degrading enzymes (7). Later, it was realized 
that the action of penicillin G stems from binding to penicillin binding proteins (PBPs) to initiate 
bacterial lysis (16). Some of the naturally resistant bacterial species maintain PBPs which do not 
readily bind penicillin G, thus conferring natural immunity (Figure 1) (17). Further, some 
previously susceptible bacteria have accumulated mutations in PBPs which confer resistance to 
penicillin (18).  
As penicillins require binding to PBPs to exert their antimicrobial action, altered transit of 
penicillins to PBPs is also a resistance mechanism (Figure 1). PBPs of gram-negative bacteria 
localize to the periplasm whereas gram-positive bacteria PBPs are localized to the cell surface 
(19, 20). In practice, this means that gram-positive PBPs are readily accessible by penicillins, 
whereas in gram-negative organisms, penicillin must first transit the outer membrane of the cell. 
Porin proteins are responsible for penicillin transit into the gram-negative periplasm, and 
mutation of these porin proteins is one mechanism of penicillin resistance (21–26). 
Penicillin resistance highlights three mechanisms of antibiotic resistance; compound degradation 
(β-lactamases), target modification (PBP alteration), and reduced antibiotic penetration (porin 
disruption and deletion) (Figure 1). These resistance mechanisms are commonly observed for 
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other antibiotics, though several additional mechanisms are also possible (8, 27–31). Similar to 
porin mediated resistance to penicillin, microbes encode several efflux pumps which can reduce 
the intracellular concentrations of antibiotic (32–38). For some inhibitors, resistance may be 
achieved through altered metabolic regulation. For the competitive inhibitor of isoprenoid 
biosynthesis, fosmidomycin, resistance can be achieved by supplying more of the upstream 
competitive metabolite (39). Metabolic rerouting around the inhibited step is also possible in 
some instances (40). Finally, some antibiotics, known as prodrugs, require activation before their 
antimicrobial effects are realized. In these cases, if prodrug activation is performed via the 
microbe then deletion or modification of the prodrug activating enzyme(s) is an alternative 
resistance strategy (9, 41–43) 
Three lessons should be taken from the story of penicillin. First, chemotherapeutics work, and 
many lives have been saved with the introduction of antibiotics. Second, microorganisms have 
an innate ability to evolve resistance to antibiotics. Finally, through careful and clever chemical 
strategies, new antibiotics can be developed which surpass the shortfalls of the previous. When 
antimicrobial development is in full force and there is a strong supply of novel antimicrobials 
and antimicrobial strategies and the production of novel antibiotics outpaces resistance. 
Alarmingly, in recent years there have been fewer antimicrobials entering the development 
pipeline and those that have tend to be modifications of existing antibiotics instead of new 
strategies (44–47). Simultaneously, there has been an exodus of companies investing in antibiotic 
development (44). As a result, several cases have already been documented where no effective 
antimicrobial therapy exists (48–51). We are already in a post-antibiotic world and as multi-drug 
resistant bacteria continue to spread there is an urgent need to revitalize antibiotic discovery. 
7 
 
1.1.3 Modern challenges in antibiotic development 
The spread of antimicrobial resistance is a pending global health crisis. Recent estimates suggest 
that as many as 10 million people will die as a result of antimicrobial resistant infections in 2050 
(52, 53). While existing antimicrobials are increasingly facing resistance, in parallel, there is a 
mass exodus from commercial antibiotic research and few new antimicrobials are entering the 
development pipeline (44). On the surface, this seems paradoxical. There is clearly a large 
demand for new antimicrobials, yet supply has not risen to meet this demand. While most public 
health inequities disparately impact poorer populations, antimicrobial resistance, like COVID-19, 
antimicrobial resistance will impact all individuals. Why then, are there not more antimicrobials 
in the development pipeline? 
Financial challenges facing antimicrobial development 
Perhaps the largest barrier to antimicrobial development is simply the cost. Most estimates place 
the cost of developing a new pharmaceutical (identification and optimization of the compound, 
development of production capacity, and clinical trials establishing safety and efficacy) at nearly 
$1B USD (54). Given that drug patents last approximately 20 years from initial disclosure and 
that initial testing typically takes ~10 years to complete, companies have approximately 10 years 
to recoup their investment. While this model is feasible for drugs that are frequently prescribed, 
antimicrobials are necessarily withheld to prevent unnecessary use and prevent the spread of 
antimicrobial resistance. Perhaps the final nail in the antimicrobial development coffin is simply 
the uncertainty in drug development. Compounds that appear highly successful in initial 
characterization in lab environments have approximately a 1-7% chance of securing approval 
from the Food and Drug Administration (FDA) (55). Even compounds, that are the most likely to 
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succeed- those that have passed clinical phases 1 and 2 of clinical development- only have 
approximately a 50% chance of entering the market. For these reasons, antibiotic development 
has stalled or has been converted to simple recombinations of existing antimicrobials as a risk-
mitigation strategy. 
While one could imagine a reinvention of the funding for drug development which encourages 
more antimicrobials to be developed, we may better served by asking the question, “why do 
novel drugs fail to secure approval so frequently?”. Failure, especially in clinical trials, 
exorbitantly increases the cost of new therapeutics. Some drugs in development fail out of 
clinical trials as they are unable to recruit and retain sufficient patients. Others fail because the 
sponsoring company no longer has sufficient funds to complete the trials. Ultimately, these 
failures do not reflect issues with potential drugs. Rather, the two drug-specific reasons for trial 
failure are unexpected drug toxicity and/or failure of the drug to perform in humans. Of these 
two, drug safety is a less likely cause of drug failure (17% of failures) than poor efficacy (57% of 
failures) (55–57). Strategies that address these failures, hopefully in a universal manner, will be 
crucial in revitalizing the drug development pipeline. 
Poor drug administration 
Oftentimes, drugs are poorly efficacious because they do not reach the desired site in high 
enough concentrations. This may be because the drug is poorly absorbed via the route of 
administration. For example, orally administered drugs must pass through the stomach and be 
absorbed via the small or large intestine prior to systemic distribution of the drug. While this 
route of administration is facile and transportable, absorption constitutes a large barrier in drug 
efficacy. In contrast, drugs that are supplied intravenously (IV) are immediately systemic and do 
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not require absorption. While one may make the case that all drugs should be administered IV as 
this eliminates barriers to drug deliver; IV delivery is not without drawbacks. IV administration 
risks introduction of pathogenic microbes into the bloodstream (58). As a result, IV 
administration is non-portable and must be performed via trained healthcare professionals. 
Additionally, IV administration can result in tissue damage at the site of injection including 
nerve damage, tissue sloughing, and scarring (58). 
Premature elimination 
In addition to improper absorption, drugs can be ineffective if they are eliminated before they 
have had sufficient time to act at their target site. Penicillin G is rapidly removed from the blood 
via the kidneys, resulting in a half-life of ~1.4 hours in adults (59). Frequent dosing can be used 
to keep systemic drug concentrations high, but this is laborious, requires large amounts of drug, 
requires high rates of patient compliance, and missed doses make it more likely for resistance to 
arise. The two primary routes of elimination are filtration via the kidney (renal) before 
subsequent loss through the urine, and filtration via the liver (biliary) and subsequent secretion 
through the bile. Exact rates of elimination vary by individual patient, complicating exact 
determination of elimination parameters (60, 61).  
Renal and biliary elimination selectively filter different compounds. Renal elimination often 
removes small, polar compounds that are not actively reabsorbed by renal tubules (62). 
Alternatively, larger molecular weight and lipophilic compounds tend to be excreted biliary (63). 
It is important to note, however, that compounds that have been excreted into the bile may be 
reabsorbed along the gastrointestinal tract (64–66). As a result, drug like molecules must thread a 
balance between size and lipophilicity to avoid secretion. 
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Poor drug penetrance 
Drugs can fail even if they are optimally administered and have a long half-life if they do not 
reach the proper site. Humans naturally have several sites that are difficult to deliver drugs to. 
Perhaps most notoriously, the brain is surrounded by a blood-brain barrier which selectively 
excludes most compounds. Reflectively, drugs targeting the nervous system have the lowest 
likelihood of passing clinical trials (55). The other major tissue difficult to dose is the skeletal 
system, primarily due to regions that are avascular (67). 
In parallel with specific tissues being difficult to deliver drugs to, the specific infection 
environment can make drug delivery problematic. Mycobacterium tuberculosis (Mtb) infections 
are characterized by granulomas- thick lesions designed to restrict replication of Mtb. 
Unfortunately, granulomas also restrict the delivery of antibiotics (68–70). Similarly, many 
bacteria can form biofilms- a series of layers of bacteria cells- during infection settings. Biofilms 
help bacteria adhere to a specific niche and prevents clearance via immune cells. Unfortunately, 
like granulomas, formation of a biofilm greatly reduces the efficacy of antibiotics, likely due to 
poor drug penetrance inside the biofilm. 
Poor animal models 
The final challenge facing drug development is a lack of good models for human disease. In vitro 
systems can be useful in the development of compounds and can rule potential compounds out as 
“too toxic”, but they do not capture the complexity of a human. Notably, as highlighted before, 
pharmacokinetics are not included in in vitro experiments. Models of disease in mice, rats, 
guinea pigs and other small mammalian models are more complex, but still have several 
shortcomings. Notably, drug metabolism in rodents does not accurately reflect that of humans. 
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While simian models are likely more reflective of human disease, there are significant ethical 
and cost limitations on simian research. Animal models that poorly reflect human disease are not 
ultimately predictive of a compound’s success. 
With the immense cost associated with drug development and the likelihood of failure, it is 
unsurprising that relatively few drugs are developed annually. Risk mitigation strategies, such as 
the reformulation or slight modification of existing antibiotics are attractive as information about 
toxicity of the original compound are likely to translate. However, reformulations and minor 
compound modifications are unlikely to be severe deterrents to the evolution of antimicrobial 
resistance. In the next section we will discuss strategies to maximize drug efficacy without 
significant modification to the existing drug scaffold. This strategy, known as prodrugging, can 
aid in the cost of drug development, may serve to reduce drug toxicity, and can be used to 
expand the number of feasible microbial drug targets. 
1.2. Prodrugs, novel tools for medicinal chemists 
The most simplistic antibiotics are administered and immediately have inhibitory effects without 
any further action being needed. Penicillin G binds PBPs to prevent further growth of the target 
bacteria. The protein synthesis inhibitor, tetracycline, similarly requires no further processing 
before inhibiting protein synthesis. In contrast, prodrugs are compounds that are inactive and 
unable to exert any inhibitory action until they have been metabolized. This added complexity is 
useful during drug development as medicinal chemists can dissociate target inhibition from other 
pharmacokinetic and pharmacodynamic properties. Depending on the goal, different protecting 
groups, or promoieties, can be added to the active (parent) drug in effort to modify lipophilicity 
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or aqueous solubility. Prodrugging strategies that make use of tissue, cell, or organism specific 
activation mechanisms can also be employed to selectively deliver active compound.  
Historically, prodrugging approaches have been most often employed to increase the oral 
bioavailability of compounds. As was discussed previously, lipophilic compounds are more 
likely to be absorbed in the intestinal tract than polar compounds which require specific 
transporters. Thus, when a compound is too polar for adequate absorption, polar moieties may be 
obfuscated by lipophilic ones. The third-generation cephalosporin, cefditoren, was developed 
with strong activity against gram-positive organisms in vitro. Unfortunately, poor oral 
bioavailability of cefditoren limited it’s potential clinical use (71, 72). The compound was 
resynthesized as a pivaloyloxymethyl (POM) modification on the carboxylate motif and became 
orally bioavailable. Similar strategies have been employed for the antibiotics adefovir dipivoxil, 
pivampicillin, and pivmecillinam . 
While prodrugs, especially POM-prodrugs, were originally applied as a last effort during drug 
development, increasingly prodrugs are implemented as a critical early strategy. Prodrugging 
approaches, namely lipophilic prodrugging, can be used to both increase cellular penetrance of 
otherwise cell impermeable drugs. Depending on the specificity of prodrug activation, prodrug 
formulation may also enable the targeted delivery of compounds with the potential to reduce 
compound toxicity. These two approaches will be explored in the following sections. 
1.2.1 Prodrugs, opportunities to expand the druggable space 
While many essential cellular processes utilize charged molecules, few charged molecules are 
found in drugs. Phosphates and phosphonates are utilized in the storage of genetic information 
(RNA and DNA), and metabolic processes regularly utilize activated di and tri-phosphate 
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moieties. While charged residues are critical for competitive inhibition these processes, charged 
residues are readily excluded from cellular membranes. As a result, any potential drugs utilizing 
phosphonate residues are unlikely to inhibit intracellular targets and thus will not make effective 
drugs. However, lipophilic prodrugging of these residues allows phosphonates to be used while 
still effectively transiting the compound inside the cell. In the following sections we will discuss 
the application of prodrugs allowing the development of nucleotide analogues, isoprenoid 
biosynthesis inhibitors, and glycolytic inhibitors.  
Nucleotide prodrugs 
Perhaps the most frequent application of lipophilic prodrugging is to nucleotide analogues. As 
nucleotide/side analogues are polar compounds, they tend to suffer from poor bioavailability, are 
readily excluded from cells, and have the potential to be toxic. Despite these limitations, several 
nucleotide analogues have been approved or given emergency use authorization to treat viral 
infections and cancer (73–75). The development of these compounds has been extensively 
reviewed elsewhere, thus we will focus on a few examples of how prodrugging strategies have 
improved nucleotide analogue bioavailability, cellular penetrance, and compound safety (75–80).  
Oseltamivir carboxylate, the active form of oseltamivir (Figure 3, Tamiflu, anti-influenza) 
suffers from low bioavailability with <5% of compound entering circulation (81). As we have 
discussed, large polar compounds are unlikely to be absorbed orally. However, modification to 
more lipophilic compounds is likely to improve absorption. Since oseltamivir carboxylate had 
sufficient activity against whole cell assays, the primary barrier to clinical application was the 
lack of oral bioavailability. Prodrugging of the carboxylate moiety with an ethyl ester improved 
oral bioavailability to nearly 80% (Figure 3) (82). Once oseltamivir is absorbed, it is rapidly 
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hydrolyzed via the serum esterase carboxylesterase 1 to return the active compound (83). Similar 
approaches were applied during the development of adefovir dipivoxil (Figure 3, anti-HBV) and 
tenofovir disoproxil (anti-HIV/HBV), though both of these compounds employ a POM moeity 
(84, 85). 
While some nucleotides/sides are sufficiently cell permeable to exert strong inhibitory action, 
most are unable to traverse the cell membrane to inhibit intracellular viral replication. 
Prodrugging approaches that increase nucleoside transporter mediated cell entrance have been 
pursued, but equally attractive is the development of compounds that passively diffuse into cells 
(86, 87). Lipophilic prodrugging can increase cell penetrance, to deliver the prodrug inside the 
cell where subsequent activation restores the parent compound. This strategy was pursued to 
generate the prodrug, Remdesivir (Figure 3), for the treatment of Ebola and SARS-CoV2 (88). 
Specifically, the phosphonate moiety of GS-441524 (Figure 3) was identified as likely 
responsible for poor cellular penetrance. Protection of the phosphonate with a McGuigan 
prodrug dramatically increased compound potency when used in whole cell assays (88, 89). 
Unfortunately, when Remdesivir is administered to humans and non-human primates, serum 
esterases rapidly remove the McGugian prodrug, resulting in the less permeable compound, GS-
441524, as the relevant compound in the infection environment (90, 91). This example highlights 
how in vitro results can poorly model in vivo realities and exemplifies the need for compound 
development to consider both drug administration and activation (92). 
HepDirect prodrugs elegantly achieve both tissue targeting while simultaneously improving the 
lipophilicity of phosphonates. Using the substrate specificity of a liver specific isoform of P450, 
CYP3A4, Erion and colleagues developed a promoiety that is selectively activated within the 
liver (93). The HepDirect strategy was applied to the parent compound of adefovir dipivoxil, 
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PMEA, and resulted in an almost 12-fold increase in PMEA levels in the liver (Figure 3) (94). 
Simultaneously, this approach led to a 2-4 fold decrease of PMEA in the kidney, and virtually no 
PMEA in the intestine (94). This prodrug specific prodrug of PMEA is currently in phase 2 
clinical trials under the name Pradefovir mesylate. While it remains unclear the extent to which 
prodrug activation is selectively in the liver and how much parent compound leaks into other 
environments, it is clear that prodrug activation was successfully enriched for liver activation. 
This approach is a shining example of the potential reductions in drug toxicity achieved through 
targeted drug delivery as well as the possibility that promoieties may remain attached for 
biologically relevant periods of time prior to reaching the desired site. 
 
Isoprenoid biosynthesis prodrugs 
Isoprenoid biosynthesis is an attractive candidate for several areas of drug development. 
Isoprenoid biosynthesis is ubiquitously essential and begins with the synthesis of two five-carbon 
building blocks, isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP). 
Humans synthesize these building blocks via the mevalonate pathway, whereas some microbes 
utilize a divergent, though equally essential, pathway, the 2-C-methyl-D-erythritol 4-phosphate 
(MEP) pathway. The divergence in these two synthesis mechanisms makes the MEP pathway an 
attractive target for antibiotics. Following IPP and DMAPP synthesis, isoprenoid biosynthesis 
reconverges and yields subsequently larger carbon chains. In humans, the later stages of 
isoprenoid biosynthesis are attractive targets for the treatment of osteoporosis, with 
bisphosphonate inhibitors such as risedronate already in use. Unfortunately, intermediates along 
the entire biosynthetic pathway maintain a phosphonate, and any competitive inhibitors 
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developed for these pathways likewise require a charged group like phosphonate to achieve 
strong enzyme inhibition. As we have discussed previously, these groups are largely cell 
impenetrable and tend to have poor oral bioavailability. Similarly, the charged phosphonate 
readily excludes these compounds from cell membranes requiring active transit for their entry. 
Lipophilic prodrugging has been applied to both bisphosphonate inhibitors and MEP pathway 
inhibitors. 
Fosmidomycin is an antibiotic that competitively inhibits an early step in the MEP pathway. 
Fosmidomycin has efficacy against Plasmodium falciparum, the protozoan parasite responsible 
for most severe malaria cases, as well as Escherichia coli, several zoonotic staphylococci, and 
several additional bacteria (8, 95–97). While fosmidomycin is well tolerated at doses up to 8 
g/day, it is poorly absorbed via oral administration and rapidly removed from circulation (98). As 
with nucleoside analogues, fosmidomycin is readily excluded from cell membranes and requires 
active transport to enter the cell (Figure 4) (8, 28, 99). Lipophilic prodrugging approaches, 
notably the POM moiety, bypass this requirement (Figure 4) (8, 28). Surprisingly, fosmidomycin 
is effective against P. falciparum despite the target enzyme being sequestered behind seven lipid 
bilayers (95). How fosmidomycin passes through these membranes remains unclear, but 
lipophilic prodrugging significantly increases the antimalarial efficacy of fosmidomycin and 
fosmidomycin analogues (100, 101). These potency gains have similarly been observed using 
fosmidomycin analogues against Mycobacterium tuberculosis, though have little increased 
efficacy against gran-negative bacteria (8, 102).  
Similar prodrugging strategies have been deployed for bisphosphonates. Significant potency 
gains were achieved by converting the parental compound to a POM-prodrug (103). These in 
vitro potency gains are exciting, though in vivo trials have not yet been reported. As POM-
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prodrugs are rapidly cleaved by serum esterases, it is unlikely that the same potency gains will be 
realized in vivo (100). 
Glycolytic prodrugs 
Glycolysis is significantly upregulated in cancerous cells and has emerged as a potential anti-
cancer target. In humans, the penultimate step in glycolysis, the conversion of 2-
phosphoglycerate to phosphoenolpyruvate, is catalyzed by three isoforms of enolase. In most cell 
types more than one isoform of enolase is present, however some cancerous cells disrupt a ENO1 
while disrupting tumor suppression (104). Consequently, these cells are left with a single isoform 
of enolase, ENO2, and exhibit increased sensitivity to selective inhibitors of ENO2. Several 
potent and selective inhibitors of ENO2 have been developed, however they utilize phosphonate 
moieties to achieve their potency and are thus cell impermeable (104). POM-modification of the 
phosphonates affords increased cellular permeability, however serum esterases rapidly hydrolyze 
the POM moiety (105). Specific activation of these compounds by glial cells is predicted to both 
improve in vivo performance while simultaneously improving the safety profile of the 
compounds, however identification and formulation of these promoieties has yet to be achieved. 
1.2.2 Prodrug activation and targeting 
To present, we have covered how prodrugs can improve pharmacokinetic properties and increase 
cellular penetrance of polar compounds such as phosphonates. The latter benefit affords 
significant potency gains in vitro, however depending on the promoiety used, they are not 
realized in clinical settings due to premature promoiety removal by serum esterases (Figure 4). 
Enabling the development of phosphonate antibiotics through the development of serum stable 
and microbially labile promoieties opens a significant portion of antimicrobial space to be 
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developed. Further, targeting prodrug activation to specific cell types (human or microbial) is 
likely to increase the safety profile of any antibiotic as is observed with the HepDirect prodrugs 
(94). Here, we will discuss various strategies for prodrug activation and several esterases that 
have been noted for their involvement in carboxy ester prodrug activation. Ultimately, for any 
prodrug strategy, where the prodrug is activated to achieve the optimal effect is the most 
important consideration. 
Host esterases- friends or foe? 
For compounds that are sufficiently active in whole cell assays but do not achieve sufficient 
bioavailability, prodrugging to increase absorption, but not alter cell membrane permeability 
may be the best strategy. We have discussed numerous compounds where this strategy was 
employed including cefditoren pivoxil, oseltamivir, adefovir dipivoxil, and tenofovir disoproxil. 
In this case, rapid drug activation by host enzymes is considered a major benefit as the parent 
compound can rapidly take effect. However, in cases where prodrugs are intended to be 
delivered to discrete sites intact, host esterases represent a significant barrier. In humans, carboxy 
ester prodrug activation is performed by human carboxylesterase (hCES) and most frequently 
occurs in the liver or serum (106, 107). 
Three isoforms of hCES are expressed in various tissues, though the predominant isoforms in the 
liver and to a lesser extent plasma are hCES1 and 2 (108–110). hCES1 and 2 have broad 
substrate specificities, however they do have substrate specificity. hCES1 prefers to hydrolyze 
substrates with a small alcohol group and a bulky acyl group. In contrast, hCES2 hydrolyzes 
compounds with a large alcohol group and a small acyl group (111, 112). While these esterases 
seemingly cover the entire substrate range, there is still hope that ester substrates can be designed 
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to avoid or reduce cleavage via these two esterases, as is demonstrated by the HepDirect 
prodrugging approach (93, 94). It is also worth noting that esterase substrate specificity and 
activity, especially for each tissue type and location within the host, is variable depending on the 
species (113–119). As a result, performance of ester prodrugs in pre-clinical models may not 
reflect their ultimate performance in the clinic. 
Bacterial prodrug activation 
We have highlighted the broad application of prodrugs and promoieties for drug development. 
The largest barrier to prodrug targeting is identifying promoieties that are specifically activated 
by microbial sources. Structure-guided approaches to microbially targeted prodrug activation 
have been hindered by a lack of information of microbial esterases and their specificities. In this 
thesis, we will present the discovery and characterization of two staphylococcal esterases, FrmB 
and GloB, which activate POM prodrugs in combination with at least one additional esterase. In 
vitro GloB and FrmB are both capable of partially deprotecting di-POM prodrugs. Neither 
enzyme either individually or in combination can fully activate a di-POM prodrug suggesting at 
least one among at least one additional enzyme is critical for the complete activation of carboxy 
ester prodrugs in vivo (chapter 3 and 4). In addition to identifying GloB and FrmB, we 
determined the three-dimensional structure of each enzyme and performed an extensive 
structure-activity relationship study using a library of ester substrates. While FrmB and GloB are 
both conserved amongst microbial populations, there is a significant amount of sequence 
variation in these two loci (chapter 4). Identification of FrmB and GloB is a major step towards 
structure guided design of prodrugs (chapter 4 115). How broadly these prodrugs will be 
applicable remains an intriguing and open question. 
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It is worth noting that both FrmB and GloB were identified because mutations in each prevented 
prodrug activation in vivo. While these mutations are well tolerated in rich axenic media, both 
GloB and FrmB are involved in cellular detoxification and may be more essential during 
infection settings. While future studies should focus on the essentiality and “native function” for 
GloB and FrmB, it may also be worthwhile to identify and characterize esterases that are known 
to be essential. Recently, 10 functional S. aureus serine hydrolases were identified using an 
activity based protein profiling approach (121). It is worth noting that one of the identified 
esterases, FphF, is the same enzyme as FrmB which has been previously discussed. Several of 
the identified serine hydrolases already have potent and selective inhibitors that have been 
developed against them, though these compounds do not have anti-staphylococcal activity 
suggesting that either the inhibitor is unable to enter the cell or these esterases are dispensable in 
culture media (121). However, disruption of one esterase, FphB, appears to disrupt S. aureus 
virulence in the liver and heart, but not the kidney (121). Esterases in other organisms similarly 
appear to play a role specifically in infection. For example, deletion of the Francisella tularensis 
outer membrane vesicle lipase, FtlA, results in avirulent bacteria (122). Identification of 
essential, or virulence essential, esterases and the characterization of them, is an important step 
towards the development of microbe specific prodrugs. 
 
Prodrug activation in P. falciparum 
Recently, mutations in the P. falciparum carboxylesterase, PfPARE (P. falciparum prodrug 
activation and resistance esterase) were found to confer resistance to carboxy ester prodrugs of 
pepstatin (43). Further analysis revealed that PfPARE mutant strains are unable to activate the 
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pepstatin prodrug and that PfPARE can hydrolyze pepstatin butyl ester in vitro. PfPARE 
mutations also confer resistance to prodrug esters of the lindenane sesquiterpenoid, 
Chlorajaponilide C, and prodrug esters of benzoxaboroles (42, 123). Based on enzyme assays on 
PfPARE and patterns of cross resistance, PfPARE appears to preferentially hydrolyze 
unbranched and minimally branched C6 substrates (42, 43, 123).  
Identification of PfPARE is a critical step towards the development of P. falciparum targeted 
prodrugs. However, as with GloB and FrmB in S. aureus, the rapid evolution of prodrug 
resistance through PfPARE disruption and the apparent non-essentiality of PfPARE raise 
concerns about the long-term efficacy of this as a targeting strategy. In addition to identifying 
essential esterases, one strategy for P. falciparum targeted prodrugs is the development of 
erythrocyte targeted prodrugs. P. falciparum is unique in that it continually resides within 
erythrocytes for most of its lifecycle. Nutrient channels have been identified which promote 
nutrient exchange between the erythrocyte cytosol and the parasite cytosol, and these may 
additional transit drug-like molecules between the two cytosols (124). Erythrocyte targeted 
prodrug activation has the benefit that esterase mutations are not a feasible resistance mechanism 
for the parasite. Indeed, some prodrugs appear to already be activated selectively by erythrocyte 
esterases as opposed to parasite esterases (125). Whether this strategy is ultimately feasible will 
depend on the substrate specificities of serum and liver esterases as opposed to erythrocyte 
esterases. 
1.3 Challenges and opportunities for prodrugs  
The utility of prodrugs is undeniable and has begun to be realized in drug development. Between 
2008 and 2018, 30 new FDA approved prodrugs entered the market (126). This expansion of 
22 
 
prodrug production has continued. In quarter 3 of 2020 alone, four new prodrugs (31% of 
approved Q3 drugs) entered the market (127). As prodrugs continue to attract attention for their 
potential, new developments in prodrug targeting will enable an expanded druggable space for 
antimicrobials while simultaneously de-risking antibiotic development. However, several 
challenges and open questions should be addressed prior to widespread prodrug development. 
Ideally, lipophilic prodrugging strategies can be developed such that any phosphonate compound 
becomes orally bioavailable, membrane permeable, and is specifically cleaved by the 
microorganism(s) of interest. This will enable any metabolic process inside the cell to be targeted 
when this was previously unachievable. Simultaneously, the specific targeting of prodrugs to 
microbial populations will reduce potential toxicity in human cells as the compound will be 
ineffective until activated. Unfortunately, promoieties that achieve this have not yet been 
identified. New research should focus on identifying prodrug activators in pathogenic microbes 
and subsequently determining the substrates cleavable by those activators. Additionally, we have 
highlighted that animal models do not accurately human esterase activity. New animal models 
need to be developed for effective pre-clinical prodrug assessment. Perhaps the best route 
forward is the development of large, high-throughput substrate libraries to enable massive 
screening of esterase activity. This has already started, and should continue (128).  
One aspect of prodrug biology that needs to be considered during drug development is the 
toxicity of promoiety biproducts upon parental compound release. POM-prodrugs are expected 
to release pivalate and formaldehyde upon activation, and long-term treatment of POM prodrugs 
has lead to depletion of carnitine (129). It remains unclear how microbe-specific prodrug 
delivery will impact promoiety toxicity, especially if activation is incredibly specific for the 
microbe(s) that are targeted. 
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Confusingly, potency increases as a result of lipophilic prodrugging are not universal. In 
zoonotic staphylococci, POM-modification of fosmidomycin analogues improves potency by 
500-1000 fold (8). Lipophilic prodrugging of bisphosphonates confers a 25-fold potency increase 
against human cells (103). Conversely, lipophilic prodrugs of fosmidomycin have no activity 
against many gram negatives, despite the parent compound being efficacious (8). Whether these 
differences are a result of poor activation in vivo by gram-negative organisms, activation in the 
incorrect cellular compartment, or a failure to transit the hydrophilic periplasmic space remains 
unknown. Understanding the limitations surrounding gram-negative prodrug activation will 
impact the scope of lipophilic prodrugging approaches. 
Finally, we have thoroughly discussed the benefits of lipophilic prodrugging regarding oral 
bioavailability. Less is known about how lipophilic prodrugs will distribute systemically. It is 
well established that lipophilic compounds are more likely to bind serum proteins and are less 
likely to undergo renal elimination. Whether lipophilic prodrugs will have a release rate from 
serum proteins sufficient to deliver active compound to microbial targets remains an open 
question. 
Lipophilic prodrugging strategies have been recognized and employed as modifiers of oral 
bioavailability for many years. Lipophilic prodrugging may also increase cell membrane 
penetration and reduce toxicity concerns around developing compounds. Targeted prodrug 
delivery is feasible for some compounds, however lipophilic promoieties that specifically target 
compounds to microbial cells have not been identified. Identification of microbial prodrug 
activators represent an attractive first step towards the development of microbe specific 
prodrugs. 
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1.4 Figures 
 
Figure 1 Penicillin resistance mechanisms. Top left- in wild-type gram negative bacteria sensitive to penicillin, extracellular penicillin is 
transited by porin proteins to reach periplasmic or cytoplasmic penicillin binding proteins (PBPs). Top right- expression of β-lactamase enzymes 
(βLs) confers protection via penicillin hydrolysis. Bottom left- Disruption of the transit mechanism confers penicillin resistance. Bottom right- 
mutation of penicillin binding protein confers resistance to penicillins.  
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Figure 2 Structures of Penicillin and Penicillin derivatives. Highlighting identifies variation from Penicillin G. Orange highlighting indicates 
the molecule is resistant to β-lactamases (second generation penicillin), green compounds are more likely to be uptaken by cells (third generation 
penicillins), and the purple highlighting illustrates expanded antimicrobial susceptibility (third generation penicillin). 
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Figure 3 Nucleotide prodrug structures. Parent compounds are displayed on the left and prodrug variants to the right. Promoieties highlighted 
in orange. 
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Figure 4 MEPicide and MEPicide prodrug action. Prodrugging bypasses GlpT mediated transit. Promoeities are removed via an intracellular 
esterase prior to DXR inhibition. Serum esterases rapidly hydrolyze POM-promoieties. 
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2.1 Abstract 
Coagulase-positive staphylococci, which frequently colonize the mucosal surfaces of animals, 
also cause a spectrum of opportunistic infections including skin and soft tissue infections, urinary 
tract infections, pneumonia, and bacteremia. However, recent advances in bacterial identification 
have revealed that these common veterinary pathogens are in fact, zoonoses that cause serious 
infections in human patients. The global spread of multidrug-resistant zoonotic staphylococci, in 
particular the emergence of methicillin-resistant organisms, is now a serious threat to both 
animal and human welfare. Accordingly, new therapeutic targets that can be exploited to combat 
staphylococcal infections are urgently needed. Enzymes of the methylerythritol phosphate 
pathway (MEP) of isoprenoid biosynthesis represent potential targets for treating zoonotic 
staphylococci. Here we demonstrate that fosmidomycin (FSM) inhibits the first step of the 
isoprenoid biosynthetic pathway catalyzed by deoxyxylulose phosphate reductoisomerase (DXR) 
in staphylococci. In addition, we have both enzymatically and structurally determined the 
mechanism by which FSM elicits its effect. Using a forward genetic screen, the glycerol-3-
phosphate transporter GlpT that facilitates FSM uptake was identified in two zoonotic 
staphylococci, Staphylococcus schleiferi and Staphylococcus pseudintermedius. A series of 
lipophilic ester prodrugs (termed MEPicides) structurally related to FSM were synthesized, and 
data indicate that the presence of the prodrug moiety not only substantially increased potency of 
the inhibitors against staphylococci, but also bypassed the need for GlpT-mediated cellular 
transport. Collectively, our data indicate that the prodrug MEPicides selectively and robustly 
inhibit DXR in zoonotic staphylococci, and further, DXR represents a promising, druggable 
target for future development 
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2.2 Introduction 
Coagulase-positive staphylococci, such as S. pseudintermedius and S. schleiferi subsp. 
coagulans, are leading causes of skin, soft tissue, and invasive infections in companion animals 
such as dogs and cats. In addition, these organisms cause zoonotic infections in humans that are 
clinically indistinguishable from infections with S. aureus including pneumonia, skin and soft 
tissue infections, hardware infections, and bacteremia(1–5). Newer clinical microbiological 
techniques, such as mass spectrometry, now readily distinguish S. aureus from zoonotic 
coagulase-positive staphylococci, which were previously often misidentified(3,6,7). Thus, there 
is a growing recognition of the importance of zoonotic staphylococci in human disease. Because 
mecA-mediated methicillin resistance is on the rise in both veterinary and human clinical 
isolates, new antibacterial strategies to specifically target zoonotic staphylococci are highly 
desirable(8–10). 
 
Two distinct and independent pathways for isoprenoid biosynthesis have evolved, the 
mevalonate pathway and a mevalonate-independent route that proceeds through methylerythritol 
phosphate, called the MEP pathway(11). Unusual among bacteria, the least common ancestor of 
all Staphylococcus spp. appears to have possessed both pathways. Primate-associated 
staphylococcal lineages, including S. aureus, possess the mevalonate pathway, and evidence 
suggests that mevalonate pathway activity is required for peptidoglycan synthesis, growth, and 
virulence(12–14). In contrast, nonprimate-associated staphylococcal species, including S. 
pseudintermedius and S. schleiferi, utilize the MEP pathway for isoprenoid biosynthesis(15). 
Importantly, humans and other mammals lack homologs of MEP pathway enzymes, and MEP 
40 
 
pathway activity is required for cellular growth in all organisms in which it has been 
experimentally determined(16–21). Thus, new chemical inhibitors of MEP pathway enzymes 
hold promise as effective antimicrobials that may provide a high margin of safety. 
 
The first dedicated enzyme of the MEP pathway, deoxyxylulose phosphate reductoisomerase 
(DXR; E.C. 1.1.1.267), is rate-limiting for MEP pathway activity. DXR is known to be 
susceptible to small molecule inhibition. For example, the phosphonic acid antibiotic 
fosmidomycin (FSM) is a slow, tight-binding, competitive inhibitor of DXR(22). FSM is safe 
and well-tolerated in humans and animals(23–25). Unfortunately, FSM has poor oral 
bioavailability and a short serum half-life, which has hampered clinical efficacy. Moreover, the 
charged nature of FSM and its phosphonate analogs has challenged their clinical development as 
the compounds are excluded from cells unless actively transported. As a result, many 
microorganisms, such as Mycobacterium tuberculosis and Toxoplasma gondii, are inherently 
resistant to FSM (due to poor cellular uptake) even though FSM potently inhibits their DXR 
orthologs in vitro(16,18,26). In Gram-negative organisms, FSM import is dependent on a 
glycerol-3-phosphate/Pi antiporter (GlpT), and FSM resistance can be achieved by reduced 
expression or activity of GlpT(27,28). 
 
In this work, we use the highly specific inhibitor FSM to chemically validate the MEP pathway 
enzyme DXR as an essential, druggable antibacterial target for zoonotic staphylococcal 
infections. Furthermore, we establish the structural and enzymatic mechanism of staphylococcal 
DXR inhibition by FSM. Using a chemical genomics approach, we define the genetic basis of 
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FSM resistance in zoonotic staphylococci and define the FSM transporter GlpT in these strains. 
Finally, we reveal that structurally related lipophilic ester prodrugs (called MEPicides) yield 
substantially increased potency and circumvent the need for GlpT-dependent import. Thus, 
lipophilic prodrugs provide a promising new approach to combat zoonotic staphylococcal 
infections. 
2.3 Methods 
2.3.1 DXR Inhibitors.  
FSM (Millipore Sigma) and FR-900098 (Millipore Sigma) were resuspended in sterile water. 
Compounds 1-4 were synthesized and resuspended in DMSO as previously described(41,42,53). 
2.3.2 Growth inhibition assays of Staphylococcus species.  
Overnight cultures were diluted 1:200 in LB media and grown at 37°C until the mid-logarithmic 
phase (OD600 = 0.5 – 0.8). Cultures were diluted in a 96-well plate to 1 x 10
5 in 150 µL LB 
media and treated with inhibitors at concentrations ranging from 2 nM to 100 μM. Bacteria were 
grown at 37°C for 20 h with cyclic shaking at 700 rpm in a FLUOstar Omega microplate reader 
(BMG Labtech). Growth was assessed over 20 h by measuring the OD600 at 20 min increments. 
The half-maximal inhibitory concentration (IC50) values were determined during logarithmic 
growth using GraphPad Prism software. All experiments were performed at least in triplicate and 
data reported represent the mean ± SEM. 
2.3.3 Minimum bactericidal (MBC) assay.  
Overnight cultures were diluted 1:200 in LB media and grown at 37°C until reaching mid-
logarithmic phase of growth. Compounds were added to cultures at their respective IC50 and at 
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10 x IC50, and the bacteria were incubated at 37°C for 24 h while shaking. Cultures were serially 
diluted in Dulbecco’s Phosphate Buffered Saline (PBS; Gibco) and plated on LB agar. Colonies 
were enumerated after overnight growth at 37°C. Values reflect the mean and standard 
deviations of at least three independent experiments. 
 
2.3.4 Sample preparation for mass spectrometry analysis.  
Overnight cultures of Staphylococcus spp. were diluted 1:200 in LB media and grown at 37°C 
until reaching mid-logarithmic phase. Cultures were then treated for 2 h with FSM at 10x their 
IC50 while shaking at 37°C. For normalization, the OD600 was determined after 2 h of treatment 
with the DXR inhibitors. Cells were pelleted by centrifugation for 5 min at 3000 x g at 4°C. The 
supernatants were removed and cells were washed twice with PBS (Gibco). The supernatants 
were removed and the pellets stored at -80°C until analysis. MEP intermediates were extracted 
from the samples using glass beads (212-300 u) and 600 µL chilled H2O: chloroform: methanol 
(3:5:12 v/v) spiked with PIPES (piperazine-N,N′-bis(2-ethanesulfonic acid) as internal standard. 
The cells were disrupted with the TissueLyser II instrument (Qiagen) using a microcentrifuge 
tube adaptor set pre-chilled for 2 min at 20 Hz. The samples were then centrifuged at 16,000 x g 
at 4ºC for 10 min, the supernatants collected, and pellet extraction repeated once more. The 
supernatants were pooled and 300 µL chloroform and 450 µL of chilled water were added to the 
supernatants. The tubes were vortexed and centrifuged. The upper layer was transferred to a 2 
mL tube PVDF filter (ThermoFisher, F2520-5) and centrifuged for 5 min at 4,000 x g at 4ºC. 
The samples were transferred to new tubes and dried using a speed-vac. The pellets were re-
dissolved in 100 μL of 50% acetonitrile. 
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2.3.5 LC-MS/MS analysis.  
For LC separation, Luna-NH2 column (3 µm, 150 x 2 mm, Phenomenex) was used flowing at 
0.4 mL/min. The gradient of the mobile phases A (20 mM ammonium acetate, pH 9.8, 5% 
acetonitrile) and B (100% acetonitrile) was as follows: 60% B for 1 min, to 6% B in 3 min, hold 
at 6% B for 5 min, then back to 60% B for 0.5 min. The LC system was interfaced with a Sciex 
QTRAP 6500+ mass spectrometer equipped with a TurboIonSpray (TIS) electrospray ion source. 
Analyst software (version 1.6.3) was used to control sample acquisition and data analysis. The 
QTRAP 6500+ mass spectrometer was tuned and calibrated according to the manufacturer’s 
recommendations. The metabolites were detected using MRM transitions that were previously 
optimized using standards. The instrument was set-up to acquire in negative mode. For 
quantification, an external standard curve was prepared using a series of standard samples 
containing different concentrations of metabolites and a fixed concentration of the internal 
standard. The limit of detection for 1-deoxy-D-xylulose 5-phosphate (DOXP), 4-
diphosphocytidyl-2-C-methylerythritol (CDP-ME), and 2-C-methyl-D-erythritol 2,4-
cyclopyrophosphate (MEcPP) was 0.0064 μM for a 10 μL injection volume. Data reflect the 
mean and SD of at least three independent experiments. T-tests were used to test for significance 
between untreated (UNT) and drug-treated bacteria (Prism). 
2.3.6 Recombinant expression and purification of DXR.  
Wild-type dxr from S. schleiferi was amplified from genomic DNA using the forward primer 5’-
CTCACCACCACCACCACCAT ATGAAAAATATAGCAATTTTAGGCGC-3’ and the 
reverse primer 3’-ATCCTATCTTACT CACCTACACCTCATATGATTTTGTTTTATAAT-5’ 
The PCR product was cloned into vector BG1861 by ligation-independent cloning to introduce a 
N-terminal 6xHis tag, and transformed into Stellar™ chemically competent cells (Clontech 
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Laboratories)(68). The sequence was confirmed by Sanger sequencing and the plasmid was 
transformed into E. coli BL21(DE3) pLysS (Life Technologies). Gene expression was induced 
for 2 h with 1 mM isopropyl-β-D-thiogalactoside (IPTG) and cells were harvested by 
centrifugation at 4274 x g for 10 min at 4°C. The cell pellet was lysed by sonication in lysis 
buffer containing 25 mM Tris HCl (pH 7.5), 100 mM NaCl, 20 mM imidazole, 10% glycerol, 1 
mM MgCl2, 1 mM dithiothreitol (DTT), 1 mg/mL lysozyme, 75 U benzonase and 1 Complete 
Mini EDTA-free protease inhibitor tablet (Roche Applied Science). The hexahistidine-tagged 
DXR protein was affinity purified from soluble lysate via nickel agarose beads (Gold 
Biotechnology). Bound protein was eluted in 300 mM imidazole, 25 mM Tris HCl (pH 7.5), 1 
mM MgCl2 and 100 mM NaCl. Purified protein was dialyzed in buffer containing 10% glycerol 
without imidazole prior to analysis. The enzyme was frozen in liquid nitrogen and stored 
permanently at -80°C. 
2.3.7 DXR enzyme activity and inhibitory constant determination.  
Oxidation of NADPH to NADP+ as a result of substrate turnover was monitored at 340 nm in a 
POLARstar Omega microplate reader (BMG Labtech)(69). The standard reaction had a final 
concentration of 62.5 nM purified DXR protein, 0.5 mM NADPH, 100 mM NaCl, 25 mM Tris 
pH 7.5, 10% glycerol, 1 mM MgCl2 and 0.09 mg/mL BSA in 50 µL volume per assay. Reactions 
were initiated by the addition of DOXP after 15 min incubation of the reaction mixture without 
DOXP at 37°C. Absorption at 340 nm was measured continuously for up to 45 min. For Km 
[DOXP] determination, DOXP concentrations between 0 and 2 mM were tested at 0.5 mM 
NADPH. The linear range of enzyme activity was determined by varying the DXR concentration 
at 1 mM DOXP and 1 mM NADPH. IC50 assays were performed using the standard reaction 
conditions with the respective amount of DXR inhibitor added to obtain the given final 
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concentrations. Data points from at least three independent replicates were analyzed by nonlinear 
regression using GraphPad Prism software. Slopes of changing absorbance values were 
converted to (µM DOXP)(mg enzyme)-1 s -1 using a NADPH standard curve (data not shown). 
For the determination of the inhibitory constant Ki [FSM] of DXR, enzyme activity over a range 
of DOXP substrate concentrations between 0 and 2 mM was measured for FSM between 0 mM 
to 4 mM. Data points from at least three independent replicates were analyzed as described 
above. 
2.3.8 Protein crystallography.  
Crystals of S. schleiferi DXR were grown at 4°C using the vapor diffusion method in hanging 
drops of a 1:1 mixture of protein (10 mg mL-1) and crystallization buffer (2 M ammonium 
sulfate, 100 mM sodium citrate/citric acid, pH 5.5). Crystals of the S. schleiferi DXR•FSM 
complex were obtained in 100 mM HEPES/MOPS (pH 7.5), 20 mM D-glucose, 20 mM D-
mannose, 20 mM D-galactose, 20 mM L-fucose, 20 mM D-xylose, 20 mM N-acetyl-D-
glucosamine, 20% glycerol, 10% PEG 4000, and 2 mM FSM. Prior to data collection, crystals 
were stabilized in cryoprotectant (mother liquor supplemented with 30% glycerol) before flash 
freezing in liquid nitrogen for data collection at 100 K. All diffraction images were collected at 
beamline 19-ID of the Argonne National Laboratory Advanced Photon Source at Argonne 
National Laboratory. HKL3000 was used to index, integrate, and scale the data sets(70). For 
phasing of the apoenzyme structure, molecular replacement was performed in PHASER using 
the x-ray crystal structure of E. coli DXR (PDB: 1T1S) as a search model(31,71). Two 
monomers were found in the asymmetric unit, with each forming a physiological dimer by 
crystallographic symmetry. For iterative rounds of model building and refinement, COOTand 
PHENIX were used, respectively(72,73). The resulting model was used to solve the structure of 
46 
 
the FSM complex by molecular replacement with PHASER. Two molecules were found in the 
asymmetric unit with crystallographic symmetry completing each dimer. Data collection and 
refinement statistics are summarized in Table S2. Atomic coordinates and structure factors of S. 
schleiferi DXR (PDB:6MH4) and the S. schleiferi DXR•FSM complex (PDB:6MH5) were 
deposited in the RCSB Protein Data Bank. 
2.3.9 Generation of FSM-resistant mutants in S. schleiferi and S. 
pseudintermedius.  
Clinical isolates of S. schleiferi (S53022327s) and S. pseudintermedius (H20421242p) were 
cloned and adapted to laboratory media via four rounds of sequential colony isolation and growth 
on LB agar plates. The isolated FSM-sensitive parental clones were incubated overnight on LB 
agar containing FSM (32 µM). Surviving single colonies were re-struck onto LB agar for clonal 
isolation. FSM resistance of isolated clones was confirmed by overnight growth on LB agar 
containing FSM (32 µM). The FSM-sensitive parental clones were used as a control to confirm 
growth and antibiotic-resistance. 
2.3.10 Quantification of MEPicide resistance.  
Minimum Inhibitory Concentration (MIC) assays were conducted by microtiter broth dilution in 
clear 96-well plates(74). MEPicides were serially diluted in duplicate at concentrations ranging 
from 1.5 mM – 19.5 nM in 75 µL of LB broth. Bacteria cultured without drug were used as a 
positive control for growth. The plates were inoculated with 75 µL bacteria diluted to 1 x 105 
CFU/mL in LB. Plates were incubated for 18-20 h while shaking at 200 RPM at 37°C. The plates 
were then visually inspected, and the MIC value was defined as the lowest concentration of 
MEPicide that prevented visual growth. 
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2.3.11 Whole genome sequencing and variant discovery.  
Genomic DNA was isolated from overnight cultures of S. pseudintermedius and S. schleiferi 
using a standard phenol-chloroform extraction and ethanol precipitation protocol. Sequencing 
libraries were prepared and sequenced by the Washington University Genome Technology 
Access Center (GTAC). 1 µg of DNA was sonicated to an average size of 175 bp. Fragments 
were blunt ended and had an A base added to the 3´ end. Sequence adapters were ligated to the 
ends and the sequence tags were added via amplification. Resulting libraries were sequenced on 
an Illumina HiSeq 2500 to generate 101 bp paired end reads. DNA quantity and quality were 
assessed by GTAC using Agilent Tapestation.  
For WGS, sequences from GenBank were retrieved from the following organisms: S. 
pseudintermedius ED99 (accession number CP002478) and S. schleiferi 1360-13 (CP009470) 
assemblies were downloaded from NCBI (ftp://ftp.ncbi.nlm.nih.gov). Paired-end reads were 
aligned to each of the available genomes using Novoalign v3.03. (Novocraft Technologies) and 
deposited in NCBI (accession number PRJNA488092). Duplicates were removed and variants 
were called using SAMtools(75). SNPs were filtered against parent variants and by mean depth 
value and quality score (minDP =5, minQ = 37)(76). Genetic variants were annotated using 
SnpEff v4.3 (Table S4)(77). For all samples, at least 90% of the genome was sequenced at 20x 
coverage. All whole genome sequencing data is available in the NCBI BioProject database and 
Sequence Read Archive. Point mutations found in the GlpT domain were mapped onto the 
predicted transmembrane topology of GlpT using Protter(78). 
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2.3.12 Sanger Sequencing of S. schleiferi and S. pseudintermedius glpT.  
Reference sequences for glpT in S. schleiferi (WP_016426432.1) and S. pseudintermedius 
(WP_014613322.1) were found with the Basic Local Alignment Search Tool (BLAST, v. 
2/2/22). The regions of interest were amplified from S. pseudintermedius and S. schleiferi using 
gene-specific primers (Table S1). Amplicons were sequenced by the Washington University 
Protein and Nucleic Acid Laboratory using BigDye Terminator v3.1 Cycle Sequencing reagents 
(Life Technologies). Representative traces for all strains are available through the NCBI Trace 
Archive. 
2.4 Results  
2.4.1 Anti-staphylococcal activity of canonical MEP pathway inhibitors. 
Because previous evidence had suggested that zoonotic staphylococci might be sensitive to MEP 
pathway inhibition, we quantified the dose-dependent antibacterial effects of FSM and FR-
900098, a structurally similar DXR inhibitor (Table 1)(15). FSM was 5-10-fold more potent 
against both S. schleiferi (IC50 = 0.78  0.13 M) and S. pseudintermedius (IC50 = 0.31  0.04 
M), respectively (Table 1), despite modest chemical differences between the two inhibitors. 
Data indicate that both compounds elicit their effect via a bacteriostatic mechanism-of-action, as 
neither caused a substantial drop in viable cells (Fig S1). Because S. aureus does not utilize the 
MEP pathway for isoprenoid biosynthesis, neither FSM nor FR-900098 inhibit S. aureus growth 
(Table 1). Together, these data indicate that both S. schleiferi and S. pseudintermedius have a 
functional MEP pathway that is required for bacterial growth.  
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2.4.2 Fosmidomycin inhibits isoprenoid metabolism in zoonotic staphylococci. 
To establish the presence of MEP pathway intermediates and to determine the cellular 
mechanism-of-action of FSM, we performed targeted metabolic profiling of MEP pathway 
intermediates in S. schleiferi and S. pseudintermedius, with and without drug treatment. We 
confirmed that both species contain MEP pathway intermediates, including the DXR substrate, 
deoxyxylulose 5-phosphate (DOXP), and the downstream metabolite, methylerythritol 
cyclodiphosphate (MEcPP) (Fig 1). Upon FSM treatment, intracellular levels of DOXP increase 
dramatically (23.8-fold; p < 0.05 and 34.8-fold; p < 0.05 for S. schleiferi and S. 
pseudintermedius, respectively), consistent with DXR inhibition. Similarly, intracellular levels of 
MEcPP are substantially reduced following FSM treatment (4.5-fold; p < 0.01 and 2.4-fold; p < 
0.05 for S. schleiferi and S. pseudintermedius, respectively), consistent with FSM-mediated 
reduction in MEP pathway metabolism. Together, these data confirm the presence of active MEP 
pathway metabolism in zoonotic staphylococci and establish that FSM inhibits growth through 
MEP pathway inhibition. 
2.4.3 Fosmidomycin is a competitive inhibitor of S. schleiferi DXR. 
To establish the enzymatic mechanism-of-action of DXR inhibitors against staphylococci, we 
cloned and purified S. schleiferi DXR (Fig S2; Table S1). Enzymatic characterization of DXR 
confirmed a Michaelis constant (Km) [DOXP] (0.52 ± 0.08 mM), similar to that of other DXR 
orthologs (Fig 2A)(29,30). Both FSM and FR-900098 inhibit S. schleiferi DXR in a dose-
dependent manner (Table 1). Further, we confirm that DXR inhibition by FSM is competitive 
with respect to the DOXP substrate, with a Ki [DOXP] of 0.29 ± 0.022 µM (Fig 2B). 
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2.4.4 Structural basis of fosmidomycin inhibition. 
To establish the structural basis of FSM action, we solved the three-dimensional structures of S. 
schleiferi DXR as an apoenzyme and a FSM complex to 2.15 Å and 2.89 Å resolution, 
respectively (Table S2; Fig 3). S. schleiferi DXR is a physiologic dimer with each monomer 
related by crystallographic symmetry (Fig 3A). A DALI search identified multiple DXR from 
Escherichia coli, Plasmodium falciparum, M. tuberculosis, and other microbes (Z-scores: 49-51; 
r.m.s.d. ~1.6 Å2 for 370-400 Cα-atoms; 39-40% amino acid sequence identity)(31–36). The 
monomer consists of three regions (Fig 3A): an N-terminal α/β-domain with a central 7-stranded 
β-sheet (β1-β7) and 7 α-helices that serves as the nucleotide binding site; a middle region of the 
protein that includes a second β-sheet (β8- β11) and 4 α-helices (α8 and α12- α14); and a C-
terminal α-helical domain (α9- α11 and α15- α18) that locks FSM into the active site(37). 
Clear electron density for FSM was observed in the active site (Fig 3B) and revealed multiple 
protein-ligand interactions (Fig 3C). Interactions with Ser170, Ser206, Asn211, and Lys212 
positions the FSM phosphonate toward the catalytic histidine (His241) and the NADP(H) 
binding site. The hydroxamic acid of the ligand contacts Asp144, Glu146, and Glu215. 
Additional van der Waals contacts are provided by Trp196, which resides in the α10- α11 loop. 
Comparison of the S. schleiferi DXR apoenzyme and FSM complex structures reveals how the 
C-terminal capping region (α9- α11 and α16-18) shift position to allow for the α10- α11 loop to 
position Trp196 adjacent to the inhibitor (Fig 3D). Movement of this flexible loop is a key 
feature for FSM inhibition of DXR from a variety of microorganisms(38). The residues that 
interact with FSM in the S. schleiferi DXR are conserved in the crystal structures of DXR from 
E. coli, P. falciparum, and M. tuberculosis with some variation in the sequence of the α10- α11 
loop, although the tryptophan that contacts FSM is conserved in all these enzymes(34,36,37). 
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2.4.5 Resistance selection reveals a candidate FSM transporter, GlpT. 
To establish the molecular basis of compound uptake, we performed independent, parallel, 
forward genetic screens for FSM resistance in both S. schleiferi and S. pseudintermedius (Fig 
4A). Candidate FSM resistant (FSMR) strains were colony purified and resistance was quantified 
by MIC determination (Fig 4B and Table S3). For both S. schleiferi and S. pseudintermedius, 
FSMR strains possessed FSM MICs >100-fold higher than the wild-type parental lines. We 
employed whole genome sequencing to characterize the single-nucleotide polymorphisms 
(SNPs) that were present in the resistant strains (Table S4). In both species, FSM selective 
pressure enriched for new nonsynonymous changes in a single homologous locus, RN70_03745 
(10/11 S. schleiferi strains) and SPSE_0697 (10/12 S. pseudintermedius strains) (Figs. S3A and 
S3B). These loci are close homologs (>90% sequence identity and 95.4% sequence similarity), 
which belong to the glycerol-3-phosphate transporter (GlpT) subfamily (Interpro: IPR005267) of 
the major facilitator superfamily (MFS) family of proteins (Interpro: IPR011701). These data 
suggest a model in which GlpT mediates FSM import, such that loss of GlpT function confers 
FSM resistance. 
2.4.6 Fosmidomycin-resistance alleles of the candidate transporter, GlpT. 
We predicted that the FSM-resistance alleles likely reduce GlpT function. In S. schleiferi, nine 
distinct alleles were found with GlpT changes: two with nonsense mutations and seven others 
with amino acid variants that are predicted to be highly deleterious (Polyphen-2 score >0.9; 
Table S3)(39). Similarly, in S. pseudintermedius, a total of seven distinct alleles were identified 
with GlpT sequence changes. Of these, one contained a nonsense mutation and six other GlpT 
variants contained amino acid substitutions that are strongly predicted to reduce function 
(Polyphen-2 score >0.9; Table S3). FSM-resistant variants map along the length of the nearly 50 
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Kd GlpT transporter, in both S. schleiferi and S. pseudintermedius (Figs S3A and S3B). 
Altogether, the finding of multiple independent loss-of-function alleles, including nonsense 
mutations, in two different selections in distinct organisms, strongly suggests that reduced GlpT 
function is responsible for FSM resistance in these strains. 
2.4.7 Lipophilic ester prodrugs with improved anti-staphylococcal potency. 
Due to their charged nature, phosphonic acid antibiotics have poor cellular penetration and 
bioavailability, and serum half-lives are relatively brief(23,25,40). In the ongoing effort to 
develop new treatments for malaria and tuberculosis by improving upon the drug-like properties 
of phosphonates, numerous lipophilic ester prodrugs that target DXR have been generated(41–
53) Our phosphonate parent compounds (1 and 3) are similar in anti-staphylococcal potency to 
FSM and FR-900098 (Table 1); however, lipophilic modification of either compound 
dramatically improves potency (in most cases by 100-fold) against both S. schleiferi and S. 
pseudintermedius (compare compound 1 to its prodrug, compound 2, and compound 3 to its 
prodrug, compound 4) (Table 1). As expected, prodrugs 2 and 4 poorly inhibit purified 
recombinant S. schleiferi DXR in vitro, since cleavage of the prodrug moiety is required for 
activity (Table 1). Our data suggest that lipophilic ester modifications improves uptake of the 
DXR inhibitors, and that active phosphonates are released intracellularly for target inhibition 
(model, Fig 6). 
2.4.8 Lipophilic prodrugs bypass need for GlpT-mediated transport. 
We anticipated that our lipophilic ester prodrugs do not require active cellular transport. To 
evaluate whether GlpT is required for prodrug uptake, we characterized the MEPicide sensitivity 
of four different FSMR glpT mutant S. schleiferi strains. As expected, we find that FSMR glpT 
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strains are cross-resistant to the phosphonate parent drug (compound 3), suggesting a common 
mechanism of transport (Fig 5). In contrast, FSMR glpT strains remain sensitive to the MEPicide 
prodrugs compounds 2 and 4, supporting a model in which GlpT mediates phosphonate 
transport, with the ester modifications substantially improving cellular uptake (Fig 6)(21). 
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2.5 Discussion 
S. schleiferi and the Staphylococcus intermedius group (SIG) (including S. pseudintermedius, S. 
intermedius, and S. delphini) cause pyodermic infections in companion animals, such as dogs 
and cats(8). Treatment of these infections is complicated by rising rates of antimicrobial 
resistance, particularly methicillin-resistance(54). A growing recognition that SIG species also 
cause zoonotic human infections, indistinguishable from infections with S. aureus, has led to new 
urgency in the search for additional therapeutics against these organisms. The non-mevalonate 
pathway of isoprenoid biosynthesis through MEP has been previously explored for development 
of targeted therapeutics for malaria and tuberculosis. In this current work, we establish the MEP 
pathway enzyme DXR as an attractive new therapeutic target for treatment of infections due to 
zoonotic staphylococci. 
The MEP pathway has a number of major advantages as an antimicrobial target for veterinarian 
applications. Since mammals utilize the mevalonate pathway for isoprenoid biosynthesis, they 
lack homologs of the MEP pathway enzymes. As a result, MEP pathway inhibition is expected to 
have a high therapeutic index, and indeed, such inhibitors have been well-tolerated in preclinical 
and Phase I and II human studies(23–25,55,56). In addition, use of antibiotics in animal health 
and agriculture has been implicated as a major driver of antimicrobial resistance in human 
pathogens(57–60). Of particular relevance to treatment of canine and feline infections, the close 
physical contact between owners and household pets facilitates not only the cross-colonization of 
organisms, but also direct transfer of drug-resistance traits(61–63). Because human-associated 
staphylococci, including S. aureus, S. warnerii, and S. epidermidis, use the mevalonate pathway 
for isoprenoid biosynthesis, they are not susceptible to MEP pathway inhibitors (Table 1). 
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Importantly, while Gram-negative organisms such as E. coli and Klebsiella pneumoniae are 
modestly susceptible to MEP pathway inhibition, our lipophilic prodrug compound 2 does not 
inhibit growth of these organisms (Table S5). Our MEPicide compounds therefore have a highly 
specific and valuable antimicrobial spectrum, which may help break the cycle of resistance 
transfer from antibiotic-treated animals to the microbiota of humans. 
In the current study, we establish the cellular, enzymatic, and structural mechanisms-of-action of 
FSM against zoonotic staphylococci. We confirm that FSM is a competitive inhibitor of 
staphylococcal DXR, interrupts cellular isoprenoid biosynthesis, and inhibits growth of zoonotic 
staphylococci. Of note, the staphylococcal DXR enzyme appears somewhat distinct from 
previously characterized orthologs, particularly in the α10- α11 loop sequence, which could be 
explored with additional SAR studies. Together, our work provides insights into differences in 
staphylococcal DXR that may be key to driving future structure-based inhibitor design efforts. 
A well-appreciated liability of antibacterial phosphonates, including fosfomycin and FSM, has 
been the ready acquisition of resistance through loss of transport (27,64–66). Our work 
establishes GlpT as the likely phosphonate transporter in zoonotic staphylococci (Fig. 6). 
Identification of multiple, independent loss-of-function alleles from independent screens in two 
separate species is compelling evidence for a role of this locus in FSM-resistance in 
staphylococci. In addition, the homology between staphylococcal GlpT orthologs and Gram-
negative phosphonate transporters suggests that the staphylococcal proteins are functionally 
similar. The finding that lipophilic prodrug MEPicides, which do not require active transport, are 
still active against the glpT mutant strains indicates that the molecular basis of phosphonate 
resistance is through loss of GlpT-mediated transport (Fig 6). The prodrug MEPicides 
circumvent GlpT, which our study has shown is easily mutated in staphylococci. Whether 
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staphylococci also readily develop resistance to the prodrug MEPicides is currently unclear, and 
is an important question for future studies. 
It is important to note that while data indicate that the glpT mutants are resistant to phosphonate 
parent compound 3, the magnitude of resistance is substantially less than that of FSM. These 
data suggest that compound 3 may preferentially use an alternative transporter, thereby 
bypassing the dependence on GlpT. Surprisingly, staphylococcal glpT mutants are hypersensitive 
to MEPicide prodrugs, suggesting that after penetration and cleavage by cellular esterases, the 
compounds may accumulate intracellularly in the absence of GlpT (Fig 5). Future studies should 
examine the cellular transport of the MEPicide compounds, and further, explore whether synergy 
exists between the parent and prodrug varieties of this class of inhibitors. 
The MEPicide prodrugs, including compounds 2 and 4, represent promising leads for ongoing 
preclinical testing and development of new therapeutics for zoonotic staphylococcal infections. 
The prodrugs harness the microbial specificity and thus safety of MEP pathway inhibition, while 
avoiding the dependency on active GlpT-mediated transport. In addition, we find that ester 
modification has a dramatic effect on anti-staphylococcal potency in vitro, suggesting that 
phosphonate transport limits the anti-bacterial efficacy of FSM and related compounds. 
Lipophilic ester modifications have previously been employed to improve pharmacokinetic 
properties and bioavailability of anti-staphylococcal agents (e.g., cefditoren pivoxil)(67). Since 
MEPicide ester modification at the site of infection is necessary to facilitate bacterial cell entry 
of inhibitors, future studies will aim to understand what chemical features drive intestinal and 
serum cleavage of the MEPicide prodrugs. 
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2.6 Figures
 
Figure 1 FSM inhibits the MEP pathway in Staphylococcus spp. MEP pathway metabolites were compared between untreated (UNT) S. 
schleiferi (A) and S. pseudintermedius (B) and bacteria treated with FSM at 10x the respective IC50 values. After 2 h treatment, bacterial 
cells were harvested and the cell pellets analyzed by LC-MS/MS. Displayed are the means ± SD of the metabolite levels from three 
independent experiments. P-values were determined using a Student’s t-test. 
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Figure 2 Inhibition of staphylococcal DXR by FSM is competitive with DOXP. (A) S. schleiferi DXR velocity in µmol NADPH/min 
with respect to the DOXP concentration in mM. Displayed are the means ± SD from three independent experiments. (B) Lineweaver−Burk 
double reciprocal plots of S. schleiferi DXR activity over a range of DOXP substrate concentrations, for illustrative purposes only. 
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Figure 3 Crystal structure of S. schleiferi DXR. (A) Overall structure of the S. schleiferi DXR•FSM complex. The dimer is shown as a 
ribbon diagram with αhelices and β-strands of one monomer colored gold and blue, respectively. The position of FSM (space-filling model) 
in one monomer is indicated. (B) Electron density for FSM is shown as a 2Fo-Fc omit map (1 σ). (C) Stereoview of FSM binding in the 
active site. Dotted lines indicate protein-ligand interactions. (D) Comparison of S. schleiferi DXR apoenzyme and FSM complex structures. 
Structural changes in the active site region between the apoenzyme (rose) and FSM complex (gold) are shown. The major change in the 
position of the α10-α11 loop is emphasized by the position of Trp196 in each structure. 
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Figure 4 Successful evolution of FSM resistance. (A) Wild-type and FSM-resistant isolates from S. schleiferi (top) or S. pseudintermedius 
(bottom) were struck on LB agar plates with (right) and without (left) 32 µM FSM. (B) Distribution of the MIC values for WT (gray) and 
FSM-resistant mutants (black) from S. schleiferi (circles) and S. pseudintermedius (triangles). Displayed are the mean values for each strain 
from three independent experiments. 
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Figure 5 glpT mutant staphylococci are sensitive to MEPicide prodrugs. Wild-type (WT) and FSM-resistant, glpT mutant S. schleiferi 
isolates (strains 3408, 4494, 7376, and 8400) were treated with MEPicides and the MIC values determined during overnight growth. 
Displayed are the mean values of the fold change (resistant isolate/WT) ± SEM from at least three independent experiments. *MIC values 
observed for glpT strain 7376 were identical in three independent experiments performed in technical duplicate. 
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Figure 6 Model. In wild-type zoonotic staphylococci, GlpT transports the MEP pathway inhibitor FSM intracellularly where it inhibits its 
target, DXR. In staphylococci with glpT mutations, FSM is excluded from cells, resulting in FSM resistance. In contrast, lipophilic prodrug 
MEPicides do not require active transport and remain effective. 
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Figure S1 DXR inhibitors are bacteriostatic. Growth in CFU/mL of S. schleiferi and S. pseudintermedius after 24 h treatment is plotted 
against the respective treatment. Cultures were treated at 1 x IC50 concentration and/or 10x IC50 concentration of the inhibitors. Shown are 
the mean values + SD from at least three independent experiments. 
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Figure S2 SDS-PAGE of purified S. schleiferi DXR. Molecular mass standard (M) and approximately 1 µg of purified recombinant S. 
schleiferi DXR. 
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Figure S3 Membrane topology of GlpT. (A) Wild-type amino acid sequences and predicted transmembrane topology of S. schleiferi GlpT. 
Residues Gly-99, Trp-148, Trp-161, Ala-267, Gly-298, Ala-309, and Gln-379 are indicated in the sequence. Red indicates a stop mutation at 
the site, while blue indicates a missense mutation. (B) Wild-type amino acid sequences and predicted transmembrane topology of S. 
pseudintermedius GlpT. Residues Asp-88, Gly-99, Gly-135, Trp-301, Gly-400, and Gly-404 are indicated in the sequence. Red indicates a 
stop mutation at the site, while blue indicates a missense mutation. Schematic diagrams were prepared with the program Protter(5). 
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2.7 Tables 
Table 1: Inhibitory effect of MEPicides against the S. schleiferi DXR enzyme and in vitro activity against 
Staphylococcus spp. 
Compound Structure S. schleiferi 
DXR enzyme 
S. schleiferi S. pseudintermedius S. aureus 
    IC50 [𝝁M]  IC50 [𝝁M] IC50 [𝝁M] IC50 [𝝁M] 
FSM 
 
0.67 ± 0.06 0.78 ± 0.13 0.31 ± 0.04 > 100 
FR-900098 
 
1.00 ± 0.18 41.06 ± 6.65 34.14 ± 6.54 > 100 
1 
 
3.31 ± 1.02 55.50 ± 2.41 54.45 ± 1.14 > 100 
2 
 
> 100 0.10 ± 0.01 0.26 ± 0.03 > 100 
3 
 
0.41 ± 0.11 4.17 ± 0.47 4.31 ± 0.51 > 100 
4 
 
12.56 ± 1.98 0.03 ± 0.00 0.21 ± 0.04 > 90 
Data represent the mean ± SEM from at least three independent experiments. POM = 
(CH3)3CCOOCH2 
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Table S2: Primers used in this study. 
Number Primer Name Species Gene Sequence (5'-3') 
IH3 SS_DXR_LIC_FWD S. schleiferi  dxr CTCACCACCACCACCACCATATGAAAAATATAGCAATTTTAGGCGC 
IH4 SS_DXR_LIC_REV S. schleiferi  dxr ATCCTATCTTACT CACCTACACCTCATATGATTTTGTTTTATAAT 
ITS4 Sp_GlpT_dwn125_rev S. pseudintermedius glpT GATACCCCTCCACTTTCCAC 
ITS5 Sp_GlpT_in576_fwd S. pseudintermedius glpT AGGCTTTGAAGGGGCATTTA 
ITS6 Sp_GlpT_up86_fwd S. pseudintermedius glpT TGTAGAAATGCGATTGACAAACT 
ITS15  Ss_GlpT_up258_fwd S. schleiferi  glpT TTGGCTGCTGATAGTGGTTA 
ITS16  Ss_GlpT_in171_fwd S. schleiferi  glpT AATGGGGTTTACAAAAGCAG 
ITS17 Ss_GlpT_in1211_rev S. schleiferi  glpT CCGCCTAAATAGCCAAATAA 
ITS18 Ss_GlpT_dwn387_rev S. schleiferi  glpT CAGCTTGATTCAACAGATCG 
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Table S3: Summary of crystallographic data collection and refinement statistics. 
Crystal apoenzyme FSM complex 
Space group P3112 C2 
Cell dimensions 
a = b = 71.37 Å, c = 318.8 Å; a = 132.7 Å, b = 53.98 Å, c = 116.8 Å; 
g = 107.7° b = 91.6° 
Data collection     
Wavelength 0.98 Å 0.98 Å 
Resolution range 40.3 - 2.15 Å 46.1 - 2.89 Å 
(highest shell) (2.23 - 2.15 Å) (2.99 - 2.89 Å) 
Reflections (total / unique) 96, 253 / 50,961 33,914 / 18,289 
Completeness (highest shell) 99.2% (96.2%) 97.4% (91.1%) 
I/s (highest shell) 33.9 (2.3) 14.7 (1.8) 
Rsym (highest shell) 10.1% (66.7%) 11.6% (53.2%) 
Model and refinement     
Rcryst / Rfree 0.197 / 0.230 0.208 / 0.265 
No. protein atoms 5,830 5,898 
No. water molecules 81 - 
No. ligand atoms 35 22 
R.M.S.D. bond lengths 0.016 Å 0.010 Å 
R.M.S.D. bond angles 1.07 ° 1.26 ° 
Avg. B-factor - protein, ligand, 
water 
64.6, 86.2, 55.5 Å2 65.1, 70.3, - Å2 
Ramachandran plot - favored, 
allowed, outlier 
97.5, 2.3, 0.3 % 95.7, 2.3, 2.0 % 
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Chapter 3: Antimicrobial prodrug activation 
by the staphylococcal glyoxalase GloB 
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3.1 Abstract 
With the rising prevalence of multidrug-resistance, there is an urgent need to develop novel 
antibiotics. Many putative antibiotics demonstrate promising in vitro potency but fail in vivo due 
to poor drug-like qualities (e.g. serum half-life, oral absorption, solubility, toxicity). These drug-
like properties can be modified through the addition of chemical protecting groups, creating 
“prodrugs” that are activated prior to target inhibition. Lipophilic prodrugging techniques, 
including the attachment of a pivaloyloxymethyl group, have garnered attention for their ability 
to increase cellular permeability by masking charged residues and the relative ease of the 
chemical prodrugging process. Unfortunately, pivaloyloxymethyl prodrugs are rapidly activated 
by human sera, rendering any membrane permeability qualities absent during clinical treatment. 
Identification of the bacterial prodrug activation pathway(s) will allow for the development of 
host-stable and microbe-targeted prodrug therapies. Here, we use two zoonotic staphylococcal 
species, S. schleiferi and S. pseudintermedius, to establish the mechanism of carboxy ester 
prodrug activation. Using a forward genetic screen, we identify a conserved locus in both species 
encoding the enzyme hydroxyacylglutathione hydrolase (GloB), whose loss-of-function confers 
resistance to carboxy ester prodrugs. We enzymatically characterize GloB and demonstrate that 
it is a functional glyoxalase II enzyme, which has the capacity to activate carboxy ester prodrugs. 
As GloB homologs are both widespread and diverse in sequence, our findings suggest that GloB 
may be a useful mechanism for developing species- or genus-level prodrug targeting strategies.  
3.2 Introduction 
In 2019, the United States recorded 2.8 million antibiotic-resistant infections, resulting in over 
35,000 deaths (1). The recent surge in antibiotic use in the setting of the COVID-19 pandemic 
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portends an acceleration of the antibiotic resistance threat (2, 3). Staphylococcus aureus is a 
formidable human pathogen that causes a wide variety of invasive and life-threatening 
infections. Closely related staphylococcal species, S. pseudintermedius and S. schleiferi, cause 
similar skin, soft tissue, and invasive infections in companion animals and are increasingly 
appreciated as serious pathogens of humans (4–7). Rising rates of methicillin resistance are 
reported in all three species, with methicillin-resistant S. aureus (MRSA) labeled a “serious 
threat” by the Centers for Disease Control and Prevention (CDC) (1, 8–10). Novel antimicrobial 
strategies that circumvent existing drug resistance mechanisms are urgently needed.  
 
Bacterial metabolism is a promising area for antimicrobial development (11, 12). Many 
metabolic processes are essential for bacterial growth and pathogenesis. However, targeting 
metabolic processes can be inherently challenging, as a substantial portion of metabolism 
involves the catalytic transformation of highly charged substrates (e.g. phosphate transfer 
reactions). Substrate-competitive inhibitors of metabolic enzymes frequently deploy phosphonate 
functional groups as isosteric phosphate mimics (13). These negatively charged phosphonate 
antimetabolite inhibitors are prone to unacceptable drug-like characteristics and often diffuse 
poorly across membranes (14–19). 
 
Prodrugging, or the modification of an inhibitor through addition of labile chemical adducts, is a 
common medicinal chemistry strategy to improve drug-like properties of an inhibitor under 
development (19–21). As promoieties are released prior to inhibitor-target engagement, 
prodrugging can temporarily cloak problematic pharmacokinetic properties such as poor 
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absorption or solubility. For example, the third-generation cephalosporin, cefditoren, is poorly 
absorbed in the small intestine unless its carboxylate is masked with a lipophilic 
pivaloyloxymethyl (POM) promoiety, in the form of cefditoren pivoxil (22). Similarly, 
nucleoside analogues are generally cell-impermeable, but their cognate prodrugs have much 
improved cellular penetration and antiviral efficacy, as seen in remdesivir (SARS-CoV2), 
tenofovir disoproxil (HIV), and sofosbuvir (hepatitis C virus, HCV) (23–26). We have recently 
employed lipophilic prodrugging strategies to increase the efficacy of broad-spectrum 
antimicrobial phosphonate antibiotics. Notably, POM ester modification of a phosphonate 
isoprenoid biosynthesis inhibitor (ERJ) increases antistaphyloccal activity by 200- and 500-fold 
for S. schleiferi and S. pseudintermedius, respectively (Figure 1A,B) (27). Similar dramatic 
potency gains are observed for the same class of compounds against Mycobacterium 
tuberculosis, Yersinia pestis, Franciscella novicida, and the malaria parasite, Plasmodium 
falciparum (16, 28–31). 
 
While POM-prodrugs demonstrate remarkable potency in vitro, POM-promoieties are known to 
be rapidly hydrolyzed by serum carboxylesterases (32, 33). If cell-impermeable phosphonate 
antibiotics are to be effective at the site of infection, the promoiety must be resistant to premature 
bioactivation during absorption and distribution in the circulation. This specificity in prodrug 
activation has been successfully achieved for liver-targeted prodrugs, using the “HepDirect” 
prodrug approach, but has not yet been deployed for antibiotic delivery. HepDirect prodrugs are 
cleaved via a hepatocyte-specific cytochrome P450 enzyme, CYP3A4, and are resistant to 
cleavage by other human esterases (34). Selective bioactivation of prodrugs within microbes 
would not only increase the circulating half-life, but may also improve the therapeutic selectivity 
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of therapeutics that target microbial enzymes with human homologs. Understanding the 
molecular basis of host and microbe prodrug activation will facilitate design of microbially 
targeted prodrugs.  
 
In this study, we use two zoonotic staphylococcal species, S. schleiferi and S. pseudintermedius, 
to uncover the enzymatic mechanism of prodrug activation in staphylococci. We identify and 
characterize the first bacterial carboxy ester prodrug activating enzyme, GloB, a type II 
glyoxalase. Using detailed biochemical analyses, we demonstrate that GloB recognizes the 
carboxy ester portion of the prodrug and is responsible for prodrug activation. Since GloB 
homologues are broadly maintained, yet have substantial sequence variation, we propose that this 
group of enzymes may be a strategy towards microbe-specific prodrug targeting. 
 
3.3 Methods 
3.3.1 Inhibitors.  
Fosmidomycin (Millipore Sigma) and FR-900098 (Millipore Sigma) were resuspended in sterile 
water. POM-ERJ and POM-HEX were synthesized and stored in DMSO as described (29, 32). 
Cefditoren pivoxil (Millipore Sigma), cefditoren sodium (Clearsynth), and mupirocin (Millipore 
Sigma) were resuspended in DMSO. The synthesis of 
[({[(E)‐benzoyloxy]methoxy}[(1E)‐3‐(N‐hydroxyacetamido)prop‐1‐en‐1-
yl]phosphoryl)oxy]methyl benzoate (BOM-ERJ) followed that of POM-ERJ, except 
chloromethyl benzoate was substituted for chloromethyl pivalate (35). 1H NMR (400 MHz, 
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Chloroform-d) δ 9.35 (s, 1H), 7.96 (dd, J = 8.1, 1.4 Hz, 4H), 7.61-7.45 (m, 2H), 7.37 (t, J = 7.8 
Hz, 4H), 6.86-6.69 (m, 1H), 6.04-5.91 (m, 1H), 5.91-5.80 (m, 4H), 4.29 (s, 2H), 2.09 (s, 3H). 13C 
NMR (101 MHz, Chloroform-d) δ 165.04, 149.18, 134.20, 130.31-130.14, 128.87-128.54, 
118.38, 116.46, 82.34, 50.64. High resolution mass-spectrometry (fast atom bombardment) 
calculated for C21H23NO9P [M+H]+, 464.1105; found, 464.1097. LC-MS (electrospray 
ionization) m/z [M+H]+ 464.1, [M+Na]+ 486.1. Purity was greater than 95% as determined by 
LC-MS. 
 
3.3.2 Generation of POM-ERJ-resistant mutants in S. schleiferi and S. 
pseudintermedius.  
Clinical isolates of S. schleiferi (S53022327s) and S. pseudintermedius (H20421242p) were 
cloned and adapted to laboratory media through three rounds of sequential colony isolation and 
growth on Luria Broth (LB) agar plates. The isolated POM-ERJ-sensitive parental clones were 
incubated overnight on LB agar containing POM-ERJ at 3.56 µM and 7.12 µM for S. schleiferi 
and 11.2 µM and 22.4 µM for S. pseudintermedius. Surviving single colonies were re-struck onto 
LB agar for clonal isolation. POM-ERJ resistance of isolated clones was confirmed by overnight 
growth on LB agar containing POM-ERJ (3.56-22.4 µM). The POM-ERJ-sensitive parental 
clones were used as a control to confirm growth and antibiotic resistance. 
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3.3.3 Quantification of resistance.  
Minimum Inhibitory Concentration (MIC) assays were performed using microtiter broth dilution 
in clear 96-well plates (83). Compounds were serially diluted in duplicate for a total of 10 serial 
dilutions. Top well concentrations were: POM-ERJ 280 µM , BOM-ERJ 53.95 µM, KMH-102 
53.95 µM, cefditoren pivoxil 201.38 µM, cefditoren sodium 56.65 µM, POM-HEX 100 µM, 
mupirocin 2.50 µM, FR-900098 1 mM, fosmidomycin 100 µM. Bacteria cultured without drug 
were used as a positive control for growth, and LB without bacteria was used as a negative 
control for contamination. Plates were inoculated with 75 µL bacteria diluted to 1 x 105 CFU/mL 
in LB. After inoculation, plates were incubated for 16-24 h while shaking at 200 RPM at 37°C. 
Plates were visually inspected, and the lowest concentration of antibiotic suppressing visual 
growth was recorded as the MIC. All experiments were performed at least in triplicate and data 
reported represent the mean ± SD.  
 
3.3.4 Transmission Electron Microscopy. 
 For ultrastructural analysis, bacteria were cultured in 5 mL LB while shaking at 37°C until 
OD600 = 0.25-1.0. A 1 mL sample of exponential phase bacteria was pelleted at 6,000 rcf and 
resuspended in 1 mL fix (2% paraformaldehyde/2.5% glutaraldehyde (Polysciences Inc., 
Warrington, PA) in 100 mM sodium cacodylate buffer, pH 7.2) for 1 h while rocking at RT. The 
fixed suspension of bacteria was washed in sodium cacodylate buffer and postfixed in 1% 
osmium tetroxide (Polysciences Inc.) for 1 h. Samples were then rinsed extensively in dH2O 
prior to en bloc staining with 1% aqueous uranyl acetate (Ted Pella Inc., Redding, CA) for 1 h. 
Following several rinses in dH2O, samples were dehydrated in a graded series of ethanol and 
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embedded in Eponate 12 resin (Ted Pella Inc.). Sections of 95 nm were cut with a Leica Ultracut 
UC7 ultramicrotome (Leica Microsystems Inc., Bannockburn, IL), and stained with uranyl 
acetate and lead citrate. Samples were viewed at 30,000X on a JEOL 1200EX transmission 
electron microscope (JEOL USA, Peabody, MA) equipped with an AMT 8 megapixel digital 
camera (Advanced Microscopy Techniques, Woburn, MA). Cell wall thickness was measured 
(ImageJ 1.38g customized for AMT images) for 100 bacteria in three independent samples (total 
n = 300). 
 
3.3.5 Whole genome sequencing and variant discovery.  
Using a standard phenol-chloroform extraction and ethanol precipitation protocol, genomic DNA 
was isolated from overnight cultures of S. pseudintermedius and S. schleiferi. Sequencing 
libraries were prepared and sequenced by the Washington University Genome Technology 
Access Center (GTAC). 1 µg of DNA was sonicated to an average size of 175 bp. Fragments 
were blunt ended and had an A base added to the 3´ end. Sequence adapters were ligated to the 
ends and the sequence tags were added via amplification. Resulting libraries were sequenced on 
an Illumina HiSeq 2500 to generate 101 bp paired end reads. DNA quantity and quality were 
assessed by GTAC using Agilent Tapestation. 
For the analysis, sequences from GenBank were retrieved from the following organisms: S. 
pseudintermedius ED99 (accession number CP002478) and S. schleiferi 1360-13 (CP009470) 
assemblies were downloaded from NCBI (ftp://ftp.ncbi.nlm.nih.gov). Paired-end reads were 
aligned to each of the available genomes using Novoalign v3.03. (Novocraft Technologies). 
Duplicates were removed and variants were called using SAMtools (37). SNPs were filtered 
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against parent variants and by both mean depth value and quality score (minDP =5, minQ = 30) 
(38). Genetic variants were annotated using SnpEff v4.3 (39). For all samples, at least 90% of the 
genome was sequenced at 20x coverage. Whole genome sequencing data is available in the 
NCBI BioProject database and Sequence Read Archive under the BioProject ID 648133. 
 
3.3.6 Sanger sequencing of S. schleiferi and S. pseudintermedius variants.  
The SNPs, the reference sequences, and gene specific primers can be found in Table S4 for both 
S. schleiferi and S. pseudintermedius. Amplicons were sequenced by GENEWIZ. 
 
3.3.7 Staphylococcal GloB homology modeling.  
SWISS-MODEL (https://swissmodel.expasy.org/) was used to generate homology models. 
Modeling parameters were left at default. Both SsGloB and SpGloB models were built using the 
solved Metallo-β-lactamase superfamily protein, 2ZWR.1.A, which is 39.2% identical in 
sequence.  
 
3.3.8 Recombinant expression and purification of GloB.  
WT GloB from S. schleiferi was amplified using the forward and reverse primers in Table S4. 
The PCR product was then cloned into the BG1861 vector by ligation-independent cloning to 
introduce a N-terminal 6xHis tag and transformed into Stellar™ chemically competent cells 
(Clontech Laboratories) for plasmid propagation (40). Proper insertion was verified using 
restriction digest and Sanger sequencing. For S. schleiferi protein expression, the plasmid was 
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transformed into E. coli Arctic Express (Agilent). Cells were grown to OD600 = 0.4-0.7, chilled to 
8°C, and GloB expression was induced with 0.5 mM isopropyl-β-D-thiogalactoside (IPTG) 
overnight. For S. aureus protein expression, the plasmid was transformed into E. coli BL21 
(DE3) pLysS cells (Promega). Cells were grown to OD600 = 0.4-0.7 and GloB expression was 
induced with 0.5 mM IPTG for 2 h. Cells were harvested by centrifugation at 4274 x g for 5 min 
at 4°C. The cell pellet was lysed by sonication in 50 mL lysis buffer containing 25 mM Tris HCl 
(pH 7.5), 20 mM imidazole, 1 mM MgCl2, 1 mM dithiothreitol (DTT), 1 mg/mL lysozyme, 75 U 
benzonase and 1 Complete Mini EDTA-free protease inhibitor tablet (Roche Applied Science). 
Insoluble proteins were removed by centrifugation twice at 20,000 x g for 20 min each. The 
hexahistidine-tagged SsGloB protein was affinity purified from soluble lysate via nickel agarose 
beads (Gold Biotechnology). Bound protein was washed with 50 mL of lysis buffer and eluted in 
300 mM imidazole, 25 mM Tris HCl (pH 7.5), 1 mM MgCl2, 10% glycerol, and 250 mM NaCl. 
Affinity purified protein was further purified over a HiLoad 16/60 Superdex 200 gel filtration 
column (GE Healthsciences) using an AKTAExplorer 100 FPLC (GE Healthsciences). FPLC 
buffer contained 25 mM Tris HCl (pH 7.5), 250 mM NaCl, 1 mM MgCl2 and 10% glycerol. 
Fractions containing >90% pure enzyme (evaluated by SDS-PAGE) were concentrated by 
centrifugation using Amicon Ultra-15 centrifugal filter units (EMD Millipore) and flash frozen in 
liquid nitrogen before permanent storage at -80°C. Protein identity was verified using mass 
spectrometry at the University of Nebraska.  
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3.3.9 GloB mutant generation.  
WT GloB for S. schleiferi was synthesized by GeneWiz, Inc (Beijing, China) with a CAT->AAT 
mutation in the 54th codon (H54N) and cloned into the BG1861 vector to introduce an N-
terminal 6xHis tag. Proper insertion was verified by Sanger sequencing. 
 
3.3.10 β-lactamase activity assay. 
 S. schleiferi GloB was tested for β-lactamase activity using the chromogenic cephalosporin 
substrate Nitrocefin (Sigma Aldrich 484400) as in (41) but with minor changes. 50 μL reactions 
containing 25 mM Tris HCl (pH 7.5), 250 mM NaCl, 1 mM MgCl2, 10% glycerol, and 200 μM 
Nitrocefin were preincubated for 15 min at 37oC, and reactions were initiated upon addition of 
GloB. Cleavage of Nitrocefin was allowed to proceed at 37°C and tracked kinetically at 486 nm. 
Assays were carried out over a range of GloB concentrations starting at 2 g of protein (1.6 M). 
 
 
3.3.11 Glyoxalase II activity assay.  
S. schleiferi GloB was tested for type II Glyoxalase activity as previously with minor changes 
(42). 50 μL reactions containing 25 mM Tris pH 7.5, 250 mM NaCl, 1 mM divalent salt, 10% 
glycerol, 200 μM 5,5′-Dithiobis(2-nitrobenzoic acid) (DTNB, Sigma D8130), and 1 mM D-
lactoylglutathione (Sigma L7140) were monitored in a 96-well plate for an increase in 
absorbance at 412 nm. Reactions were pre-incubated at 37°C and initiated with the addition of 
GloB. The conversion of DTNB to the yellow colored substrate, TNB, by glutathione produced 
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by GloB, was measured through time at 37°C and 412 nm. Assays were carried out over a range 
of GloB concentrations to ensure that the reaction rates are linear over the period of the assay. To 
determine metal dependence of GloB, assays were performed using assay buffer with a final 
concentration of 1 mM divalent salts. Divalent salts were provided as follows: zinc chloride, 
manganese chloride, magnesium chloride, cobalt chloride, and calcium chloride. 
 
3.3.12 Sample preparation for GloB vs. POM-ERJ mass spectrometry 
analysis.  
Reactions containing 25 mM Tris HCl (pH 7.5), 250 mM NaCl, 10% glycerol, 1 mM MnCl2, and 
1 mM POM-ERJ were pre-warmed to 37°C before addition of WT GloB, catalytically inactive 
GloB (H54N), boiled GloB, or an equal amount of protein storage buffer to a final concentration 
of 1 μM. Reactions were placed at 37°C and sampled at 0, 15, 30, 60, 90, and 120 min. A 50 µL 
sample was withdrawn from each reaction at the times indicated, and the sample reaction was 
quenched by the addition of 200 µL acetonitrile containing 100 ng/μL enalapril as an internal 
standard. The samples were immediately frozen on dry ice and stored at -80°C until analysis.  
 
The quenched reaction mixtures were centrifuged at 3200 rpm for 5 min, and 2 μL of the 
supernatant was diluted to 500 µL with water containing 100 ng/mL enalapril as an internal 
standard. Samples were analyzed by LC-MS/MS using an Applied Biosystems-Sciex API 4000. 
Analyte/internal standard peak area ratios were used to determine concentration and evaluate 
stability. Standards were evaluated over the range of 1 ng/mL to 1000 ng/mL. The MRM 
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transitions for enalapril and POM-ERJ were m/z: 376.9 > 91.2 and 424.0 > 364.0, respectively. 
A Phenomenex Luna Omega polar C18 column (2.1 × 50 mm, 5 μm) was used for 
chromatographic separation. Mobile phases were 0.1% formic acid in water and acetonitrile with 
a flow rate of 0.5 mL/min. The starting phase was 1% acetonitrile increased to 100% acetonitrile 
over 0.9 min. Peak areas were integrated using Analyst Software (AB Sciex, Foster City, CA). 
 
3.3.13 In vivo cleavage of POM-ERJ.  
S. schleiferi cultures of WT and POM-ERJR strains were grown to an OD600 = 0.5-0.8 and then 
treated with 1 μM of POM-ERJ. The cultures were grown shaking at 37°C and 200 rpm and 50 
μL were sampled at 0, 1, 2, and 3 h. The reactions were quenched by pelleting the cells at 4274 x 
g at 4°C and resuspending in 200 μL of acetonitrile with 100 ng/μL enalapril as an internal 
standard. The reactions were repeated in triplicate for each timepoint and strain. The LC-MS 
analysis was performed as described above.  
 
3.3.14 NMR characterization of GloB POM-prodrug products. 
Five hundred micromolar POM-ERJ and POM-HEX were incubated with 50 μl buffer (50 mM 
tris pH 7.5, 50 mM NaCl, 1mM MgCl2)  and 20 μl SaGloB or 40 μl SsGloB with stock 
concentrations of 200 μM and 100 μM respectively at 37 °C for 90 minutes. Samples were 
prepared for NMR studies by resuspending them in water and 10% (50 μl) D2O (Deuterium 
Oxide 99.9 atom % D, contains 0.75 wt %3-(trimethylsilyl)propionic -2,2,3,3-d4 acid, sodium 
salt, Sigma–Aldrich). NMR spectra are acquired on a Bruker Avance III HD 500 MHz 
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spectrometer equipped with a cryoprobe. Two-dimensional (2D) 1H-31P heteronuclear single 
quantum correlation (HSQC) measurements were obtained using hsqcetgp pulse program (with 
duration of 15 minutes and scan parameters of 4 scans, td=1024 and 128, gpz2 %=32.40, 31P 
SW= 40 ppm, O2p=20 ppm, cnst2=22.95) and analyzed using 3.1 TopSpin. The 1D projection of 
columns excluding the water signal was obtained from the 2D 1H-31P HSQC spectrum by 
obtaining spectra of positive projection of columns 1 to 600 and 650 to 1024 and adding them.   
 
3.3.15 Phylogenetic tree construction.  
The sequences of S. schleiferi GloB and RpoB homologs were retrieved from NCBI using BlastP 
against each specified organism. Organisms were selected to represent a wide array of 
commensal and pathogenic bacteria (43). Additional sequences were added from Mus musculus, 
Homo sapiens, and other previously characterized GloB orthologs for additional comparison. 
Sequence alignment was performed using MUSCLE, and visualized using iTOL (44, 45). 
 
3.4 Results  
3.4.1 Selection of prodrug-resistant staphylococci.  
In our previous study, we identified phosphonate antibiotics with activity against zoonotic 
staphylococci (S. schleiferi and S. pseudintermedius) (27). Lipophilic carboxy ester prodrug 
modification of these phosphonates dramatically increases antistaphylococcal potency, 
presumably through increased cellular penetration (Figure 1A, B). However, prodrug 
modifications block direct engagement of inhibitors with their enzyme target (27). For this 
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reason, we hypothesized that one or more staphylococcal esterases were required for intracellular 
prodrug activation (Figure 1A). To identify candidate prodrug activating enzymes, we designed a 
genetic screen/counter-screen strategy to enrich for staphylococcal strains that fail to activate 
lipophilic ester prodrugs.   
 
In our strategy, we took advantage of inhibitor pairs with the same target engagement, with and 
without prodrug modification. We employed the phosphonate antibiotic ERJ, which selectively 
inhibits the intracellular enzyme deoxyxylulose phosphate reductoisomerase (DXR), and POM-
ERJ, the bis-pivaloyloxymethyl prodrug form of ERJ, which inhibits intracellular DXR even 
though it has been shown to lack direct activity against purified recombinant DXR in vitro (27). 
We sought to enrich for staphylococcal strains that were resistant to prodrugged inhibitors (e.g. 
POM-ERJ) but remained sensitive to the parent phosphonate ERJ itself (27). For this reason, we 
first isolated staphylococcal colonies that arose from solid media containing POM-ERJ. Next, we 
screened these POM-ERJ-resistant isolates for cross-resistance to our parent compound, ERJ. 
POM-ERJ-resistant strains that remained sensitive to ERJ were subjected to whole genome 
sequencing to identify candidate genetic mutations giving rise to the resistance phenotype 
(Figure 1C). To identify conserved resistance mechanisms, we performed this screen/counter-
screen independently in two staphylococcal species, S. schleiferi and S. pseudintermedius. We 
isolated and characterized a total of 18 POM-ERJ-resistant staphylococcal strains, with MIC90 
values ~10-50 fold higher than that of the respective wild-type (WT) parental lines (Figure 
1D). In axenic growth in rich media, no changes in growth rate are observed between WT and 
three POM-ERJ-resistant isolates (Figure S1). 
91 
 
3.4.2 POM-ERJ resistance does not alter cell wall size in staphylococci.  
In previous work, we and others have found that cellular entry of the phosphonate antibiotic ERJ 
and ERJ analogs requires the phosphonate transporter GlpT (16, 27, 35, 36). In contrast, entry of 
POM-ERJ is transporter-independent (16, 27). POM-ERJ resistance could therefore arise through 
cell wall modifications that directly disrupt cell penetration of prodrugs. Such cell wall 
alterations might therefore lead to cross-resistance to other antimicrobials, such as daptomycin or 
vancomycin. To establish the selectivity of POM-ERJ-resistance, we determined the 
antimicrobial sensitivity of a subset of our prodrug-resistant strains against a panel of 18 clinical 
antibiotics with diverse mechanisms-of-action. We find that POM-ERJ-resistant strains are not 
cross-resistant to other inhibitors, including daptomycin and vancomycin (Table S1), suggesting 
a prodrug-specific mechanism of resistance. Additionally, we quantified the cell wall size in 
POM-ERJ-resistant staphylococci by transmission electron microscopy, because an established 
daptomycin and vancomycin resistance strategy for S. aureus is the generation of thickened cell 
walls that reduce inhibitor entry (48, 49). We find no changes in cell wall thickness in prodrug-
resistant isolates compared to their prodrug-sensitive WT parental lines (Fig 2).  
3.4.3 POM-ERJ-resistant staphylococci are cross-resistant to other carboxy 
ester prodrug antibiotics. 
If POM-ERJ resistance is due to loss of a prodrug activating enzyme(s), we hypothesized that 
POM-ERJ-resistant staphylococci would likewise be cross-resistant to other carboxy ester 
prodrug antibiotics. To evaluate this possibility, we selected several additional pairs of inhibitors 
(carboxy ester prodrugs and their cognate parent (non-prodrugged) compounds), with distinct 
cellular targets (e.g. penicillin binding protein, deoxyxylulose reductoisomerase (DXR), and 
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enolase) (Figure 3) (22, 32). For three of our POM-ERJ-resistant S. schleiferi isolates, we 
determined the minimum inhibitory concentration (MIC) for each compound, compared to the 
WT parental strain (Figure 4).  
 
We find that POM-ERJ-resistant staphylococci remain equally sensitive to non-prodrugged 
compounds (such as ERJ analogues) and the third-generation cephalosporin cefditoren. In 
contrast, POM-ERJ-resistant staphylococci exhibit significantly increased MICs to multiple 
classes of lipophilic ester prodrugs, exhibiting cross-resistance to both cefditoren pivoxil (cell 
wall inhibitor) and POM-HEX (inhibitor of enolase) (Figure 4, Table S2). Thus, POM-ERJ-
resistant staphylococci are cross-resistant to other POM-prodrug inhibitors, regardless of the 
intracellular target. Our data suggest that POM-prodrugs follow a common and conserved 
activation mechanism that has been disrupted in our POM-ERJ-resistant isolates.  
 
To explore how changes in the chemical structure of the prodrug group impacts prodrug 
resistance, we also evaluated whether our POM-ERJ-resistant isolates were cross-resistant to 
antimicrobial prodrugs that possess another common carboxy ester prodrug moiety, 
benzoyloxymethyl (BOM) (Figure 3). Indeed, we find our POM-ERJ-resistant isolates are also 
cross-resistant to BOM-ERJ (Figure 4). 
 
Carboxy ester prodrugs are more lipophilic than their parental molecules. To evaluate whether 
prodrug resistance in our strains is driven by the lipophobicity of the molecule rather than its 
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ester bond, we selected an additional highly lipophilic antibiotic, mupirocin, which inhibits 
protein biosynthesis (Figure 3). POM-ERJ-resistant staphylococci were not cross-resistant to 
mupirocin, further supporting that prodrug resistance in these strains is specific to the carboxy 
ester bond of the prodrug (Figure 4). 
 
3.4.4 POM-ERJ resistant staphylococci are enriched in mutations in the GloB 
gene. 
To characterize the genetic changes associated with carboxy ester prodrug resistance, we 
performed whole genome sequencing of prodrug resistant isolates of both S. schleiferi and S. 
pseudintermedius. The whole genomes of each isolate were compared to the respective parental 
genome and candidate genetic changes were verified by Sanger sequencing. We prioritized 
nonsynonymous genetic changes that were represented in more than one strain. A complete list 
of identified mutations is found in Table S3. 
 
In both independent genetic screens, we found that prodrug resistant staphylococci were enriched 
in mutations in an evolutionarily conserved locus. We identified multiple isolates (3/16 S. 
schleiferi, 14/18 S. pseudintermedius) with sequence modifications in the locus annotated as 
hydroxyacylglutathione hydrolase, gloB (LH95_06060 in S. schleiferi, SPSE_1252 in S. 
pseudintermedius, Table S3). Most genetic changes in gloB were nonsynonymous single 
nucleotide polymorphisms, though two nonsense alleles that would truncate approximately 50% 
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of the protein were also identified (Figure 5, Table S3). In several strains, the only genetic 
variation that distinguished WT and resistant genomes was within the gloB locus.  
 
Of the 17 identified GloB mutations, 12 unique alleles were identified in prodrug-resistant 
staphylococci. Using PROVEAN, an algorithm which quantifies the predicted impact of amino 
acid substitutions on protein function, each of these 12 alleles is predicted to have deleterious 
effects on protein function (below the threshold score of -2.5) (Figure 5) (50). S. schleiferi and S. 
pseudintermedius are non-model organisms that possess endogenous CRISPR-Cas9 systems and 
transformation of these organisms has not yet been described (51). Attempts to ectopically 
complement gloB mutant strains with WT GloB (>90 independent transformation attempts using 
established methods for S. aureus, S. epidermidis, and B. subtilis) were unsuccessful in 
recovering transformed colonies, despite preparing plasmid from the S. aureus restriction 
deficient cloning intermediate, RN4220, and the cytosine methyltransferase negative E. coli 
mutant, DC10B (52–58). However, the independent selection of 12 unique loss-of-function 
alleles in two different species strongly suggests that loss of GloB function is responsible for 
prodrug resistance in S. schleiferi and S. pseudintermedius.  
 
3.4.5 Structural basis of GloB loss-of-function. 
As prodrug-resistance mutations in GloB map along its entire linear sequence, we next examined 
the structural basis for GloB loss-of-function. We generated homology models of both SsGloB 
and SpGloB using SWISS-MODEL (59). The resulting staphylococcal model is based on the 
sequence-similar metallo-β-lactamase superfamily member from Thermus thermophilus (PDB 
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2ZWR) (60). This hit had a global model quality estimate (GNQE) of 0.71 and 0.70 for S. 
schleiferi and S. pseudintermedius GloB homologs, respectively, suggesting the built models are 
reliable and accurate. In both protein models, we find that POM-ERJ-resistance mutations are 
primarily located towards the interior of the protein, occupying the same cavity as the well 
conserved glyoxalase II metal binding motif (THxHxDH) (61). This modeling thus indicates that 
these prodrug-resistance alleles impair the GloB active site (Figure 5).  
 
3.4.6 GloB is a functioning type II glyoxalase, not a β-lactamase. 
GloB is predicted to be a type II glyoxalase and a member of the large metallo-β-lactamase 
protein superfamily (INTERPRO IPR001279). Members of this superfamily hydrolyze thioester, 
sulfuric ester, and phosphodiester bonds, such as the ester linkage present in POM-ERJ (42, 61–
63). Type II glyoxalases catalyze the second step in the glyoxalase pathway that is responsible 
for the conversion of methylglyoxal (a toxic byproduct endogenously produced during 
metabolism) to lactic acid. Specifically, GloB catalyzes the conversion of D-lactoylglutathione to 
D-lactate.  
To determine whether SsGloB encodes a functional type II glyoxalase, we evaluated whether 
SsGloB hydrolyzes S-lactoylglutathione using an assay in which hydrolysis of S-
lactoylglutathione is linked to a change in absorbance (Figure 6A). We purified recombinant WT 
SsGloB protein and its catalytically inactive variant, SsGloBH54N, in which the histidine of the 
canonical metal binding motif (THxHxDH) has been altered to an asparagine (Figure S2) (61–
63). We find that SsGloB, but not SsGloBH54N, hydrolyzes S-lactoylglutathione with a specific 
activity of 0.493 μmol*min-1mg-1 (Figure S3, Figure 6B,C). This activity is similar to other 
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characterized microbial type II glyoxalases (Saccharomyces cerevisiae, 1.34 μmol*min-1mg-1; 
Trypanosoma brucei, ~8 μmol*min-1mg-1), but is much lower than that of previously 
characterized type II glyoxalases from plants and mammals (20-2000 μmol*min-1mg-1) (64–72). 
We determined the metal dependence of SsGloB and find that SsGloB is a functional type II 
glyoxalase in manganese, cobalt, calcium, and zinc, with a modest preference noted towards 
magnesium (Figure S4). 
 
As some members of the metallo-β-lactamase protein superfamily mediate hydrolysis of β-
lactam antibiotics, we considered whether GloB also had β-lactamase activity. Because gloB 
mutant strains are not cross-resistant to the β-lactam-containing antibiotics (except for the 
prodrugged cephalosporin, cefditoren pivoxil) (Figure 4, Table S2), we predicted that GloB was 
not a functional metallo-β-lactamase. As expected, we find that SsGloB does not hydrolyze the 
β-lactamase ring of nitrocefin (a canonical β-lactamase substrate), in contrast to the active B. 
cereus β-lactamase (Figure S3). 
 
3.4.7 Staphylococcal GloB hydrolyzes POM-ERJ in vitro and in vivo. 
Loss-of-function mutation in GloB is associated with resistance not only to POM-ERJ, but also 
to other ester prodrugs. Because GloB does not mediate resistance to ERJ or other phosphonates, 
our data suggested that GloB might directly catalyze the conversion of POM-ERJ to ERJ. To 
determine whether GloB de-esterifies POM-ERJ, we developed a liquid chromatography-mass 
spectrometry (LC-MS)-based assay to quantify POM-ERJ concentrations. Incubation of purified 
recombinant SsGloB protein, but not its inactive variant (SsGloBH54N), with POM-ERJ results in 
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rapid loss of POM-ERJ, consistent with SsGloB-mediated cleavage (Figure 7A). To determine 
whether prodrug activation activity is conserved among staphylococcal GloB homologs, we also 
purified recombinant GloB from the human pathogen S. aureus (Figure S2). We find that 
SaGloB also directly hydrolyzes POM-ERJ (Figure 7A). 
 
To determine whether GloB mediates intracellular prodrug activation, we evaluated the 
intracellular concentrations of POM-ERJ in drug-treated WT and gloB mutant staphylococci. We 
prepared staphylococcal cultures treated with POM-ERJ and quenched the reaction at several 
timepoints to monitor the course of intracellular prodrug depletion. As expected, we find that 
POM-ERJ is rapidly depleted in WT S. schleiferi, consistent with enzymatic activation. In 
contrast, POM-ERJ concentrations do not decrease over time in gloB mutant strains, in which the 
sole genetic change in each strain compared to WT is in the gloB locus (Figure 7B). This 
suggests that the initial step in carboxy ester prodrug activation in staphylococci lacks functional 
redundancy and is exclusively dependent on GloB. 
 
3.4.8 POM-ERJ is a GloB substrate 
We next characterized the reaction products resulting from POM-ERJ incubation with GloB. 
Using a highly sensitive 31P-1H HSQC NMR protocol, we find that WT S. schleiferi and WT S. 
aureus GloB remove at least one carboxy ester from POM-ERJ but are unable to fully deprotect 
the compound in appreciable quantities (Figure S5A). We hypothesize that the intermediate 
product may be the singly de-POMylated version of POM-ERJ (Hemi-POM-ERJ). To evaluate 
whether other POM-containing inhibitors were also direct substrates, we repeated this 
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experiment using POM-HEX (Figure S5B). We find that GloB is likewise capable of partially 
activating POM-HEX, but is unable to act upon Hemi-POM-HEX, suggesting at least one 
additional enzyme may be required for prodrug activation in vivo. 
 
3.4.9 Staphylococcal GloB enzymes represent a distinct clade of bacterial 
glyoxalases. 
Because staphylococcal GloB mediates de-esterification of ester prodrugs, we sought to evaluate 
the feasibility of using these enzymes to design prodrugs specifically targeted for activation in 
staphylococci. We constructed a phylogenetic tree of GloB homologs across diverse microbial 
genomes, as well as in humans and mice (Figure S6A), specifically including sequences of 
previously characterized GloB homologs. We find that considerable sequence variation exists 
within GloB homologs, with no clear clustering by phylogeny except for those GloB homologs 
originating in plants and mammals. This contrasts with a phylogenetic tree generated using the 
DNA-directed RNA polymerase subunit beta (rpoB), which generally follows the traditional tree 
of life (Figure S6B). 
 
While sequence differences between staphylococcal GloB and human GloB suggest that there 
may be substrate utilization differences between humans and staphylococci, ultimately 
differences within the active site are likely to drive substrate specificity. Using pymol, we 
aligned our homology model of SsGloB with the glutathione-bound GloB from humans (PDB 
ID: 1qh5) (73, 74). The two structures align well with a root-mean-square deviation (RMSD) of 
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1.528Å, and are well conserved in the overall structure as well as the characteristic Zn binding 
motif, THxHxDH (Figure S7A,B). Notably, however, HsGloB has a significant C-terminal 
extension which is not present in SsGloB. This C-terminal extension forms an α-helix which 
borders the active site and contains two residues, K252 and R249, which appear to be involved in 
coordinating the co-crystallized glutathione substrate (Figure S7C). The absence of this C-
terminal extension in our SsGloB homology model suggests that HsGloB and SsGloB have 
distinct active site chemistry that may be exploited to drive prodrug activation selectively by 
SsGloB vs HsGloB.  
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3.5 Discussion 
Antimicrobial resistance is a substantial challenge for treatment of both human and animal 
staphylococcal infections. Widespread methicillin resistance contributes both to poor clinical 
outcomes and increased treatment costs, and resistance is emerging to agents of last resort such 
as vancomycin and linezolid (1). Current antimicrobial therapies target a fraction of essential 
cellular processes, and metabolism remains a promising area for therapeutic development (11, 
12). Many metabolic genes are essential for growth, especially in the nutrient limited setting of 
infection (75–78). Additionally, chemical ligands are readily designed with high potency by 
mimicking natural substrates used by metabolic enzymes. Finally, because active site mutations 
that disrupt binding of competitive inhibitors are likely to deleteriously affect enzyme function, 
the barrier to resistance can be high (79, 80). Although many metabolic processes are conserved 
between humans and microbes, selective targeting of microbes is achievable as is demonstrated 
by the success of folate antagonists (trimethoprim/sulfamethoxazole) and bedaquiline (a F0F1 
ATP synthase inhibitor of Mycobacterium tuberculosis) (81–83).  
 
Unfortunately, many metabolic inhibitors require cell-impermeable phosphonic acids for 
efficient target inhibition. Prodrugging strategies to increase cellular penetration have been 
developed for a variety of therapeutics, most notably the anti-cancer and anti-viral nucleosides 
(19). These prodrug strategies must be sufficient labile that the compound is activated within the 
target cell, yet stable enough to resist premature prodrug activation by the sera. Prodrugs which 
are selectively activated within target cells have the added benefit of reducing off-target toxicity 
effects. To achieve cell-targeted prodrug activation, knowledge of the activation mechanisms in 
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sera, as well the target cell, are essential. While prodrug targeting has been achieved for liver 
therapies, this strategy has yet to be employed for bacterial antibiotics that employ ester prodrug 
moieties (34). 
 
In this work, we have identified a new mechanism for the de-esterification and activation of 
lipophilic ester prodrugs though a conserved staphylococcal esterase in the metallo-β-lactamase 
superfamily. Loss-of-function of GloB confers resistance to lipophilic carboxy ester prodrugs in 
two zoonotic pathogens, S. schleiferi and S. pseudintermedius (Figure 1D, Table S3). Purified 
recombinant GloB from S. schleiferi and the related human pathogen S. aureus directly catalyzes 
pro-drug de-esterification in vitro (Figure 7A). Because gloB mutant staphylococci are cross-
resistant to other POM-containing prodrugs that differ in “warhead” and intracellular targets 
(Figure 4), we propose that substrate-specificity of GloB appears driven by recognition of the 
lipophilic promoiety, rather than the target inhibitory portion of each compound. 
 
Bacterial prodrug ester activation through GloB hijacks a conserved bacterial protective 
mechanism in bacteria, as hydroxyacylglutathione hydrolase represents the second enzyme of the 
two-step glyoxalase pathway. During normal metabolism, the glycolytic intermediates 
glyceraldehyde-3-phosphate (GAP) and dihydroxyacetone phosphate (DHAP) undergo 
nonenzymatic decomposition to methylglyoxal, a toxic metabolite. GloB is required for 
glutathione mediated methylglyoxal detoxification, as methylglyoxal is highly reactive and 
irreversibly glycates proteins and nucleic acids (84–86). A secondary pathway for methylgloxal 
detoxification utilizing the glutathione independent enzyme, glyoxalase III, was recently 
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described in S. aureus and orthologs are found in S. schleiferi and S. pseudintermedius (77). The 
redundancy of the glutathione-dependent and -independent glyoxalase pathways remains unclear. 
In S. aureus, methylglyoxal accumulation potentiates antibiotic susceptibility (87). In addition, 
methylglyoxal is itself directly antibacterial and postulated to be the primary antistaphylococcal 
ingredient in Manduka honey (used on chronic wounds) (87–90). Our studies suggest that strains 
of S. schleiferi and S. pseudintermedius lacking GloB have preserved axenic growth in rich 
media, which raises concern for the ease of resistance development when GloB-targeted 
prodrugs are used as anti-infectives. However, the known toxicity of methylglyoxal in a host 
infection setting suggests that reduced methylglyoxal detoxification as the result of GloB loss-of-
function would not be well tolerated in vivo.  
 
Identification of GloB as a prodrug activating enzyme in staphylococci is a major step forward 
for highly selective microbial targeting of compounds. Though GloB homologs are widespread 
in microbes and are present in humans, significant sequence variation exists in GloB sequences, 
which results in a variety of GloB substrate preferences (Figure S6). For example, human GloB 
has an additional α-helix along the active site that introduces two additional residues, K252 and 
R249 to the substrate binding pocket (Figure S7) (74). These residues, and this α-helix, are 
notably absent in microbial GloBs, suggesting that there are underlying substrate differences 
between human and microbial GloB enzymes. Furthermore, there is substantial sequence 
variation in GloB orthologs across all microbes, suggesting that GloB substrate specificities may 
discern between individual clades of bacteria. We expect that development of prodrugs specific 
to GloB would result in a narrow-spectrum antibiotic, which would reduce off-target effects on 
the microbiome and decrease the broad pressure to evolve resistance.  
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3.6 Figures 
 
 
Figure 1 POM-prodrug activation and resistance generation. (A) Predicted POM-ERJ activation pathway. POM-promoiety highlighted 
in pink. (B) Dose-dependent growth inhibition of zoonotic staphylococci, S. schleiferi (left) and S. pseudintermedius (right), by ERJ (blue) 
and POM-ERJ (pink). Displayed values are the means ± SD of three independent experiments performed in technical duplicate. (C) 
Screening strategy to identify prodrug activating enzymes. (D) Distribution of MIC values for WT (pink) and POM-ERJ resistant mutants 
from S. schleiferi (left) and S. pseudintermedius (right). Displayed values are the means values for each strain from three independent 
experiments performed in technical duplicate. 
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Figure 2 POM-ERJ resistant Staphylococci exhibit normal cell wall sizes. (A-D) Representative transmission electron micrographs of 
WT (A) or three independent POM-ERJ resistant S. schleiferi strains (B-D). Scale bars = 500 nm. (E) Distribution of cell wall thickness in 
WT and POM-ERJ resistant S. schleiferi as measured in a total of 300 cells from three independent experiments of 100 cells each. Midline 
indicates mean of all measurements. 
 
105 
 
 
Figure 3 Structures of antistaphylococcal inhibitors used in this study. Structures are grouped by mechanism of action. For prodrugged 
compounds, promoieties are highlighted in pink. 
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Figure 4 Cross-resistance to lipophilic ester prodrugs in POM-ERJ-resistant S. schleiferi. WT and POM-ERJ resistant S. schleiferi 
were treated with the compounds displayed in Figure 3. Compounds are grouped by mechanism of action and color coded to indicate 
whether a given compound is a carboxy ester prodrug. Displayed are the mean values of the fold change (resistant isolate/WT) of three 
independent experiments performed in technical duplicate. * indicates compounds whose MIC values were too high to measure. Numerical 
data additionally provided in Table S2. 
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Figure 5 POM-ERJ resistant staphylococci are enriched for mutations in the locus encoding hydroxyacylglutathione hydrolase 
(GloB). (A) Locations and identities of GloB mutations discovered by whole-genome sequencing and independently verified by Sanger 
sequencing. Line coloring represents predicted impact of a given mutation on GloB function, scores below -2.5 are predicted to be 
deleterious. (B, C) Homology models of S. schleiferi (B) and S. pseudintermedius (C) GloB generated using SWISS-MODEL. Residues 
found to be mutated in POM-ERJ resistant staphylococci explicitly shown in blue. 
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Figure 6 Enzymatic function of GloB. (A) Enzymatic catalysis of S-lactoylglutathione by GloB. DTNB conversion to TNB results in 
increased absorbance at 412 nm. (B) Reaction progress curve for SsGloB (blue) and catalytically inactive SsGloB H54N (pink), using S-
lactoylglutathione as a substrate. (C) SsGloB and SsGloB H54N specific activity for S-lactoylglutathione. Displayed are the means ± SD 
from three independent experiments performed in technical duplicate. 
109 
 
 
Figure 7 GloB functions activates POM-prodrugs in vitro and in vivo. (A) Recombinant SsGloB, catalytically inactive SsGloB H54N, 
GloB from S. aureus (SaGloB), or buffer were incubated with POM-ERJ and prodrug concentrations were measured by LC-MS. (B) Wild-
type and POM-ERJ-resistant gloB mutant S. schleiferi isolates were treated with POM-ERJ and intracellular drug concentrations were 
measured by LC-MS. Displayed are the mean values ± SD from three independent experiments. Error bars may not be visible due to 
precision in measurement. 
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Figure S1 Growth rates of WT and POM-ERJ resistant S. schleiferi. (A) Average optical density (600 nm) of WT and POM-ERJ 
resistant S. schleiferi in LB media. Average is of three biological replicates in technical duplicate. (B) Doubling times for WT and POM-ERJ 
resistant S. schleiferi in LB media. Experiment performed in technical duplicate and biological triplicate. Error bars denote SEM. Means are 
not statistically different [Kruskal-Wallis test (p = 0.179)]. 
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Figure S2 SDS-PAGE/Coomassie of purified recombinant SsGloB, SsGloBH54N, and SaGloB. 
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Figure S3 GloB does not have β-lactamase activity. (A) Nitrocefin activation mechanism. Cleavage of the β-lactam ring results in 
increased absorbance at 486 nm. (B) Progress curve for nitrocefin cleavage by SsGloB, SsGloBH54N, and commercially available β-lactamase 
from B. cereus. (C). Specific activity for SsGloB, SsGloBH54N, and B. cereus β-lactamase against nitrocefin. 
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Figure S4 Assay validation for SsGloB S-lactoylglutathione cleavage and detection via DTNB. (A) S-lactoylglutathione cleavage rate as 
a function of increasing SsGloB. (B) SsGloB metal dependence for cleavage of S-lactoylglutathione. SsGloB was incubated with 1 mM of 
each divalent salt prior to S-lactoylglutathione reaction initiation. 
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Figure S5 NMR characterization of POM-ERJ and POM-HEX prodrug activation by SsGloB and SaGloB. Two-dimensional (2D) 
1H-31P HSQC NMR spectra of products following incubation of SaGloB, SsGloB, catalytically inactive (boiled) GloB, or buffer alone with 
POM-ERJ (A) or POM-HEX (B). Also included are the 1H-31P HSQC NMR spectra of ERJ and HEX. Displayed are representative traces of 
three independent experiments.  
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Figure S6 Phylogenetic trees of GloB (A) and RpoB (B) sequences. Pink highlighting overlain on staphylococcal species. 
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Figure S7 Structural conservation of GloB. Alignment between HsGloB (orange, PDB ID: 1qh5) and SsGloB (blue) homology model. (A) 
Overall protein alignment, RMSD = 1.528Å. (B) Metal binding pocket (left), sequence alignment of residues contacting the bound Zn (HsGloB) 
and their analogous residues colored according to amino acid chemical properties (right). (C) Substrate binding pocket (left), sequence alignment 
of residues contacting the bound glutathione colored according to amino acid chemical properties (GSH, right).
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3.7 Tables 
Table S1: Zones of inhibition for POM-ERJ resistant zoonotic staphylococci against common frontline therapeutics. Presented are the zones of inhibition and whether the isolate is sensitive to the 
therapeutic (S), resistant (R), or intermediate (*) according to Clinical and Laboratory Standards Institute (CLSI) standard breakpoints. 
    
WT S. 
pseudintermedius Sp80xa Sp80xb Sp80xc Sp80xd 
Antimicrobial Mechanism of Action 
Zone (in 
mm) S/R? 
Zone 
(in 
mm) S/R? 
Zone 
(in mm) S/R? 
Zone 
(in mm) S/R? 
Zone 
(in mm) S/R? 
Cefoxitin Cell wall synthesis inhibitor 40 * 40 * 40 * 40 * 41 * 
Penicillin Cell wall synthesis inhibitor 21 R 24 R 24 R 26 R 22 R 
Ceftaroline Cell wall synthesis inhibitor 36 * 37 S 37 S 38 S 36 S 
Linezolid Protein Synthesis Inhibitor 38 S 38 S 37 S 39 S 38 S 
Doxycycline Protein Synthesis Inhibitor 32 S 34 S 34 S 36 S 34 S 
Rifampin RNA synthesis inhibitor 37 S 37 S 38 S 41 S 37 S 
TMP-SMX 
DHFR inhibitor 
(thymidine/DNA synthesis) 33 S 34 S 35 S 35 S 34 S 
Clindamycin Protein Synthesis Inhibitor 29 S 30 S 30 S 30 S 30 S 
Erythromycin Protein Synthesis Inhibitor 32 S 33 S 36 S 35 S 32 S 
Vancomycin Cell wall synthesis inhibitor 20 * 20 * 20 * 22 * 20 * 
Delafloxacin DNA gyrase inhibitor 51 * 53 * 52 * 54 * 52 * 
Chloromphenicol Protein Synthesis Inhibitor 25 S 25 S 25 S 26 S 25 S 
Synercid Protein Synthesis Inhibitor 30 S 32 S 32 S 31 S 32 S 
Ciprofloxacin DNA gyrase inhibitor 37 S 40 S 39 S 39 S 39 S 
Gentamicin PRotein Synthesis Inhibitor 33 S 35 S 34 S 35 S 34 S 
Nitrofurantoin RNA and DNA disruption 25 S 28 S 28 S 31 S 26 S 
Oxacillin Cell wall synthesis inhibitor 22 S 22 S 21 S 23 S 22 S 
                        
Daptomycin (e-test) 
Cell membrane disruptor, cell 
depolarizer 0.032 S 0.032 S 0.032 S 0.064 S 0.047 S 
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  Sp80xe Sp80xf Sp80xg Sp80xh SpMJ40.1 SpMJ40.2 Sp40xa 
Antimicrobial 
Zone 
(in mm) S/R? 
Zone 
(in mm) S/R? 
Zone 
(in mm) S/R? 
Zone 
(in mm) S/R? 
Zone 
(in mm) S/R? 
Zone 
(in mm) S/R? 
Zone 
(in mm) S/R? 
Cefoxitin 41 * 40 * 41 * 40 * 40 * 40 * 37 * 
Penicillin 24 R 24 R 24 R 23 R 23 R 21 R 17 R 
Ceftaroline 37 S 38 S 36 S 36 S 37 S 36 S 33 S 
Linezolid 37 S 37 S 38 S 38 S 38 S 36 S 34 S 
Doxycycline 34 S 35 S 34 S 33 S 38 S 33 S 31 S 
Rifampin 37 S 37 S 37 S 38 S 38 S 38 S 34 S 
TMP-SMX 35 S 34 S 35 S 34 S 34 S 34 S 32 S 
Clindamycin 30 S 30 S 30 S 29 S 29 S 29 S 26 S 
Erythromycin 33 S 33 S 32 S 32 S 33 S 33 S 29 S 
Vancomycin 20 * 21 * 20 * 20 * 20 * 20 * 18 * 
Delafloxacin 52 * 53 * 52 * 53 * 52 * 52 * 42 * 
Chloromphenicol 25 S 25 S 25 S 25 S 26 S 25 S 24 S 
Synercid 32 S 32 S 32 S 32 S 33 S 31 S 30 S 
Ciprofloxacin 40 S 39 S 39 S 39 S 39 S 38 S 36 S 
Gentamicin 35 S 34 S 35 S 33 S 34 S 32 S 30 S 
Nitrofurantoin 27 S 27 S 27 S 27 S 26 S 26 S 24 S 
Oxacillin 22 S 21 S 22 S 22 S 22 S 22 S 22 S 
                              
Daptomycin (e-test) 0.047 S 0.032 S 0.032 S 0.032 S 0.032 S 0.047 S 0.047 S 
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  Sp40xb Sp40xc Sp40xd Sp40xf Sp40xh Sp40xe Sp40xf 
Antimicrobial 
Zone 
(in mm) S/R? 
Zone 
(in mm) S/R? 
Zone 
(in mm) S/R? 
Zone 
(in mm) S/R? 
Zone 
(in mm) S/R? 
Zone 
(in mm) S/R? 
Zone 
(in mm) S/R? 
Cefoxitin 39 * 36 * 38 * 38 * 38 * 40 * 38 * 
Penicillin 22 R 18 R 21 R 22 R 21 R 21 R 20 R 
Ceftaroline 36 S 34 S 34 S 34 S 34 S 35 S 35 S 
Linezolid 36 S 35 S 33 S 35 S 34 S 36 S 35 S 
Doxycycline 34 S 31 S 31 S 34 S 32 S 36 S 38 S 
Rifampin 35 S 34 S 34 S 35 S 36 S 36 S 35 S 
TMP-SMX 35 S 32 S 33 S 34 S 33 S 34 S 34 S 
Clindamycin 29 S 26 S 27 S 28 S 28 S 28 S 28 S 
Erythromycin 31 S 29 S 30 S 29 S 30 S 31 S 31 S 
Vancomycin 20 * 18 * 19 * 19 * 20 * 20 * 20 * 
Delafloxacin 50 * 48 * 49 * 49 * 49 * 50 * 50 * 
Chloromphenicol 25 S 25 S 24 S 25 S 25 S 26 S 26 S 
Synercid 31 S 30 S 30 S 30 S 30 S 31 S 30 S 
Ciprofloxacin 38 S 37 S 36 S 36 S 36 S 36 S 37 S 
Gentamicin 30 S 29 S 29 S 31 S 30 S 31 S 29 S 
Nitrofurantoin 27 S 25 S 26 S 27 S 25 S 28 S 27 S 
Oxacillin 23 S 21 S 22 S 27 S 22 S 22 S 22 S 
                              
Daptomycin (e-test) 0.023 S 0.047 S 0.032 S 0.047 S 0.016 S 0.023 S 0.023 S 
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  WT S. schleiferi Ss40xa Ss40xd Ss40xg Ss40xe 
Antimicrobial 
Zone 
(in 
mm) S/R? 
Zone 
(in 
mm) S/R? 
Zone 
(in 
mm) S/R? 
Zone 
(in 
mm) S/R? 
Zone 
(in 
mm) S/R? 
Cefoxitin 36 * 39 * 35 * 36 * 36 * 
Penicillin 50 S 48 S 58 S 46 S 48 S 
Ceftaroline 42 * 42 * 42 * 40 * 40 * 
Linezolid 33 S 32 S 32 S 36 S 32 S 
Doxycycline 33 S 32 S 31 S 38 S 31 S 
Rifampin 37 S 36 S 36 S 38 S 35 S 
TMP-SMX 29 S 27 S 27 S 28 S 28 S 
Clindamycin 29 S 29 S 27 S 29 S 26 S 
Erythromycin 30 S 28 S 29 S 30 S 27 S 
Vancomycin 19 * 19 * 19 * 20 * 18 * 
Delafloxacin 42 * 40 * 41 * 41 * 40 * 
Chloromphenicol 25 S 26 S 25 S 24 S 23 S 
Synercid 30 S 30 S 31 S 29 S 28 S 
Ciprofloxacin 32 S 31 S 31 S 30 S 30 S 
Gentamicin 33 S 30 S 29 S 30 S 28 S 
Nitrofurantoin 25 S 25 S 24 S 24 S 23 S 
Oxacillin 25 S 26 S 25 S 26 S 25 S 
                      
Daptomycin (e-test) 0.047 S 0.047 S 0.032 S 0.032 S 0.047 S 
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  Ss80xa Ss80xe Ss80xf Ss80xg 
Antimicrobial 
Zone 
(in 
mm) S/R? 
Zone 
(in 
mm) S/R? 
Zone 
(in 
mm) S/R? 
Zone 
(in 
mm) S/R? 
Cefoxitin 36 * 34 * 34 * 35 * 
Penicillin 50 S 48 S 48 S 48 S 
Ceftaroline 42 * 42 * 42 * 42 * 
Linezolid 35 S 34 S 35 S 40 S 
Doxycycline 33 S 31 S 33 S 35 S 
Rifampin 37 S 35 S 38 S 37 S 
TMP-SMX 27 S 29 S 29 S 30 S 
Clindamycin 29 S 28 S 31 S 31 S 
Erythromycin 32 S 30 S 35 S 35 S 
Vancomycin 19 * 18 * 21 * 20 * 
Delafloxacin 42 * 41 * 43 * 43 * 
Chloromphenicol 25 S 24 S 28 S 27 S 
Synercid 30 S 30 S 32 S 33 S 
Ciprofloxacin 32 S 31 S 32 S 34 S 
Gentamicin 30 S 29 S 31 S 33 S 
Nitrofurantoin 24 S 24 S 26 S 27 S 
Oxacillin 25 S 26 S 26 S 27 S 
                  
Daptomycin (e-test) 0.047 S 0.032 S 0.047 S 0.047 S 
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Table S2 Minimum inhibitory concentrations (MIC) for values for selected antistaphylococcals against POM-ERJ resistant staphylococci, R1-R3. Displayed are the mean ± SD of three 
independent biological experiments performed in technical duplicate. In some cases, SD is listed as N/A as MIC values are discrete measurements and each replicate provided the same measurement, 
hence there is no variability.  
Compound Wild-Type R1 R2 R3 
  
MIC 
(μM) SD MIC (μM) SD 
MIC 
(μM) SD MIC (μM) SD 
FSM 6.3 N/A 5.2 1.6 5.2 1.6 5.2 1.6 
FR-900098 500 N/A 500 N/A 500 N/A 500 N/A 
BOM-ERJ 7.9 4.6 27 N/A 27 N/A 27 N/A 
POM-ERJ 0.50 N/A 180 N/A 37 13 180 N/A 
  
        
Cefditoren Sodium 0.74 0.54 0.55 0.27 0.59 0.23 0.59 0.23 
Cefditoren Pivoxil 0.76 N/A 12 N/A 6.0 N/A 10 3.1 
  
        
HEX 
        
POM-HEX 3.1 N/A 100 N/A 50 N/A 100 N/A 
  
        
Mupirocin 0.010 0.0041 0.010 0.0041 0.010 0.0041 0.0092 0.0032 
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Table S3. Single Nucleotide Polymorphisms identified via whole-genome sequencing. 
Strain Species Base 
WT 
Allele SNP 
Read 
Depth Gene Annotation 
sp40xa S. pseudintermedius 45418 G A 5 SPSE_0038 P-type Copper Transporter 
sp40xa S. pseudintermedius 1282386 A T 219 SPSE_1252  Hydroxyacylglutathione hydrolase 
sp40xa S. pseudintermedius 2227530 C A 562 SPSE_2164 Putative glutamyl-endopeptidase 
sp40xa S. pseudintermedius 2228995 C A 519 SPSE_2165 Putative glutamyl-endopeptidase 
sp40xb S. pseudintermedius 45418 G A 5 SPSE_0038 P-type Copper Transporter 
sp40xb S. pseudintermedius 1282347 C A 230 SPSE_1252  Hydroxyacylglutathione hydrolase 
sp40xc S. pseudintermedius 45418 G A 5 SPSE_0038 P-type Copper Transporter 
sp40xc S. pseudintermedius 1110010 A T 75 SPSE_1082 Transposase 
sp40xc S. pseudintermedius 2227530 C A 722 SPSE_2164 Putative glutamyl-endopeptidase 
sp40xd S. pseudintermedius 1282655 C T 358 SPSE_1252  Hydroxyacylglutathione hydrolase 
sp40xe S. pseudintermedius 1282745 G T 406 SPSE_1252  Hydroxyacylglutathione hydrolase 
sp40xe S. pseudintermedius 1651160 C A 493 SPSE_1610 Putative oxidoreductase 
sp40xf S. pseudintermedius 1282565 C T 283 SPSE_1252  Hydroxyacylglutathione hydrolase 
sp40xf S. pseudintermedius 2228995 C A 618 SPSE_2165 Putative glutamyl-endopeptidase 
sp40xg S. pseudintermedius 2228995 C A 526 SPSE_2165 Putative glutamyl-endopeptidase 
sp40xh S. pseudintermedius 1282347 C A 279 SPSE_1252  Hydroxyacylglutathione hydrolase 
sp40xh S. pseudintermedius 1651160 C A 492 SPSE_1610 Putative oxidoreductase 
sp40xh S. pseudintermedius 2227530 C A 611 SPSE_2164 Putative glutamyl-endopeptidase 
sp80xa S. pseudintermedius 1282655 C T 328 SPSE_1252  Hydroxyacylglutathione hydrolase 
sp80xb S. pseudintermedius 2227530 C A 679 SPSE_2164 Putative glutamyl-endopeptidase 
sp80xc S. pseudintermedius 1282655 C T 372 SPSE_1252  Hydroxyacylglutathione hydrolase 
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Strain Species Base 
WT 
Allele SNP 
Read 
Depth Gene Annotation 
sp80xd S. pseudintermedius 2228995 C A 586 SPSE_2165 Putative glutamyl-endopeptidase 
sp80xe S. pseudintermedius 668455 T G 5 SPSE_0610 RNA-directed DNA polymerase 
sp80xe S. pseudintermedius 1282874 G A 292 SPSE_1252  Hydroxyacylglutathione hydrolase 
sp80xe S. pseudintermedius 1651160 C A 415 SPSE_1610 Putative oxidoreductase 
sp80xf S. pseudintermedius 668455 T G 6 SPSE_0610 RNA-directed DNA polymerase 
sp80xf S. pseudintermedius 1282386 A T 327 SPSE_1252  Hydroxyacylglutathione hydrolase 
sp80xf S. pseudintermedius 2227530 C A 545 SPSE_2164 Putative glutamyl-endopeptidase 
sp80xg S. pseudintermedius 1282347 C A 280 SPSE_1252  Hydroxyacylglutathione hydrolase 
sp80xg S. pseudintermedius 2227530 C A 613 SPSE_2164 Putative glutamyl-endopeptidase 
sp80xh S. pseudintermedius 1282385 G T 35 SPSE_1252  Hydroxyacylglutathione hydrolase 
sp80xh S. pseudintermedius 2228043 A C 174 SPSE_2164 Putative glutamyl-endopeptidase 
sp80xh S. pseudintermedius 2227746 C A 226 SPSE_2164 Putative glutamyl-endopeptidase 
sp80xh S. pseudintermedius 2227738 G A 242 SPSE_2164 Putative glutamyl-endopeptidase 
sp80xh S. pseudintermedius 2227731 C A 251 SPSE_2164 Putative glutamyl-endopeptidase 
sp80xh S. pseudintermedius 2227735 G C 255 SPSE_2164 Putative glutamyl-endopeptidase 
sp80xh S. pseudintermedius 2227530 C A 579 SPSE_2164 Putative glutamyl-endopeptidase 
sp80xh S. pseudintermedius 2228995 C A 589 SPSE_2165 Putative glutamyl-endopeptidase 
spmj401 S. pseudintermedius 1282794 G T 225 SPSE_1252  Hydroxyacylglutathione hydrolase 
spmj401 S. pseudintermedius 2228995 C A 520 SPSE_2165 Putative glutamyl-endopeptidase 
spmj402 S. pseudintermedius 1282329 G T 240 SPSE_1252  Hydroxyacylglutathione hydrolase 
spmj402 S. pseudintermedius 2227530 C A 597 SPSE_2164 Putative glutamyl-endopeptidase 
ss40xa S. schleiferi 925052 G A 526 gatA Galactitol PTS system EIIA component 
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Strain Species Base 
WT 
Allele SNP 
Read 
Depth Gene Annotation 
ss40xd S. schleiferi 925052 G A 465 gatA Galactitol PTS system EIIA component 
ss40xe S. schleiferi 178904 G T 543 LH95_00765 Putative Tributyrin Esterase 
ss40xf S. schleiferi 124153 G T 564 murQ 
N-acetylmuramic acid 6-phosphate 
etherase  
ss40xg S. schleiferi 971929 G A 18 LH95_04455 tRNA Val 
ss40xg S. schleiferi 971915 A T 43 LH95_04455 tRNA Val 
ss40xg S. schleiferi 971919 G T 43 LH95_04455 tRNA Val 
ss40xg S. schleiferi 971911 C A 45 LH95_04455 tRNA Val 
ss40xg S. schleiferi 971900 G T 155 LH95_04455 tRNA Val 
ss40xg S. schleiferi 2095855 T C 541 LH95_09910 
Potassium-transporting ATPase 
potassium-binding subunit 
ss80xa S. schleiferi 1282737 C A 347 LH95_06060 Hydroxyacylglutathione hydrolase 
ss80xe S. schleiferi 1282513 G A 424 LH95_06060 Hydroxyacylglutathione hydrolase 
ss80xe S. schleiferi 1291886 G A 386 LH95_06115 Lipoyl(octanoyl) transferase 
ss80xf S. schleiferi 1282335 C T 289 LH95_06060 Hydroxyacylglutathione hydrolase 
ss80xg S. schleiferi 1291886 G A 294 LH95_06115 Lipoyl(octanoyl) transferase 
ss80xh S. schleiferi 1319671 G T 406 LH95_06255 Ribonuclease Z 
ss80xh S. schleiferi 1478053 C G 458 LH95_07010 Unknown function 
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Table S4. Primers used during this study. 
Primer Sequence Gene Species  Purpose 
ATATCGCTGCATTAGATGATG SPSE_1252(gloB) S. pseudintermedius Sequencing 
AGGCACATCATATCGTGTTAG SPSE_1252(gloB) S. pseudintermedius Sequencing 
TGCTGCATTCCTTCATCAAGTG SPSE_1252(gloB) S. pseudintermedius Sequencing 
CCGTTCAATAAAGGGCTCGATC SPSE_1252(gloB) S. pseudintermedius Sequencing 
TGATGAATTTGCAGTAGTGGGC SPSE_1252(gloB) S. pseudintermedius Sequencing 
TTAACCTTGACCGTCTAAAAACG SPSE_1252(gloB) S. pseudintermedius Sequencing 
CTGGGCAAAAGCAGTATTGACAGGC SPSE_2164 S. pseudintermedius Sequencing 
GTTAGCGGTTTCACAGATGCC SPSE_2164 S. pseudintermedius Sequencing 
AGTTCGGGTTATTCATCCTAACACC SPSE_2164 S. pseudintermedius Sequencing 
CGTCAACTGTCGCATTAACTGC SPSE_2164 S. pseudintermedius Sequencing 
TAATTTGCGTTTTTGTTAACCC SPSE_2164 S. pseudintermedius Sequencing 
GTTAGCGGTTTCACAGATGCC SPSE_2164 S. pseudintermedius Sequencing 
ATGAAAATTTCCTACCTGACTTTAG LH95_06060(gloB) S. schleiferi Sequencing 
ATTTTTTTTGATTCTGAAGATGGG LH95_06060(gloB) S. schleiferi Sequencing 
ATGCACAGCCTACTGCGATCGAAG LH95_06060(gloB) S. schleiferi Sequencing 
TTACTCATGCACATTTTGATC LH95_06060(gloB) S. schleiferi Sequencing 
AATGCCCAGGTGTATGCAATGC LH95_06060(gloB) S. schleiferi Sequencing 
TTAGCCATGAAGATAAGGATTC LH95_06060(gloB) S. schleiferi Sequencing 
GGAGTGAGTATTTTGGCACG LH95_00765 S. schleiferi Sequencing 
AGGATCAAAAGGTGTCCCCACAAC LH95_00765 S. schleiferi Sequencing 
GCGGTGATTATGCCCAATGCAGACC LH95_00765 S. schleiferi Sequencing 
TTATACCATCTCACGCGTATGATGG LH95_00765 S. schleiferi Sequencing 
CTCACCACCACCACCACCATATGAAAATTTCCTACCTGACTTTAG LH95_06060(gloB) S. schleiferi  LIC Cloning 
ATCCTATCTTACTCACTTAGCCATGAAGATAAGGATTC LH95_06060(gloB) S. schleiferi  LIC Cloning 
CTCACCACCACCACCACCATATGAATATTTCTAATCTTACTTTAG SPSE_1252(gloB) S. pseudintermedius LIC Cloning 
ATCCTATCTTACTCACTTAACCTTGACCGTCTAAAAACG SPSE_1252(gloB) S. pseudintermedius LIC Cloning 
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4.1 Abstract 
 
Carboxy ester prodrugs have been widely employed as a means of increasing oral absorption and 
potency of phosphonate antibiotics. These prodrugs can be used to mask problematic drug 
residues that prevent cellular uptake as well as target delivery of compounds to specific tissue 
types. Unfortunately, many carboxy ester promoieties are rapidly hydrolyzed by serum esterases 
limiting their potential benefits in clinical applications. While carboxy ester-based prodrug 
targeting is feasible, it has been limited in microbes due to a paucity of information about the 
selectivity of microbial esterases. Here we identify the bacterial esterases, GloB and FrmB, 
which are required for carboxy ester prodrug activation in Staphylococcus aureus. Additionally, 
we determine the substrate specificities for FrmB and GloB, and demonstrate the structural basis 
of these preferences. Finally, we establish the carboxy ester substrate specificities of human and 
mouse sera, identifying several promoieties likely to be serum esterase resistant while still being 
microbially labile. 
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4.2 Introduction 
Antimicrobial resistance presents a major challenge to modern healthcare (1, 2). In 2019, 2.8 
million antibiotic resistant infections occurred in the United States and resulted in 35,000 deaths 
(3). Some estimates have suggested that antimicrobial resistant infections will cause as many as 
10 million deaths annually in 2050 (4). Staphylococcus aureus is an efficient human pathogen 
capable of displaying methicillin-resistance and has been labeled a “serious threat” by the 
Centers for Disease Control and Prevention (3, 5, 6). New antimicrobials, especially those with 
novel mechanisms of action, are urgently needed, however most developing antiinfectives are 
reformulations of existing antibiotic scaffolds (7, 8). 
While many metabolic processes are essential for microbial growth and pathogenesis, few 
existing antimicrobials exploit this target making bacterial metabolism a promising avenue for 
new antibiotic discovery (9–11). Metabolic drug design can be facile, using natural substrates as 
a template for competitive inhibitors. As metabolism often involves the transformation of highly 
charged metabolites, most metabolic inhibitors deploy phosphonate functional groups to achieve 
target binding (12). Unfortunately, these negatively charged phosphonate groups are readily 
excluded from cell membranes and often exhibit poor drug-like properties (13–21). New 
strategies enabling effective deployment of antimetabolites will serve to expand the druggable 
space for antimicrobials.  
One means of improving phosphonate cellular permeability is to chemically mask the negative 
charge with lipophilic groups. This action, termed prodrugging, can be designed as a reversible 
process such that the original phosphonate antibiotic is returned following removal of the 
masking group, termed promoiety (Figure 1A) (19–21). We have previously demonstrated that 
addition of the lipophilic prodrugging motif, pivaloyloxymethyl (POM), to the isoprenoid 
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biosynthesis inhibitor, fosmidomycin, bypasses active cellular entry mechanisms while 
simultaneously increasing compound potency against the zoonotic staphylococci, S. schleiferi 
and S. pseudintermedius (14). Similar potency increases have been observed for this class of 
compounds against several additional microorganisms (16, 22–25). Regrettably, POM-
promoieties are rapidly hydrolyzed by serum carboxylesterases limiting the efficacy of POM-
prodrugs as a means of improving phosphonate cellular entry (15, 26). 
 
To enable effective cellular delivery of phosphonate antibiotics, new lipophilic prodrugging 
strategies that are resistant to serum carboxylesterases yet cleavable by microbial esterases are 
needed. This feat has been achieved for prodrugs targeting delivery to human liver cells, but no 
strategies have been described yet enabling drug delivery specifically to microbes (27, 28). 
Notably, liver-targeted prodrug delivery was achieved by understanding the substrate specificity 
of the liver specific isoform of P450, CYP3A4 (27, 28). Accordingly, understanding how 
microbes activate prodrugs, and the specificities of their activating enzymes, will facilitate the 
development of microbe-specific prodrugs. 
 
We recently described the staphylococcal enzyme, GloB, which is responsible for partially 
activating carboxy ester prodrugs in the zoonotic staphylococci S. schleiferi and S. 
pseudintermedius (29). Notably, GloB is unable fully activate prodrugs in vitro, suggesting that 
at least one additional enzyme is necessary for complete prodrug activation. Here, we describe 
how two staphylococcal esterases, GloB and FrmB, each act on carboxy ester prodrugs and 
contribute to carboxy ester prodrug activation in S. aureus. We demonstrate that both esterases 
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have defined substrate specificities which diverge from the substrate specificities of human and 
mouse sera. Additionally, we demonstrate that ester modifications have critical roles during the 
in vivo activation of prodrugs, and finally we present the three-dimensional structures of GloB 
and FrmB to enable structure-guided design of FrmB and GloB targeted prodrug activation. 
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4.3 Methods 
4.3.1 Materials. POM-HEX, Hemi-HEX, and HEX were synthesized and resuspended in 
DMSO as described previously. Fluorescent ester compounds were generously provided by the 
laboratory of Geoffrey Hoops (30). Pooled, delipidated, defibronated, and lyophilized human and 
mouse serum was obtained from Rockland Inc. 
4.3.2 Quantification of resistance. Half maximal inhibitory concentration (IC50) 
determination was performed using microtiter broth dilution in clear 96-well plates (31). Briefly, 
POM-HEX was added to 75 µL LB media at a final concentration of 20 – 50 µM POM-HEX and 
0.5% DMSO, with POM-HEX concentrations varying according to resistant strain. 
Subsequently, POM-HEX was serially diluted in LB media containing 0.5% DMSO for a total of 
10 dilutions. Two wells were left without drug, one used to define 100% growth, and the other 
used to control for media contamination and to define 0% growth. 75 µL of mid-log phase S. 
aureus diluted to 1 x 105 colony forming units/mL were subsequently added to the plate. 
Following inoculation, plates were incubated at 37 ºC with shaking, and OD600 measurements 
were taken every 20 minutes for a total of 16 hours. Half maximal inhibitory concentrations were 
determined by fitting the OD600 of each condition following 10 hours of growth to a nonlinear 
regression using GraphPad Prism software. Experiments were performed in triplicate with 
technical duplicates. 
 
4.3.3 Generation of POM-HEX resistant strains was performed by plating log-phase S. 
aureus Newman on LB agar containing 3.33 μM POM-HEX and incubating at 37 °C overnight. 
Surviving single colonies were grown overnight in LB media and frozen in 10% glycerol for 
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long term storage. All assays were performed from fresh overnight inoculations from glycerol 
stocks. 
 
4.3.4 Whole Genome Sequencing. Genomic DNA integrity was determined using Agilent 
4200 Tapestation. Library preparation was performed with 0.25-0.5ug of DNA. DNA was 
fragmented using a Covaris E220 sonicator using peak incident power 175, duty factor 10%, 
cycles per burst 200 for 240 seconds at 4 degrees Celsius. DNA was blunt ended, had an A base 
added to the 3’ ends, and then had Illumina sequencing adapters ligated to the ends. Ligated 
fragments were then amplified for 9 cycles using primers incorporating unique dual index tags. 
Fragments were sequenced on an Illumina MiSeq using paired-end reads extending 150 bases. 
4.3.5 WhatsGNU Analysis. The S. aureus database was used to produce WhatsGNU 
proteomic reports for all the strains using WhatsGNU_main.py script in the ortholog 
mode. Eighteen S. aureus (9 atopic dermatitis (AD) and 9 soft and skin tissue infection 
(SSTI)) isolates from an ongoing project representing different clonal complexes 
(CC1/5/8/22/30) were used for the comparison. The CC details for the 18 isolates are provided in 
the attached excel sheet. The reports were then used to produce a heat map of the GNU scores of 
GloB and FrmB using the heat map function in the WhatsGNU_plotter.py script. The heatmap 
was annotated with the ortholog variant rarity index where 'r' represents a rare GNU score (in the 
context of other alleles in the same protein ortholog group). 
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4.3.6 Phylogenetic tree construction. Sequences of GloB, FrmB, and RpoB orthologs were 
retrieved from NCBI using the BlastP function with each organism on the tree as an individual 
search set. Of the returned sequences, the first complete sequence with the lowest E-value was 
selected for further analysis. Organisms were selected to include a wide variety of pathogenic 
and commensal microbes (32). In one instance, several of the top E. coli sequences were found 
to be highly similar to S. aureus, and on further analysis we discovered that the original 
sequencing samples had high levels of S. aureus reads. These contaminated sequences were 
disregarded in our analysis. Sequence alignment was performed using MUSCLE, and the 
unrooted phylogenetic trees were visualized using iTOL (33, 34). 
 
4.3.7 Recombinant expression and purification of FrmB and GloB. WT FrmB and GloB 
sequences from S. aureus were cloned into the BG1861 vector by GeneWiz Inc (Beijing, China) 
to introduce a hexahistidine tag (35). The resultant plasmids were transformed into Stellar 
chemically competent cells (Clontech Laboratories), selected with carbenicillin, and the 
sequence was confirmed by Sanger sequencing. Subsequently, plasmids were transformed into 
chemically competent BL21 (DE3) cells and selected with ampicillin. Overnight liquid cultures 
were diluted 1:500 into LB media supplemented with ampicillin, grown shaking at 220 rpm to an 
OD600 of 0.5-0.8 at 37 °C, chilled to 16 °C
 and induced with 0.5 mM Isopropyl β-D-1-
thiogalactopyranoside (IPTG) for 16-20 h. Cells were harvested by centrifugation at 6,000 x g 
for 10 min at 4°C. The cell pellet was lysed by sonication in 50 mL lysis buffer containing 25 
mM tris HCl (pH 7.5), 250 mM NaCl, 20 mM imidazole, 1 mM MgCl2, 10% glycerol, and 200 
µM phenylmethylsulfonyl fluoride (PMSF). Insoluble proteins were removed by centrifugation 
twice at 20,000 x g for 20 min. The hexahistidine-tagged proteins were affinity purified from 
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soluble lysate using nickel agarose beads (Gold Biotechnology). Bound protein was washed with 
50 mL lysis buffer before elution using 5 mL of elution buffer containing 25 mM tris HCl (pH 
7.5), 250 mM NaCl, 300 mM imidazole, 1 mM MgCl2, 10% glycerol. Affinity purified protein 
was further purified over a HiLoad 16/60 Superdex 200 gel filtration column (GE 
Healthsciences) using an AKTA Explorer. FPLC buffer contained 25 mM tris HCl (pH 7.5), 250 
mM NaCl, 1 mM MgCl2, and 10% glycerol. Fractions containing >90% pure protein (evaluated 
by SDS-PAGE) were concentrated using an Amicon Ultra-15 centrifugal unit (EMD Millipore) 
and flash frozen in liquid nitrogen before storage at -80°C. 
 
Protein used during crystallography experiments was generated via the same FrmB and GloB 
sequences, but expression was performed from vector pET28a. FrmB was cloned into the 
pET28a vector by GeneWiz Inc (Beijing, China) and GloB was cloned from the BG1861 vector 
using the forward primer 5’- TGCTCGAGTGCGGCCGCTTAACCGTGTAAAAATGGATTT3’ 
and the reverse primer 5’- CGCGCGGCAGCCATATGATGAGGATTTCAAGCTTAACTTT 
-3’. The PCR product was cloned into vector pET28a digested with restriction enzymes NotI and 
NdeI using InFusion HD Cloning (Takara Bio). Both cloning strategies introduce a hexahistidine 
tag followed by a thrombin cleavage sequence. FrmB and GloB encoding pET28a was 
transformed into chemically competent BL21 (DE3) cells. Protein expression of FrmB proceeded 
as previously, except FrmB containing cells were grown in Terrific broth.  
 
Selenomethionine labeled GloB was prepared according to Van Duyne with minor modifications 
(36). Briefly, overnight cultures were grown in LB media, washed, and resuspended in M9 
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minimal media (per liter: 64 g Na2HPO4, 15g KH2PO4, 2.5 g NaCl, and 5 g NH4Cl) 
supplemented with 50 mg EDTA, 8 mg FeCl3, 0.5 mg ZnCl2, 0.1 mg CuCl2, 0.1 mg CoCl2, 0.1 
mg H3BO3, 16 mg MnCl2, 0.1 mg Ni2SO4, 0.1 mg molybdic acid, 0.5 mg riboflavin, 0.5 mg 
niacinamide, 0.5 mg pyridoxine monohydrate, and 0.5 mg thiamine per liter. Resuspended 
cultures were grown overnight. The following day, cultures were back diluted 1:50 and grown to 
an OD600 of 0.5-0.8 at 37 °C. Once at the appropriate OD, the following amino acids were added 
to the culture media at: 100 mg/L: lysine, phenylalanine, and threonine, 50 mg/L: isoleucine, 
leucine, and valine, 60 mg/L: selenomethionine. Cultures were grown for an additional 15 
minutes at 37 °C before cells were chilled to 16 °C and induced with 0.5 mM IPTG for 16-20 
hours.  
Protein purification of FrmB and selenomethionine labeled GloB for crystallography proceeded 
as previously except following affinity purification the elution was dialyzed for 16-20 h at 4°C 
with 20U thrombin protease to remove the hexahistidine tag. Dialysis buffer contained 50 mM 
tris pH 7.5, 50 mM NaCl, and 1 mM MgCl2. Following dialysis, uncleaved protein, the 
hexahistidine tag, and thrombin were removed by flowing dialyzed protein over a benzamidine 
Sepharose and nickel agarose bead column. Column flow through was further purified over a 
HiLoad 16/60 Superdex 200 gel filtration column equilibrated with dialysis buffer. Protein was 
concentrated to 8-10 mg/mL in an Amicon Ultra-15 centrifugal unit and frozen at -80°C. 
 
4.3.8 Glyoxalase II activity assay. Glyoxalase II activity was assessed as previously with 
minor changes (29, 37). Briefly, reactions were mixed to form a final concentration of 25 mM 
Tris pH 7.5, 250 mM NaCl, 1 mM MnCl2, 10% glycerol, 200 µM 5,5’-Dithiobis(2-nitrobenzoic 
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acid) (DTNB, Sigma D8130), 1 mM D-lactoylglutathione (Sigma L7140) and 0.15-0.63 µg 
protein (130-550 nM GloB, 100-430 nM FrmB). Protein concentrations were varied to ensure the 
reaction was linear across protein concentrations. Reactions without D-lactoylglutathione were 
pre-incubated at 37 ºC for 10 minutes prior to assay initiation with the addition of substrate. 
Release of glutathione from D-lactoylglutathione was quantified spectrophotometrically at 37 ºC 
and 412 nm through the conversion of DTNB to TNB. Experiments were performed in triplicate 
with technical duplicates. 
 
4.3.9 4-nitrophenyl ester substrate activity assays. 4-nitrophenyl substrate specific activity 
was determined in 50 µL reactions containing 25 mM Tris pH 7.5, 250 mM NaCl, 1 mM MnCl2, 
10% glycerol, 1 µM protein, and 1 mM 4-nitrophenyl substrate. The tested substrates, 4-
nitrophenyl acetate (Sigma, N8130), 4-nitrophenyl butyrate (Sigma N9876), and 4-nitrophenyl 
trimethylacetate (Sigma 135046) were resuspended in acetonitrile at 100 mM. Reactions without 
4-nitrophenyl substrate were preincubated at 37 ºC for 10 minutes prior to assay initiation via 
substrate addition. Conversion of 4-nitrophenyl substrates to 4-nitrophenol was tracked 
photometrically at 37 ºC and 405 nm. Experiments were performed in triplicate with technical 
duplicates. 
 
4.3.10 NMR characterization of GloB and FrmB activation products. 200 or 400 µM POM-
HEX was incubated with 4 nmol protein (GloB, FrmB, or 4 nmol each) in 500 µL reactions. 
Reactions were buffered to a final concentration of 50 mM tris pH 7.5, 50 mM NaCl, 1 mM 
MgCl2. Reactions were allowed to proceed for 1 hour at 37 ˚C prior to analysis. Samples were 
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prepared for NMR studies by resuspending them in water  and 10% (50 µL) D2O (Deuterium 
Oxide 99.9% D, contains 0.75 wt% 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid, sodium salt, 
Sigma–Aldrich). NMR spectra are acquired on a Bruker Avance III HD 500 MHz spectrometer 
equipped with a cryoprobe. Two-dimensional (2D) 1H-31P heteronuclear single quantum 
correlation (HSQC) measurements were obtained using hsqcetgp pulse program (with duration 
of 15 minutes and scan parameters of 2 scans, td=1024 and 256, gpz2 %=32.40, 31P SW= 40 
ppm, O2p=20 ppm, cnst2=22.95) and analyzed using 3.1 TopSpin. The 1D projection of 
columns excluding the water signal was obtained from the 2D 1H-31P HSQC spectrum by 
obtaining spectra of positive projection of columns 1 to 600 and 650 to 1024 and adding them. 
 
4.3.11 Esterase substrate specificity determination using fluorogenic SAR library. Kinetic 
measurements were performed according to White et al. with minor variation (38). Lyophilized 
human and mouse sera were resuspended according to manufacturer instructions in highly pure, 
filtered water at protein concentrations of 85 mg/mL and 70 mg/mL respectively. 1 mL of 
resuspended serum was added to a 24 mL mastermix for a final concentration of 31.25 mM tris 
pH 7.5, 312.5 mM NaCl, 1.25 mM MgCl2, 12.5% glycerol, and 3.4 mg/mL or 2.8 mg/mL protein 
for human and mouse serum respectively. For purified proteins, 5 mL of a 75 µg/mL stock was 
added to yield a 20 mL mastermix containing 31.25 mM tris pH 7.5, 312.5 mM NaCl, 1.25 mM 
MgCl2, 12.5% glycerol, and 18.75 µg/mL protein. Mastermix was stored on ice when not in use. 
20 µL of mastermix was transferred to a black, 96-well half area microplate (Corning, CLS3993) 
and prewarmed at 37 °C. Fluorogenic substrates were prepared as 10 mM stock solutions in 
DMSO and were diluted in water to a starting concentration of 500 µM. Enzyme catalyzed 
substrate hydrolysis was initiated by addition of 5 µL substrate dilution in technical duplicate to 
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the prewarmed serum or protein solution. Final assay concentrations were: 25 mM tris pH 7.5, 
250 mM NaCl, 1 mM MgCl2, 10% glycerol, and protein at a concentration of 2.72 mg/mL 
(human serum), 2.24 mg/mL (mouse serum), or 15 µg/mL (FrmB, GloB). The resulting change 
in fluorescence (λex = 485 nm, λem = 520 nm) was followed for 15 minutes at 37 °C, collecting 
data every 30 seconds on a FLUOstar Omega microplate reader (BMG Labtech). Fluorescence 
measurements were converted to molar concentrations using a fluorescein standard curve (2.5 
nmol-0.6 pmol). The initial rates of reaction were measured three independent times with two 
technical replicates per measurement and fit to a line using Graphpad Prism (GraphPad Software, 
La Jolla, CA). Initial rates of reaction were plotted versus the concentration of substrate and fit to 
a standard Michaelis-Menten equation, yielding estimates of Vmax and Km. Values for kcat and 
kcat/Km were calculated based on amount of enzyme added when purified enzymes were used. 
For substrates where saturating conditions were not met, kcat/vmax was estimated using the 
following derivation of Michaelis Menten- 
Equation (1)       
 
When Km>>[S] 
Equation (2)      
 
Therefore 
Equation (3)      
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4.3.12 Microfluidics measurements on S. aureus. Overnight cultures of S. aureus were grown 
in LB media, back diluted 1:500, and grown to early exponential phase (OD600 0.1-0.15), then 
washed in phosphate buffered saline and loaded on a bacterial CellASIC Onix microfluidic plate. 
Prior to cell loading, the microfluidics plate lines were flushed with PBS + 1% DMSO or 10 µM 
fluorescent prosubstrate in PBS + 1% DMSO, and the plate was preincubated at 37 °C. The 
microfluidics plate was loaded onto a Nikon Ti-E inverted microscope (Nikon Instruments, Inc) 
equipped with a 100x Plan N (N.A. = 1.45) Ph3 objective, X-cite 120 LED light source (Lumen 
Dynamics), and an OrcaERG CCD camera (Hammamatsu Photonics, Bridgewater, N.J), which 
was used to obtain both phase contrast and fluorescent images. Filter sets were purchased from 
Chroma Technology Corporation. Cells were loaded until a single field of view contained 50-150 
cells or cell clusters. Following cell loading, PBS was flown through the flow cell (t = 0) and 
cells were observed in both phase and fluorescent channels for 10 minutes before the flow media 
was switched to PBS containing 1% DMSO and 10 µM fluorescent pro-substrate. Images were 
captured every two minutes for a total of 44 minutes, and all experiments were undertaken at 37 
°C. The phase contrast exposure time was kept constant at: 200 ms, and the fluorescent channel 
exposure time was kept constant at 500 ms. For fluorescent images, the gain remained constant 
across all experiments. Image capture and analysis was performed using Nikon Elements 
Advanced Research software. Individual cells or clusters of cells were auto detected in the 
fluorescent channel using the intrinsic background fluorescence of each cell. Manual curation 
followed autodetection to remove debris or cells that did not stay within the field of view 
throughout the experiment. Fluorescent intensity for each individual cell or cluster of cells was 
measured through the duration of the experiment and normalized to the area of the identified cell 
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to yield the mean fluorescent intensity. Background cell autofluorescence was corrected by 
subtracting the average fluorescence across all identified objects from t = 0 through t = 10. Each 
experiment was performed in duplicate, with >50 individual cells analyzed in each experiment. 
 
4.3.13 Protein crystallography, phasing, and data refinement. Crystals of S. aureus FrmB 
were grown at 16°C using vapor diffusion in 20 µL hanging drops containing a 1:1 mixture of 
protein (6 mg/mL) and crystallization buffer (0.1M Tricine pH 7.7, 15% PEG6K, 2.5M NaCl, 
0.125% n-Dodecyl-B-D-glucoside). Crystals were observable as early as 2 days following 
mixing. Prior to data collection, crystals were stabilized in cryoprotectant (mother liquor 
supplemented with 20% glycerol) before flash freezing in liquid nitrogen for data collection at 
100 K. Crystals of selenomethionine labeled S. aureus GloB were grown at 16 °C using vapor 
diffusion in 2 µL hanging drops containing a 1:1 mixture of protein (8 mg/mL) and 
crystallization buffer (0.1 M imidazole pH 6.9, 0.2 M ammonium sulfate, 0.1 M calcium 
chloride, and 21% PEG 8k). Selenomethionine labeled GloB crystals were stabilized in well 
solution supplemented with 15% glycerol and flash frozen in liquid nitrogen. All diffraction 
images were collected at beamline 19-ID of the Argonne National Laboratory Advanced Photon 
Source at Argonne National Laboratory. HKL3000 was used to index, integrate, and scale the 
data sets (39). To phase the initial dataset of FrmB, molecular replacement was performed in 
PHASER using the x-ray crystal structure of a low-temperature active alkaline esterase (PDB ID: 
4RGY) as a search model (40, 41). Selenomethionine labeled GloB was phased using the x-ray 
crystal structure of TTHA1623 from Thermus thermophilus HB8 (PDB ID: 2ZWR) (42). 
Buccaneer was used to build both initial models, and subsequent, iterative rounds of model 
building and refinement used COOT and PHENIX respectively (43–45). Data collection and 
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refinement statistics are summarized in Table S6. Atomic coordinates and structure factors of S. 
aureus FrmB and S. aureus GloB are deposited in the RCSB Protein Data Bank. 
 
4.3.13 Substrate Docking. GloB and FrmB structures were prepared for substrate autodocking 
using AutoDock Tools 1.5.7 (46). Metals and water molecules were removed from the crystal 
structure of FrmB as canonical serine hydrolases do not utilize metal in their reaction 
mechanism. Solvent water in the GloB crystal structure was removed, but the active site water 
and heavily coordinated zinc molecules were left in place. The three-dimensional structure of 
substrate 1O was generated using ChemDraw3D, and prepared for docking using AutoDock 
Tools 1.5.7.  Substrate docking of FrmB and GloB was performed using AutoDock Vina (47). 
 
4.3.14 Fresh human serum was collected from a willing volunteer in untreated BD vacutainer 
tubes (BD, BD366430). Whole blood was allowed to clot at room temperature and aggregates 
were separated from the remaining serum through centrifugation at 400 x g for 8 minutes. Sera 
was obtained from the same volunteer on two separate occasions. 
 
4.3.15 Serum half-life determination. Lyophilized human sera was obtained from Rockland 
Inc. and resuspended in pure water. 20 µL lyophilized sera or fresh sera was prewarmed at 37 ºC 
in a 96-well half area microplate (Corning, CLS3993). Following plate warming, 5 µL of the 
fluorogenic substrates were added to the plate for a final concentration of 25 µM. Substrate 
hydrolysis was tracked over a period of three hours at 37 ºC, with fluorescence measurements 
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(λex = 485 nm, λem = 520 nm) being taken every two minutes on a FLUOstar Omega microplate 
reader (BMG Labtech). The resulting fluorescence values were converted to % substrate 
hydrolyzed using a fluorescein standard curve and fit to a one-phase decay model using 
GraphPad Prism. Experiments were performed in technical and biological duplicate.  
 
4.4 Results  
4.4.1 Identification of microbial esterases responsible for carboxylesterase activity. 
Recently, we described that in the zoonotic staphylococcal species S. schleiferi and S. 
pseudintermedius, loss of the enzyme GloB, a hydroxyacylglutathione hydrolase, confers 
resistance to carboxy ester prodrugs because carboxy ester prodrugs do not become deprotected 
(29). However, purified GloB alone does not fully activate carboxy ester prodrugs in vitro, 
indicating that at least one additional cellular enzyme is required. Based on the predicted carboxy 
ester activation pathway, we predicted the missing enzyme(s) might be another carboxylesterase 
or a phosphodiesterase (Figure 1B). To identify the full suite of enzymes required for carboxy 
ester prodrug activation by S. aureus we made use of the Nebraska Transposon Mutant Library 
(NTML), in which nearly 2,000 of the non-essential genes of S. aureus have been individually 
disrupted by a stable transposon insertion (48). Using the gene ontology feature on the NTML 
website (https://app1.unmc.edu/fgx/gene-ontologies.html), we identified 6 carboxylic ester 
hydrolases (including GloB), 11 phosphatases, and 9 phosphoric diester hydrolases as candidate 
activators of carboxy ester prodrugs (Table S1), and screened each identified transposon mutant 
for resistance to the carboxy ester prodrug, POM-HEX. POM-HEX is a pivaloyloxymethyl 
prodrug of the compound, HEX, which inhibits enolase (Figure 1B, Figure 2A). Of the 26 
candidate esterase transposon mutants, only two strains were significantly more resistant to 
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POM-HEX than the S. aureus parental strain, JE2, as determined by half maximal growth 
inhibitory concentration (IC50) (Figure 2B). One of these strains had a transposon disrupting the 
glyoxalase II enzyme, GloB, which we have previously found to function as a prodrug activating 
enzyme, mutation in which confers resistance to POM-HEX in S. schleiferi (29). The second 
strain harbored a transposon insertion in the locus encoding the predicted carboxylesterase 
annotated as FrmB. FrmB has been previously identified as FphF, a serine hydrolase, and is the 
primary S. aureus target of the fluorophosphonate, JCP678 (49). As S-formylglutathione 
hydrolase is more likely to reflect the biological function of this protein, we will refer to this 
protein as FrmB. 
 
In parallel, we also employed an unbiased forward genetics approach to identify genetic changes 
associated with POM-HEX resistance. POM-HEX-resistant staphylococci were derived by 
exposing wild-type (WT) S. aureus Newman to growth inhibitory concentrations of POM-HEX. 
In total, we selected and cloned 25 isolates with IC50 values ranging from 1.5-16x that of WT S. 
aureus Newman (Figure 2 C, D, Supplemental Table 2).  
 
Whole genome sequencing of POM-HEX-resistant strains revealed mutations in FrmB (n = 7) 
and GloB (n = 10), with most mutations being nonsynonymous single nucleotide polymorphisms 
(SNPs) (Figure 2D, Supplemental Table 2). In three instances, GloB was the only verified 
genetic change in the genome. Additionally, FrmB and GloB each had one instance of a mutation 
resulting in a premature stop codon truncating the protein at less than a 100 amino acid sequence. 
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Overwhelmingly the observed mutations in both FrmB and GloB are predicted to have 
deleterious effects on protein function (PROVEAN score below a threshold of -2.5) (Figure 2E).  
 
To evaluate the sequence conservation of FrmB and GloB among S. aureus, we performed a 
WhatsGNU analysis on all available S. aureus genomes. WhatsGNU is a bioinformatic tool that 
can compress large databases and provide a readout of how many instances a specific gene has a 
100% sequence and identity match within the entire database (50). This parameter, the gene 
novelty unit (GNU) score, is high when a sequence is under strong selective pressure within the 
population, and low when the gene is variable. GloB exhibits an exceptionally high GNU score 
of 8215 (of 10350 possible) indicating that there is very strong selective pressure to maintain 
GloB in S. aureus. Conversely, FrmB sequences appear to be extremely conserved within 
individual S. aureus clonal complexes but varies between each complex (GNU scores of 2218 or 
3370 of 10350, Figure S1). We also built a phylogenetic tree of GloB and FrmB sequences 
among microbial populations. GloB orthologs are generally present, though the primary 
sequence is highly variable between bacteria and does not readily cluster according to the tree of 
life (Figure S2). FrmB sequences are also highly sequence divergent, though they tend to cluster 
closer to the expected tree of life (Figure S2). 
 
Ultimately, the agreement between our forward and reverse genetic screens strongly suggest that 
prodrug activation is performed by two discrete predicted esterases and not a pool of redundant 
cellular esterases. Additionally, the finding that mutation in either FrmB or GloB is sufficient to 
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confer POM-HEX resistance suggests that the two enzymes may work in concert to bioconvert 
POM-HEX into HEX. 
 
4.4.2 FrmB and GloB are carboxylesterases with diverging substrate specificity. 
GloB is predicted to be a type II glyoxalase and a member of the large metallo-β-lactamase 
protein superfamily (INTERPRO IPR001279). Glyoxalase II enzymes, including the closely 
related GloB ortholog from S. scheiferi, catalyze the second step in the glyoxalase pathway 
which is responsible for the cellular conversion of methylglyoxal (a toxic glycolytic byproduct) 
to lactic acid (29, 37, 51). Conversely, FrmB orthologs hydrolyze p-nitrophenyl esters of short 
chain fatty acids (C2-C6) and are thought to mediate detoxification of cellular formaldehyde 
(52).  
 
We purified recombinant WT SaFrmB and SaGloB and proceeded to evaluate the substrate 
utilization for each enzyme (Figure S3A). We first assessed glyoxalase II activity using an assay 
which couples hydrolysis of the glyoxalase II substrate, S-lactoylglutathione, to a change in 
absorbance (Figure S3B). SaGloB hydrolyzes S-lactoylglutathione with a specific activity 
comparable to previously characterized microbial type II glyoxalases, but SaFrmB lacks 
appreciable activity.  
 
We next assessed the ability of FrmB and GloB to hydrolyze p-nitrophenyl esters of short chain 
fatty acids which have a photometric change upon hydrolysis (Figure S3C). FrmB has modest 
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activity against 4-nitrophenyl acetate and butyrate but no activity against 4-nitrophenyl 
trimethylacetate suggesting a preference for simple short chain fatty acids (Figure S3C). This 
finding is in agreement with a previous characterization of FrmB cleaving short chain 
hydrophobic lipid substrates (53). GloB has no detectable activity against these substrates. 
Notably, neither GloB nor FrmB has activity against 4-nitrophenyl trimethylacetate despite 4-
nitrophenyl trimethyl acetate bearing striking similarity to POM-HEX as a potential substrate. 
This may be due to the absence of the acyloxymethyl ether moiety in 4-nitrophenyl substrates 
which is found in POM-prodrugs. 
 
We also sought to directly assess the role of GloB and FrmB in POM-HEX activation. We 
incubated each enzyme, with POM-HEX, and characterized the products via 31P-1H-
heteronuclear single quantum coherence (HSQC) nuclear magnetic resonance (NMR). We have 
previously shown that GloB removes only one POM moiety, resulting in an accumulation of 
mono-POM-HEX (Figure 1B) (29). Similarly, FrmB is capable of removing only one POM-
moiety (Figure S4). We hypothesized that the two esterases may be stereoselective and incubated 
both enzymes with POM-HEX. We find that incubation of POM-HEX with GloB and FrmB still 
results in an accumulation of mono-POM-HEX, suggesting the two esterases may be unable to 
cleave the charged mono-POM species (Figure S4)  
 
4.4.3 GloB and FrmB substrate specificity. 
To facilitate microbially targeted prodrug activation using these two enzymes, we next sought to 
extensively characterize GloB and FrmB substrate specificity, using a 32-compound fluorescent 
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ester substrate library that fluoresces upon esterase activity (Figure S5) (30). This library 
systematically varies ester substrate length, branching patterns, and ether and sulfide positioning 
within the substrate, thereby allowing for the precise determination of structure-activity-
relationships. Kinetic measurements were performed for both FrmB and GloB over a range of 
substrate concentrations for the entire library allowing for the extraction of the catalytic 
specificity (kcat/Km) (Supplemental table S4, S5).  
 
We find that FrmB and GloB tend to have the highest activity towards oxygen ethers (Figure 
S6). GloB has the highest activity for short chain ethers (compounds 1-3) with some tolerance 
for branching at the first carbon beyond the ester carbonyl (compounds 7-9), though extensive 
branching strongly reduces activity (compound 10). Remarkably, GloB is also tolerant of the 
extreme steric bulk introduced with the phenoxyacetic acid substrate if the substrate contains an 
oxygen or sulfur ether (compound series 11). GloB exhibits a strong preference for oxygen at the 
β-position to the carbonyl over the γ-position but is indifferent to the positioning of sulfur. While 
GloB has a wider range of catalytic specificities, FrmB exhibits lower overall and narrower 
range of catalytic specificity. FrmB is generally capable of hydrolyzing unbranched substrates 
with little regard for chain length or the end of chain bulk (compound series 1-3, 11). Branching 
at the position following the ester carbonyl (compound series 7-9, 12) is deleterious to FrmB 
activity. When oxygen is included in the chain, positioning at the β-position to the carbonyl is 
strongly preferred over the γ-position. 
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4.4.4 Importance of substrate specificity in vivo. 
While in vitro enzymatic substrate profiling is informative for how individual enzymes activate 
prodrugs, it does not necessarily reflect the complex biochemical processes happening in vivo, 
where additional cellular esterases may impact overall compound activation. We designed a live, 
single-cell assay to measure the real-time activation of pro-fluorescent substrates. S. aureus is 
loaded onto a microfluidics device and tracked on both fluorescent and phase contrast channels. 
Intracellular fluorescence resulting from the rapid introduction of substrate into the chamber was 
thus quantified through time.  
 
We selected four pro-fluorescent substrates of varying catalytic specificity against FrmB and 
GloB to observe in our microfluidics experiments. In vitro, substrate 1O displays high catalytic 
specificity for both FrmB and GloB, 3C displays moderate catalytic specificity for FrmB and 
GloB, 5O has moderate catalytic specificity against GloB but poor catalytic specificity against 
FrmB, and 9C has poor catalytic specificity against both GloB and FrmB. Comparing the 
activation of these substrates through time, we find that our in vitro catalytic specificity 
determination correlates well with our in vivo activation rates (Figure 3, supplemental movies 1-
4). Compound 1O, which exhibits high catalytic specificity for GloB and FrmB reaches 
fluorescence saturation within the initial time point observed. Compound 3C, which has 
moderate catalytic specificity for both GloB and FrmB, slowly activates over the duration of the 
experiment, and 5O and 9C, which have moderate to poor catalytic specificity against both GloB 
and FrmB never appreciably activate during the 30 minutes of observation (Figure 3). As 
fluorescent activation is quantified per cell, we can also assess the uniformity of prodrug 
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activation across the population. We observe remarkably homogenous activation of prodrugs 
across all observed cells (Figure 3).  
 
4.4.5 Three-dimensional structure of FrmB 
To establish the structural basis for FrmB and GloB substrate specificity and enable future 
structure guided design of protherapies, we solved the three-dimensional structures of both S. 
aureus FrmB and GloB. S. aureus FrmB was solved at 1.60 Å using molecular replacement with 
the low-temperature active alkaline esterase, est12 (PDB ID: 4RGY) as a search model (41). 
Refinement parameters and statistics are displayed in Table S6. A single dimer of FrmB is 
observable in the asymmetric unit, matching the apparent molecular weight of FrmB as we have 
observed via size exclusion chromatography. The overall fold of FrmB is characteristic of the α/β 
hydrolase fold. Six parallel β-strands and one anti-parallel β-strand pair form a central eight 
stranded β-sheet, which is encompassed by α-helices (Figure 4A). One monomer of FrmB has 
electron density for a single magnesium ion, whereas the second monomer has two magnesium 
present.  
 
A structural similarity search was performed using the DALI server to identify proteins related to 
SaFrmB. The structure of SaFrmB was most similar to the molecular replacement model, Est12 
from deep sea bacteria (PDB ID 4RGY, root mean squared deviation (r.m.s.d.) = 1.020 Å), but 
also had similarity to the ferulic acid esterase BiFae1A from Bacteroides intestinalis (PDB ID 
5VOL, r.m.s.d. = 1.137 Å) and the tributyrin esterase, estA, from Streptococcus pneumonia 
(PDB ID 2UZ0, r.m.s.d. = 1.329 Å) (54, 55). All structures display strong structural conservation 
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including the positioning of the prototypic serine hydrolase catalytic triad: Ser120, Asp204, and 
His233 (S. aureus) (Figure S7). The most striking difference between the related structures is the 
flexible cap domain, implicated in substrate specificity of estA and est12 (41). While this 
manuscript was in preparation, an independent structure of FrmB was solved (53). The two 
structures are nearly identical (PDB ID 6ZHD, r.m.s.d = 0.433 Å), with slightly differential 
positioning of the capping domain. 
We compared SaFrmB to its closest human ortholog, human esterase D (PDB ID 3fcx), finding 
moderate structural similarity both in the overall fold (r.m.s.d = 4.625 Å) and in the positioning 
of the catalytic triad. However, SaFrmB and human esterase D notably differ in the solvent-
accessible surface around the active site, suggesting the potential for distinct substrate utilization, 
primarily driven by differential positioning of the cap domain (Figure 4B). 
 
We modeled the highest catalytic specificity substrate of FrmB, 1O, onto the active site of FrmB. 
Serine hydrolases classically bind the substrate carbonyl oxygen in an oxyanion hole and 
substrate hydrolysis is initiated through attack of the catalytic serine on the ester carbonyl. The 
docking of 1O on FrmB mimics the initial state of a serine hydrolase reaction, with the carbonyl 
oxygen buried and the catalytic serine poised for attack (Figure 4C). The pocket directly next to 
the oxyanion hole is relatively narrow, suggesting that steric hindrance explains FrmB’s poor 
ability to hydrolyze branched substrates. The active site pocket extends and opens significantly 
after passing by the oxyanion hole, supporting FrmB’s ability to hydrolyze substrates with large 
steric groups far from the carbonyl carbon such as 11O. 
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4.4.6 Three-dimensional structure of GloB 
We also solved the structure of SaGloB 1.65 Å, using selenomethionine (SeMet)-substituted 
GloB and molecular replacement using the metallo-β-lactamase, TTHA1623, from Thermus 
thermophilus as a search model. Final structural refinement parameters and statistics are 
presented in Table S6. Four monomers of SaGloB are observed in the asymmetric unit with each 
displaying crystallographic symmetry. SaGloB exhibits the classic αβ/βα-fold that defines the 
metallo-β-lactamase fold proteins, including glyoxalase II enzymes (Figure 5A).  
As with SaFrmB, a DALI server search was performed to identify proteins structurally similar to 
SaGloB. SaGloB displays extremely high similarity to the unusual type II glyoxalase, YcbI from 
Salmonella enterica (PDB ID: 2XF4, r.m.s.d = 0.898 Å), the molecular replacement search 
model TTHA1623 from Thermus thermophilus (PDB ID: 2ZWR, r.m.s.d. = 0.767), and to the 
Arabidopsis thaliana glyoxalase II (PDB ID: 1XM8, r.m.s.d = 1.165 Å), with the exception that 
AtGloB has a 50 amino acid C-terminal extension (Figure S8A) (42, 37, 56). Also consistent 
with previously observed GloB structures, SaGloB shows clear electron density for two zinc 
molecules coordinated by six histidine residues and two aspartate residues (Figure S8B). Density 
for a water molecule is also visible and appears to be coordinated by the two zinc atoms, as 
observed for human glyoxalase II (57).  
 
Overlaying S. aureus GloB with Homo sapiens GloB (PDB: 1qh5) reveals that the two structures 
are remarkably similar (r.m.s.d = 1.249 Å), with a few notable exceptions. HsGloB has two 
extensions – one a 34 amino acid insertion, the other a 32 amino acid C-terminal extension, both 
of which form helix-turn-helices that abut the active site (Figure 5B) (57). On the opposite side 
159 
 
of the active site, SaGloB has a 19 amino acid flexible loop which is partially observed in the 
electron density. This loop is positioned such that it may cover the active site or at the very least 
sterically hinder substrate access (Figure 5B). Overall, these differences between HsGloB and 
SaGloB suggest differential substrate utilization between S. aureus and humans. 
 
We modeled the highest catalytic specificity substrate for GloB, 1O , onto our structure. 
Autodock places 1O with the carbonyl oxygen directly next to the active site water (Figure 5C). 
The GloB active site channel appears moderately wide, explaining why extensively branched 
substrates are not tolerated. Towards the end of the active site channel, GloB appears to form a 
tunnel. This is tunnel is not reached by substrate 1O, but presumably would be occupied in more 
sterically bulky substrates such as 11O. One arm of this tunnel is comprised of the highly 
flexible loop which is only partially visible in our electron density suggesting that during 
catalysis this loop may be movable to accommodate larger substrates such as 11O. 
 
4.4.7 Esterase specificity of human and mouse sera 
We sought to evaluate whether ester promoieties could be designed for microbe-specific 
activation. Using the same 32-compound fluorescent substrate library, we determine each 
substrate’s serum half-life. Both reconstituted and fresh sera function comparably in their 
activity and substrate preferences (Figure S9).  
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We next proceeded to perform full kinetic profiling of lyophilized human sera. As sera is a 
mixture of multiple proteins instead of a single protein species, we are unable to obtain true kcat 
values. Instead, we report a modified catalytic specificity, which is the Vmax/Km, normalized to 
the total amount of protein added to the assay (Figure S10A). As we observed for FrmB and 
GloB (Figure S10B, C), human sera has highest catalytic specificity for oxygen and sulfur ethers. 
However, as opposed to FrmB and GloB, human sera is relatively uniform in its catalytic 
specificity across the substrate library. Short chain substrates exhibit the highest catalytic 
specificity, and though branching slightly reduces the catalytic specificity, it is not to the same 
extent as with FrmB. The substrates displaying the poorest catalytic specificity are universally 
the carbon series, with added branching resulting in the decreased substrate utilization. 
 
As murine models are frequently used in the development and testing of novel pharmaceuticals, 
we wanted to additionally characterize the substrate preferences of mouse sera. Notably, mice 
are well known for their extremely active and broad serum esterase activity. Indeed, we find that 
mouse sera exhibits on average 100-fold more catalytic specificity per mg serum protein than 
human sera (Figure S10D, S11). However, this increase in catalytic specificity is not uniform 
across the substrate library. Human sera underperforms on the carbon series, and does 
comparatively better on the oxygen and sulfur ethers (Figure S11B). Thus, use of mouse sera 
alone is likely insufficient to predict prodrug human serum stability and accurately model human 
pharmacokinetics and dynamics. 
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Finally, we wanted to compare how GloB and FrmB substrate specificities could be used to drive 
microbe-targeted prodrugs. As each esterase is likely to encounter multiple potential substrates in 
vivo, we utilized our modified catalytic specificity (Vmax/Km) as a comparator. We performed 
pairwise analysis for each combination of FrmB and GloB against human and mouse sera 
(Figure 6A-D). The exact enrichment of catalytic specificity for microbial esterases compared to 
serum esterases that will result in a host-resistant prodrug is difficult to estimate. Using a cutoff 
of 210-fold enrichment in catalytic specificity for the microbial enzymes over the serum enzymes, 
FrmB displays a preference over human sera for two compounds: 3C and 6C, whereas GloB 
displays a preference for 6 compounds: 2S, 3C, 10C, 11C, 11O, and 11S (Figure 6E). 
Conversely, mouse sera is able to hydrolyze all compounds within this cutoff. Lowering the 
cutoff to a 25-fold enrichment in catalytic specificity over mouse sera, FrmB and GloB both are 
more specific for compound 2S, and GloB additionally displays specificity for compound 11O. 
4.5 Discussion 
Targeted microbial delivery and activation of lipophilic ester prodrugs is a highly desirable 
strategy to enable the expansion of druggable targets within bacteria while simultaneously 
improving drug selectivity. Identification of microbe-specific pro-moieties is crucial to this goal. 
Here, we have demonstrated that S. aureus uses two discrete esterases, FrmB and GloB, to 
activate the carboxy ester prodrug, POM-HEX. FrmB and GloB both exhibit distinct ester 
substrate specificities, which are supported by the structure of their active sites. Importantly, 
enzymatic substrate specificity correlates with the rate of cellular ester activation. Accordingly, 
simple modifications to ester prodrugs are sufficient to change their rates of activation in vivo. 
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Simple ester modifications can also change the pattern of prodrug activation. For the 
development of microbially targeted ester prodrugs to be feasible, compounds need to be stable 
against human enzymes. Here we demonstrate that human sera has distinct ester substrate 
preferences, and that both FrmB and GloB utilize substrates differentially from human sera. How 
microbes beyond S. aureus activate prodrugs, as well as the substrate specificities of pathogenic 
and commensal microbes remains an important, open question which will dictate how narrow 
spectrum an ester prodrug will be. As microbe-specific prodrugs begin to enter clinical 
development, careful attention needs to be paid to the models used to establish the 
pharmacokinetic/pharmacodynamic profiles and efficacy of ester prodrugs. Our studies indicate 
that mice are an inadequate model for ester prodrug activation and therapeutic efficacy in 
humans. This work paves the way for structure-guided development of S. aureus-specific 
prodrugs and establishes a pipeline for the identification of microbial prodrug activating 
enzymes. We anticipate that these approaches will not only guide the development of novel 
antimicrobials, but also aid in the development of in vivo imaging for diagnostic purposes. 
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4.6 Figures 
 
Figure 1 Prodrug activation model and proposed mechanism. Carboxy ester promoieties highlighted in green. 
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Figure 2 Forward and reverse genetics approaches identify FrmB and GloB as potential POM-prodrug 
hydrolases. (a) Reverse genetics identification of potential prodrug activating enzymes. (b) POM-HEX 
susceptibility of identified potential prodrug activating enzymes from (a). (c) Forward genetic screen approach. (d) 
POM-HEX susceptibility of POM-HEX resistant staphylococci. (e) Mutations identified by whole-genome 
sequencing in FrmB and GloB. In all experiments GloB is colored green and FrmB orange. Displayed are the means 
of three independent biological experiments.
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Figure 3 Ester promoiety selection impacts in vivo activation rates. Time series of activation of various pro-
fluorescent substrates (Figure S5). Profluorescent substrates were added into the microfluidics chamber at t = 10 
minutes. Displayed on the right is the quantification of individual cell or cell cluster fluorescence. Faint traces are 
individual cells and darker traces represent the mean of a given experiment. Each experiment was performed in 
biological duplicate. Error bars denote SD.
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Figure 4 Three-dimensional structure of FrmB. (a) overall fold, alpha helices colored in orange and β-strands 
colored in purple. (b) comparison between SaFrmB (orange) and the closest human ortholog, estD (gray). Active site 
residues denoted in orange spheres. (c) docking of substrate 1O (sticks) in the active site of FrmB. Left, surface 
view, red indicates highly hydrophobic and white hydrophilic residues. Right, stick and cartoon view with catalytic 
triad annotated. 
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Figure 5 Three-dimensional structure of GloB. (a) overall fold, alpha helices colored in green and β-strands 
colored in purple. (b) comparison of SaGloB (green) and Human GloB (gray). (c) docking of the substrate 1O 
(sticks) in the active site of GloB. Left, partial cartoon view, Right surface view. White represents hydrophilic 
residues whereas red represents hydrophobic residues. Zn ions indicated as silver spheres; water indicated as blue 
sphere. 
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Figure 6 Comparison between microbial esterase and serum esterase catalytic specificity. (a-d) volcano plots of 
catalytic specificity. Displayed are the means of three independent experiments. P-values calculated as pairwise t-
tests with Holm-Sidak correction for multiple comparisons. (a) comparison between human sera and GloB, (b) 
human sera and FrmB, (c) mouse sera and GloB, (d) mouse sera and FrmB). (e) structures of ester substrates with 
210 enrichment in catalytic specificity for microbial esterases over human serum (left), or 25 enrichment over mouse 
serum. Dashed line indicates a p-value of 0.05. 
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Figure S1 Conservation of FrmB and GloB within S. aureus. (a) WhatsGNU analysis of GloB and FrmB. 
Control genes, argG – argininosuccinate synthase, fba- Fructose-bisphosphate aldolase, menD – 2-succinyl-5-
enolpyruvyl-6-hydroxy-3-cyclohexene-1carboxylate synthase, menC- o-succinylbenzoate synthase. GNU stands for 
gene novelty unit and is a count of how many sequences in the database have an exact match to the queried 
sequence, with higher counts indicating sequence conservation. Strains across the x-axis are representative strains 
from the 18 S. aureus colony complexes which were used to query the S. aureus database. (b, c) MAFFT alignment 
of GloB (b) and FrmB (c) sequences across the S. aureus sequence database. 
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Figure S2 Phylogenetic tree of FrmB and GloB. Sequences of GloB, FrmB, and RpoB were retrieved from NCBI 
using BlastP against each organism. Sequence alignment performed using MUSCLE. 
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Figure S3 Enzymatic characterization of GloB and FrmB. (a) SDS-PAGE gel of GloB and FrmB protein 
preparations. Expected molecular weights are 23.3 kDa and 29.5 kDa respectively. (b) Glyoxalase II activity assay, 
enzymatic conversion of S-lactoylglutathione releases free glutathione and reacts with DTNB resulting in increased 
absorbance at 412 nm. (c) 4-nitrophenyl activation results in increased absorbance at 405 nm. Left to right, activity 
when supplied 4-nitrophenyl acetate, butyrate, and trimethyl acetate. Displayed in points is the mean of two 
technical replicates for individual experiments, bars indicate mean of three independent biological experiments 
performed in technical duplicate. Error bars denote SD. 
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Figure S4 NMR characterization of POM-HEX activation by GloB and FrmB. Two-dimensional (2D) 1H-31P 
HSQC NMR spectra of products following incubation of FrmB, GloB, catalytically inactive (boiled) GloB and 
FrmB, or buffer alone. Also included are the 1H-31P HSQC NMR spectra of POM-HEX and HEX. Displayed are 
representative traces of three independent experiments. HEMI-POM HEX peak inferred by predicted shift. 
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Figure S5 Profluorescent substrate library. Activation of substrates via esterase action results in fluorescence. 
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Figure S6 Catalytic specificity of GloB and FrmB. Numbers correspond to the structures displayed in Figure S5, 
compounds in the carbon series denoted in orange, oxygen series in blue, and sulfur series in green. 
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Figure S7 Structural conservation of FrmB. (a) Overall structural alignment of FrmB (orange) with estA from S. 
pneumonia (2UZ0), ferulic acid esterases from B. intestinalis (5VOL), and est12 from deep sea bacteria (4RGY). (b) 
positioning of the serine hydrolase catalytic triad, histidine, serine, aspartate. 
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Figure S8 Structural conservation of GloB. (a) Overall structural alignment of GloB (green) with YcbI from S. 
enterica (2XF4), TTHA1623 from T. thermophilus (2ZWR), and A. thaliana glyoxalase II (1XM8). Zinc 
coordinating residues are colored in green spheres. (b) positioning of the Zinc coordinating residues, zinc colored in 
green spheres. 
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Figure S9 Comparison of esterase activity between fresh and lyophilized human sera. Points represent 
individual experiments; bars represent the mean of the four replicates. Error bars denote SD. 
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Figure S10 Modified catalytic specificity (pmol fluorescein produced * min-1*µg-1 protein) of human sera, 
GloB, FrmB, and mouse sera. X-axis corresponds to compound identities in Figure S5. Carbon containing 
compounds indicated in orange, oxygen in blue, and sulfur in green. Displayed are the means of three independent 
biological experiments with error bars denoting SD. 
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Figure 11 Comparison of mouse and human sera. (a) Modified catalytic specificity (pmol fluorescein produced * 
min-1*µg-1 protein) of human and mouse sera. Displayed is a linear regression of the fit between mouse and human 
sera. (b) Volcano plot of catalytic specificity. Displayed are the means of three independent experiments. P-values 
calculated as pairwise t-tests with Holm-Sidak correction for multiple comparisons. Dashed line indicates a p-value 
of 0.05. 
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4.7 Tables 
Table S1 Half maximal inhibitory concentration (IC50) values for POM-HEX against predicted prodrug activating esterases. * p<0.05, ** p<0.01, *** p<0.005, 
**** p<0.0001 
SAUSA300 gene Newman gene 
StrID 
(NARSA) 
Pan gene 
symbol 
POM-HEX 
IC50 (µM) 
POM-HEX 
IC50 SD 
(µM) 
Significantly 
different from 
WT (JE2)? 
Adjusted 
P-value Predicted function GO term 
Parental Strain  JE2  1.54 0.40   N/A Parental Strain 
SAUSA300_0742 NWMN_0727 
NE145 uvrA 
1.46 0.17 ns 0.9999 
Exonuclease ABC, A 
subunit 
carboxylic ester 
hydrolase activity, 
carboxylesterase 
activity 
SAUSA300_1902 NWMN_1859 
NE202  
0.700 0.066 ns 0.9101 Hypothetical protein 
phosphoric diester 
hydrolase activity 
SAUSA300_2173 NWMN_2121 NE223 truA 1.39 0.29 ns 0.9997 
tRNA pseudouridine 
synthase A phosphatase 
SAUSA300_1285 NWMN_1303 NE293  1.41 0.64 ns 0.9997 
ABC transporter, 
ATP-binding protein  phosphatase 
SAUSA300_2515 NWMN_2477 
NE355 gbaA 
1.73 0.48 ns 0.9997 
Transcriptional 
regulator, TetR 
family 
 carboxylic ester 
hydrolase activity 
SAUSA300_1505 NWMN_1449 NE377 gloB 10.6 3.2 **** <0.0001 
Hydroxyacylglutathio
ne hydrolase 
 
hydroxyacylglutathion
e hydrolase 
SAUSA300_0142 NWMN_0084 
NE478 phnE 
1.61 0.81 ns 0.9999 
Phosphonate ABC 
transporter, 
permease protein 
 phosphoric diester 
hydrolase activity 
SAUSA300_2564 NWMN_2528 NE503 estA, frmB 6.28 2.25 **** <0.0001 
Tributyrin esterase 
 carboxylic ester 
hydrolase activity 
SAUSA300_2473 NWMN_2434 
NE532 
 1.56 0.51 ns >0.9999 
Hypothetical Alkaline 
Phosphatase  phosphatase 
SAUSA300_0581 NWMN_0561 NE621  1.62 0.55 ns 0.9999 Hypothetical protein  phosphatase activity 
SAUSA300_0299  NE812  1.64 0.56 ns 0.9998 Hypothetical protein  phosphatase activity 
SAUSA300_1993 NWMN_1947 NE937 fruC 1.67 0.52 ns 0.9998 PfkB family kinase  phosphatase 
SAUSA300_1752 NWMN_1700 
NE949 
hsdM2 1.73 0.53 ns 0.9996 
type I restriction-
modification system, 
M subunit 
 phosphoric diester 
hydrolase activity 
SAUSA300_0312 NWMN_0254 
NE1039 
psuG 1.73 0.51 ns 0.9997 Hypothetical protein 
 carboxylic ester 
hydrolase activity 
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SAUSA300 gene Newman gene 
StrID 
(NARSA) 
Pan gene 
symbol 
POM-HEX 
IC50 (µM) 
POM-HEX 
IC50 SD 
(µM) 
Significantly 
different from 
WT (JE2)? 
Adjusted 
P-value Predicted function GO term 
SAUSA300_0538 NWMN_0515 
NE1071 
capD 1.54 0.41 ns >0.9999 
NAD-dependent 
epimerase/dehydrat
ase family protein  phosphatase activity 
SAUSA300_1792 NWMN_1735 NE1173  1.84 0.40 ns 0.9994 Hypothetical protein  phosphatase activity 
SAUSA300_0421 NWMN_0414 
NE1225 
 2.15 0.48 ns 0.9938 Hypothetical protein 
 carboxylic ester 
hydrolase activity, 
carboxylesterase 
SAUSA300_0214 NWMN_0156 
NE1238 
 2.08 0.54 ns 0.9986 Hypothetical protein 
 phosphoric diester 
hydrolase activity 
SAUSA300_0690 NWMN_0674 NE1296 saeS 2.07 0.53 ns 0.9986 
Sensor histidine 
kinase SaeS  phosphatase 
SAUSA300_1639 NWMN_1586 
NE1486 
phoP 2.18 0.41 ns 0.9932 
Alkaline 
phosphatase 
synthesis 
transcriptional 
regulatory protein 
 phosphoric diester 
hydrolase activity 
SAUSA300_0840 NWMN_0808 
NE1505 
 2.20 0.54 ns 0.9927 Hypothetical protein 
 phosphoric diester 
hydrolase activity 
SAUSA300_1563 NWMN_1507 
NE1519 
accC 1.75 0.70 ns 0.9996 
Acetyl-CoA 
carboxylase, biotin 
carboxylase 
 phosphoric diester 
hydrolase activity 
SAUSA300_2508  NE1547  1.48 0.23 ns >0.9999 Hypothetical protein  phosphatase activity 
SAUSA300_0996 NWMN_962 
NE1610 
pdhD 1.23 0.81 ns 0.9993 
Dihydrolipoamide 
dehydrogenase 
 phosphoric diester 
hydrolase activity 
SAUSA300_2367 NWMN_2320 NE1682 hlgB 1.37 0.19 ns 0.9997 
Gamma-hemolysin 
component B  phosphatase 
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Table S2 Genotype and phenotype of POM-HEX resistant S. aureus. Displayed are the whole genome sequencing mutations that have been verified. Called 
mutations that were not observed via confirmatory Sanger sequencing are excluded. 
Gene 
(Newman) WT_SAUR R1 R2 R3 R4 R5 R6 R7 R8 R9 
NWMN_1449 
(gloB)       
c.376G>T 
p.Val126Leu  
c.430T>A 
p.Phe144Ile 
c.433G>A 
p.Ala145Thr 
NWMN_2528 
(estA, frmB)    
c.40G>C 
p.Gly14Arg       
NWMN_0144     
c.1472G>T 
p.Arg491Met      
NWMN_0240           
NWMN_0309    
c.23A>C 
p.Asn8Thr  
c.23A>C 
p.Asn8Thr    
c.23A>C 
p.Asn8Thr 
NWMN_0471 
(tilS)           
NWMN_0523 
(sdrC)           
NWMN_0564           
NWMN_0954           
NWMN_1152           
NWMN_1311 
(lysA)           
NWMN_1425 
(recN)           
NWMN_1655   
c.17G>A 
p.Arg6His 
c.17G>A 
p.Arg6His       
NWMN_1735           
NWMN_1754           
NWMN_2040 
(pdp)           
NWMN_2253  
c.1412C>T 
p.Ala471Val 
c.1412C>T 
p.Ala471Val   
c.1412C>T 
p.Ala471Val     
NWMN_2388           
           
POM-HEX 
IC50 (µM) 1.921 6.337 5.932 9.561 10.54 3.752 11.09 10.71 16.96 17.71 
Std. 
Deviation 1.111 0.8778 0.7325 0.4846 6.261 2.594 4.974 6.602 7.264 10.65 
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Gene 
(Newman) R10 R11 R12 R13 R14 R15 R16 R17 R18 
NWMN_1449 
(gloB) 
c.70G>T 
p.Val24Phe 
c.166C>T 
p.His56Tyr 
c.326C>A 
p.Pro109His 
c.70G>T 
p.Val24Phe 
c.70G>T 
p.Val24Phe 
c.289C>T 
p.Gln97*    
NWMN_2528 
(estA, frmB)       
c.218_219insCATATGCCATGTTAGCA 
p.Met74fs c.366G>A p.Met122Ile  
NWMN_0144          
NWMN_0240    
c.432G>T 
p.Met144Ile      
NWMN_0309 
c.23A>C 
p.Asn8Thr    
c.23A>C 
p.Asn8Thr 
c.23A>C 
p.Asn8Thr  c.23A>C p.Asn8Thr  
NWMN_0471 
(tilS)        
c.760_765dupTTTAAT 
p.Phe254_Asn255dup  
NWMN_0523 
(sdrC)  
c.2299A>G 
p.Asn767Asp        
NWMN_0564       c.230_231delCT p.Ser77fs   
NWMN_0954   
c.359C>A 
p.Pro120His       
NWMN_1152          
NWMN_1311 
(lysA)          
NWMN_1425 
(recN)          
NWMN_1655  
c.17G>A 
p.Arg6His  
c.17G>A 
p.Arg6His 
c.17G>A 
p.Arg6His 
c.17G>A 
p.Arg6His  c.17G>A p.Arg6His  
NWMN_1735    
c.2754C>A 
p.Phe918Leu      
NWMN_1754        c.232T>A p.Leu78Ile  
NWMN_2040 
(pdp)  
c.426G>T 
p.Leu142Phe        
NWMN_2253         
c.1412C>T 
p.Ala471Val 
NWMN_2388    
c.195G>T 
p.Gln65His      
          
POM-HEX 
IC50 (µM) 8.353 31.66 11.47 6.746 4.033 5.61 5.559 3.882 2.788 
Std. 
Deviation 
 3.673 32.94 4.009 2.199 1.276 5.394 2.96 1.153 0.538 
184 
 
 
Gene 
(Newman) R19 R20 R21 R22 R23 R24 R25 
NWMN_1449 
(gloB)      
c.401C>T 
p.Pro134Leu  
NWMN_2528 
(estA, frmB) 
c.40G>C 
p.Gly14Arg  
c.366G>A 
p.Met122Ile  
c.356G>A 
p.Gly119Asp  
c.40G>C 
p.Gly14Arg 
NWMN_0144        
NWMN_0240        
NWMN_0309 
c.23A>C 
p.Asn8Thr     
c.23A>C 
p.Asn8Thr 
c.23A>C 
p.Asn8Thr 
NWMN_0471 
(tilS)        
NWMN_0523 
(sdrC)        
NWMN_0564        
NWMN_0954        
NWMN_1152      
c.1570G>T 
p.Asp524Tyr  
NWMN_1311 
(lysA)      
c.1145C>A 
p.Ser382Tyr  
NWMN_1425 
(recN) 
c.1130T>C 
p.Leu377Ser       
NWMN_1655 
c.17G>A 
p.Arg6His 
c.17G>A 
p.Arg6His 
c.17G>A 
p.Arg6His 
c.17G>A 
p.Arg6His 
c.17G>A 
p.Arg6His   
NWMN_1735        
NWMN_1754   
c.232T>A 
p.Leu78Ile     
NWMN_2040 
(pdp)        
NWMN_2253        
NWMN_2388        
        
POM-HEX 
IC50 (µM) 5.678 3.847 3.923 4.568 3.794 8.396 3.519 
Std. 
Deviation 
 2.073 1.061 1.087 4.194 0.903 1.049 0.112 
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Table S3 Half maximal inhibitory concentration (IC50) values for POM-HEX against transposon mutations in genes identified by whole-genome 
sequencing. 
 
SAUSA300 gene Newman gene 
StrID 
(NARSA) 
Pan gene 
symbol 
POM-HEX 
IC50 (µM) 
POM-HEX 
IC50 SD (µM) 
Significantly 
different from 
WT (JE2)? 
Adjusted P-
value Predicted function 
Parental Strain   JE2 
 
1.54 0.40   
N/A 
SAUSA300_1781 NWMN_1723 NE64 hemY 1.43 0.15 ns 0.9998 protoporphyrinogen oxidase 
SAUSA300_0671 NWMN_0654 
NE364  
1.65 0.72 ns 0.9998 
ABC transporter, ATP-binding 
protein, MsbA family 
SAUSA300_1505 NWMN_1449 NE377 gloB 10.6 3.2 **** <0.0001 
hydroxyacylglutathione 
hydrolase 
SAUSA300_1708 NWMN_1655 NE386 rot 1.40 0.15 ns 0.9997 
staphylococcal accessory 
regulator Rot 
SAUSA300_2564 NWMN_2528 NE503 estA, frmB 6.28 2.25 **** <0.0001 tributyrin esterase 
SAUSA300_1452 NWMN_1410 
NE520 proC 
1.47 0.75 ns 0.9999 
pyrroline-5-carboxylate 
reductase 
SAUSA300_0201 NWMN_0144 
NE541  
1.60 0.52 ns >0.9999 
peptide ABC transporter, 
permease protein 
SAUSA300_1085 NWMN_1101 NE874  1.64 0.57 ns 0.9998 conserved hypothetical protein 
SAUSA300_2105 NWMN_2057 
NE929 mtlF 
1.70 0.55 ns 0.9997 
PTS system, mannitol specific 
IIBC component 
SAUSA300_0778 NWMN_0762 NE1051 
 
1.46 0.25 ns 0.9999 hypothetical protein 
SAUSA300_1290 NWMN_1308 
NE1118 dapD 
1.69 0.59 ns 0.9997 
tetrahydrodipicolinate 
acetyltransferase 
SAUSA300_0414 NWMN_0407 NE1127 lpl4 1.72 0.62 ns 0.9997 tandem lipoprotein 
SAUSA300_0028   NE1283 tnp 2.10 0.36 ns 0.9986 putative transposase 
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Table S4 Michaelis Menten parameters for SaGloB  
  
Vmax (pmol*min
-
1*μg protein-1) 
Km (μM) 
Vmax/Km (pmol*min
-
1*mg GloB-1µM-1) 
kcat (10
-3 s-1) kcat/Km (M
-1 s-1) kcat/kuncat (10
3) ((kcat/Km)/kuncat) (10
9 M-1) 
((Vmax/Km)/kuncat) 
(1012pmol*mg GloB-
1µM-1) 
Substrate Value SEM Value SEM Value SEM Value SEM Value SEM Value SEM Value SEM Value SEM 
1C 0.497 0.074 6.23 3.39 79.9 22 0.0744 0.0111 11.9 3.28 21.2 16.3 3.41 4.81 380 536 
2C 0.292 0.051 18.3 9.0 15.9 5.6 0.0436 0.0076 2.38 0.845 17.2 7.9 0.940 0.881 105 98 
3C     >50   10.4 1.0     1.55 0.15     0.256 0.061 28.5 6.8 
6C 0.444 0.130 48.0 29.5 9.24 4.40 0.0663 0.0194 1.38 0.658 12.7 33.4 0.265 1.133 29.6 126.3 
7C     >50   6.43 0.31     0.961 0.046     0.109 0.041 12.2 4.6 
8C 0.351 0.113 84.9 47.9 4.13 2.36 0.0524 0.0169 0.618 0.353 79.1 26.3 0.932 0.549 104 61 
9C     >50   0.28 0.01     0.042 0.002     0.0244 0.0020 2.72 0.22 
10C   >50   0.79 0.07     0.118 0.011    0.0752 0.0392 8.38 4.37 
11C     >50   0.88 0.04     0.132 0.005     0.261 0.006 29.1 0.7 
1O 217 41.5 73.5 25.7 2960 1620 32.5 6.2 442 242 38.6 15.3 0.525 0.595 58.6 66.5 
2O 46.4 9.95 42.0 19.8 1103 503 6.93 1.49 165 75.3 19.4 11.8 0.462 0.595 51.5 66.4 
3O 4.21 0.515 8.41 3.52 500. 146 0.630 0.077 74.8 21.9 4.91 1.41 0.584 0.400 65.0 44.6 
4O 1.39 0.15 18.0 5.37 77.2 27.3 0.208 0.022 11.5 4.08 8.42 5.18 0.468 0.964 52.1 107.5 
5O 0.731 0.15 21.2 11.8 34.5 12.7 0.109 0.023 5.15 1.91 17.0 24.1 0.803 2.038 89.5 227.2 
6O 2.91 0.26 12.0 3.3 242 76.8 0.435 0.038 36.1 11.5 5.76 1.09 0.479 0.325 53.4 36.3 
7O 23.1 4.50 20.5 10.9 1130 412 3.45 0.67 168 61.7 23.6 21.2 1.15 1.95 129 217 
8O 1.01 0.149 15.5 6.8 64.9 22.0 0.151 0.022 9.71 3.30 6.80 1.80 0.437 0.267 48.7 29.7 
9O 2.54 0.83 55.5 36.5 45.7 22.8 0.380 0.125 6.84 3.41 14.6 16.0 0.264 0.439 29.4 48.9 
10O     >50   2.96 0.22     0.442 0.033     0.0715 0.0346 7.97 3.85 
11O   >50   248 21.9     37.1 3.27    0.0411 0.0369 4.58 4.12 
12O 1.04 0.190 36.9 15.4 28.2 12.3 0.156 0.028 4.21 1.84 1.28 0.67 0.0348 0.0438 3.87 4.88 
1S 14.9 3.92 32.5 20.4 457 192 2.22 0.59 68.4 28.8 11.4 13.6 0.351 0.666 39.2 74.3 
2S     >50   422 39.5     63.1 5.91     0.0529 0.0665 5.90 7.41 
3S   >50   31.0 2.34     4.63 0.350    0.0259 0.0088 2.89 0.98 
4S     >50   126 15.2     18.8 2.27     0.278 0.057 30.9 6.4 
5S 0.18 0.049 31.7 21.1 5.60 2.34 0.0266 0.0074 0.840 0.351 4.35 2.45 0.137 0.116 15.3 12.9 
6S 4.19 1.17 65.8 34.9 63.7 33.6 0.627 0.176 9.53 5.03 12.9 7.8 0.197 0.224 21.9 25.0 
7S 0.722 0.150 49.5 21.4 14.6 7.01 0.108 0.022 2.18 1.05 7.86 3.04 0.159 0.142 17.7 15.9 
8S 1.02 0.40 79.8 56.2 12.8 7.19 0.153 0.060 1.92 1.08 9.01 7.64 0.113 0.136 12.6 15.2 
9S   >50   11.1 0.86     1.66 0.128    0.0215 0.0613 2.40 6.84 
11S     >50   20.5 2.87     3.07 0.429     0.0662 0.0219 7.38 2.44 
12S   >50   1.86 0.03     0.278 0.005    0.0310 0.0005 3.46 0.06 
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Table S5 Michaelis Menten parameters for SaFrmB 
  
Vmax (pmol*min
-
1*μg protein-1) 
Km (μM) 
Vmax/Km (pmol*min
-
1*mg FrmB-1µM-1) 
kcat (10
-3 s-1) kcat/Km (M
-1 s-1) kcat/kuncat (10
3) 
((kcat/Km)/kuncat) (10
9 M-
1) 
((Vmax/Km)/kuncat) 
(1012 pmol*mg 
FrmB-1µM-1) 
Substrate Value SEM Value SEM Value SEM Value SEM Value SEM Value SEM Value SEM Value SEM 
1C 0.149 0.059 30.4 29.5 4.89 2.01 0.0280 0.0112 0.921 0.379 7.99 16.5 0.263 0.557 23.3 49.3 
2C 0.0637 0.0274 26.5 28.9 2.40 0.95 0.0120 0.0052 0.452 0.179 4.74 5.38 0.179 0.186 15.8 16.5 
3C 
  
>50 
 
10.2 0.64 
  
1.92 0.12 
  
0.316 0.050 28.0 4.4 
6C 
  
>50 
 
1.84 0.14 
  
0.347 0.026 
  
0.0666 0.0444 5.90 3.93 
7C 
  
>50 
 
1.01 0.08 
  
0.191 0.015 
  
0.0217 0.0133 1.92 1.17 
8C 
  
>50 
 
0.314 0.012 
  
0.0591 0.0022 
  
0.0892 0.0034 7.89 0.30 
9C 
  
>50 
 
0.160 0.009 
  
0.0301 0.0018 
  
0.0177 0.0019 1.56 0.17 
10C 
  
>50 
 
0.233 0.029 
  
0.0438 0.0055 
  
0.0279 0.0194 2.47 1.72 
11C 
  
>50 
 
0.682 0.062 
  
0.128 0.012 
  
0.254 0.014 22.5 1.2 
1O 5.98 0.677 30.3 8.33 197 81.3 1.13 0.127 37.2 15.3 1.34 0.31 0.0442 0.0377 3.91 3.34 
2O 2.04 0.328 13.9 6.76 147 48.6 0.385 0.062 27.7 9.14 1.08 0.49 0.0777 0.0723 6.88 6.40 
3O 0.621 0.191 9.95 10.06 62.4 18.9 0.117 0.036 11.7 3.57 0.911 0.656 0.0916 0.0653 8.11 5.78 
4O 0.183 0.038 30.0 15.2 6.12 2.51 0.0345 0.0072 1.15 0.47 1.40 1.70 0.0467 0.1118 4.14 9.89 
5O 
  
>50 
 
1.54 0.10 
  
0.290 0.020 
  
0.0452 0.0210 4.00 1.86 
6O 0.597 0.091 9.17 4.66 65.2 19.4 0.112 0.017 12.3 3.66 1.49 0.48 0.163 0.104 14.4 9.2 
7O 2.57 0.96 107 64.8 24.0 14.8 0.485 0.180 4.52 2.78 3.31 5.69 0.0309 0.0877 2.73 7.77 
8O 0.163 0.031 18.3 9.66 8.92 3.17 0.0307 0.0058 1.68 0.60 1.38 0.47 0.0757 0.0482 6.70 4.27 
9O 
  
>50 
 
7.24 0.31 
  
1.36 0.06 
  
0.0525 0.0076 4.65 0.67 
10O 0.163 0.053 74.2 43.6 2.20 1.21 0.0307 0.0099 0.414 0.227 4.97 10.26 0.0671 0.2351 5.94 20.81 
11O 
  
>50 
 
79.1 2.7 
  
14.9 0.51 
  
0.0165 0.0058 1.46 0.51 
12O 
  
>50 
 
3.18 0.26 
  
0.598 0.048 
  
0.00493 0.00115 0.44 0.10 
1S 
  
>50 
 
12.5 0.6 
  
2.36 0.11 
  
0.0121 0.0026 1.07 0.23 
2S 
  
>50 
 
169 14 
  
31.8 2.58 
  
0.0266 0.0290 2.36 2.57 
3S 
  
>50 
 
7.79 0.19 
  
1.47 0.04 
  
0.0082 0.0009 0.728 0.081 
4S 0.505 0.147 52.7 31.3 9.58 4.70 0.0950 0.0277 1.80 0.89 1.40 0.70 0.0266 0.0223 2.36 1.97 
5S 0.0295 0.0030 11.1 3.61 2.66 0.83 0.00556 0.00056 0.500 0.156 0.910 0.187 0.0818 0.0517 7.24 4.58 
6S 0.629 0.169 36.3 22.3 17.3 7.5 0.118 0.032 3.27 1.42 2.44 1.42 0.0674 0.0633 5.97 5.61 
7S 
  
>50 
 
1.55 0.12 
  
0.292 0.023 
  
0.0213 0.0032 1.88 0.28 
8S 
  
>50 
 
2.20 0.24 
  
0.415 0.046 
  
0.0244 0.0058 2.16 0.51 
9S 
  
>50 
 
5.38 0.48 
  
1.01 0.09 
  
0.0131 0.0435 1.16 3.85 
11S 
  
>50 
 
10.8 1.1 
  
2.04 0.21 
  
0.0440 0.0105 3.89 0.93 
12S 
  
>50 
 
1.02 0.07 
  
0.191 0.013 
  
0.0213 0.0013 1.89 0.12 
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Table S6 Summary of crystallographic data collection and refinement statistics. 
 
 
Data Collection SaFrmB SaGloB (SeMet) 
 Space Group C2 P 1 21 1 
 Cell dimensions a= 128.8Å, b= 80.6Å a= 93.7Å, b= 44.76Å 
  c=67.1Å, β=114.1
o c=105.0Å, β=96.7
o 
 Wavelength (Å) 0.979 1.000  
 Resolution (Å) (highest shell) 36.8-1.60 (1.63-1.60) 48 - 1.65 (1.71 - 1.65) 
 Reflections (total/unique) 145907 / 78193 102457 
 Completeness (highest shell) 96.4% (99.1%) 96.1 % (88.8 %) 
 <I/σ> (highest shell) 27.1 (4.1) 
 
 Rsym (highest shell) 6.6% (57.3%) 
 
   
 
Refinement  
 
 Rcryst / Rfree  0.156 / 0.179 0.225 / 0.251 
 No. of protein atoms 4164 6323 
 No. of waters 496 431 
 No. of ligand atoms 3 28 
 R.m.s.d., bond lengths (Å)  0.009 0.007 
 R.m.s.d., bond angles (
o) 1.34 1.21 
 
Avg. B-factor (Å2): protein, 
water, ligand 25.8, 37.6, 15.9 
39.6, 44.9, 47.5 
 
Stereochemistry: most 
favored, allowed, disallowed 98.4, 1.6, 0 % 
96.2, 3.8, 0 % 
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Table S7 Michaelis Menten parameters for human sera  
  
Vmax (pmol*min
-1*mg 
sera-1) 
Km (μM) 
Vmax/Km (pmol*min
-
1*mg sera-1µM-1) 
((Vmax/Km)/kuncat) (10
12 
pmol*mg sera-1µM-1) 
Substrate Value SEM Value SEM Value SEM Value SEM 
1C 1.06 0.15 36.2 11.5 0.0293 0.0128 0.139 0.315 
2C 0.356 0.191 71.5 70.6 0.00498 0.00271 0.0328 0.0471 
3C 
  
>50 
 
0.00161 0.00022 0.00443 0.00151 
6C 
  
>50 
 
0.00121 0.00013 0.00389 0.00381 
7C 0.441 0.029 64.18 8.03 0.00688 0.00355 0.0130 0.0531 
8C 
  
>50 
 
0.000791 0.000062 0.0199 0.0016 
9C 
  
>50 
 
0.000581 0.000026 0.00568 0.00045 
10C 
  
>50 
 
0.000483 0.000042 0.00513 0.00251 
11C 
  
>50 
 
0.000711 0.000027 0.0234 0.0005 
1O 68.6 25.6 64.1 45.8 1.07 0.560 0.0212 0.0230 
2O 43.8 10.53 40.4 21.5 1.09 0.489 0.0507 0.0645 
3O 11.7 2.81 22.2 14.2 0.529 0.198 0.0687 0.0604 
4O 5.88 1.90 44.5 30.9 0.132 0.061 0.0894 0.2420 
5O 2.25 0.48 35.4 17.4 0.0635 0.0274 0.165 0.489 
6O 11.7 3.82 54.6 35.9 0.215 0.107 0.0475 0.0503 
7O 5.73 1.16 30.3 14.9 0.189 0.078 0.0216 0.0411 
8O 3.93 0.71 27.7 12.4 0.142 0.057 0.107 0.077 
9O 4.35 1.18 111.7 48.9 0.0389 0.0242 0.0250 0.0519 
10O 1.46 0.38 63.3 31.8 0.0230 0.0121 0.0621 0.2080 
11O 
  
>50 
 
0.122 0.008 0.00225 0.00158 
12O 4.00 0.68 42.2 15.7 0.0948 0.0433 0.0130 0.0171 
1S 30.5 9.90 71.8 43.0 0.425 0.230 0.0364 0.0890 
2S 
  
>50 
 
0.315 0.025 0.00440 0.00472 
3S 8.80 2.92 74.3 45.0 0.118 0.065 0.0111 0.0273 
4S 3.81 0.39 27.9 7.08 0.137 0.055 0.0336 0.0230 
5S 0.690 0.246 31.0 26.7 0.0222 0.0092 0.0606 0.0510 
6S 
  
>50 
 
0.0257 0.0025 0.00886 0.00182 
7S 1.60 0.43 30.2 19.7 0.0528 0.0216 0.0641 0.0490 
8S 
  
>50 
 
0.0140 0.0007 0.0138 0.0015 
9S 
  
>50 
 
0.0247 0.0021 0.00532 0.01651 
11S 
  
>50 
 
0.0190 0.0017 0.00682 0.00149 
12S 
  
>50 
 
0.00504 0.00036 0.00937 0.00062 
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Table S8 Michaelis Menten parameters for mouse sera 
  
Vmax (pmol*min
-
1*mg sera-1) 
Km (μM) 
Vmax/Km (pmol*min
-
1*mg sera-1µM-1) 
((Vmax/Km)/kuncat) (10
12 
pmol*mg sera-1µM-1) 
Substrate Value SEM Value SEM Value SEM Value SEM 
1C 
  
>50 
 
4.56 0.51 21.7 12.4 
2C 
  
>50 
 
1.62 0.33 10.7 5.7 
3C 
  
>50 
 
0.52 0.02 1.43 0.13 
6C 17.6 9.4 53.5 58.1 0.33 0.16 1.05 4.65 
7C 
  
>50 
 
2.04 0.27 3.86 4.04 
8C 
  
>50 
 
1.35 0.13 34.0 3.3 
9C 3.18 0.66 12.3 8.0 0.26 0.08 2.53 1.46 
10C 
  
>50 
 
0.93 0.08 9.87 4.74 
11C 
  
>50 
 
0.28 0.01 9.34 0.18 
1O 
  
>50 
 
14.01 0.83 0.28 0.03 
2O 
  
>50 
 
15.90 1.12 0.74 0.15 
3O 
  
>50 
 
57.0 43.2 7.41 13.17 
4O 
  
>50 
 
6.76 0.21 4.57 0.82 
5O 
  
>50 
 
20.3 12.0 52.6 214.7 
6O 437 135 11.5 8.65 38.1 15.6 8.42 7.39 
7O 929 103 25.9 7.30 35.8 14.1 4.08 7.40 
8O 
  
>50 
 
15.7 0.4 11.8 0.5 
9O 
  
>50 
 
6.69 0.17 4.30 0.36 
10O 
  
>50 
 
2.93 0.14 7.91 2.36 
11O 
  
>50 
 
3.24 0.16 0.06 0.03 
12O 
  
>50 
 
11.9 0.4 1.64 0.15 
1S 
  
>50 
 
14.2 1.4 1.22 0.54 
2S 
  
>50 
 
5.07 0.21 0.07 0.04 
3S 
  
>50 
 
9.47 0.76 0.88 0.32 
4S 
  
>50 
 
24.2 2.6 5.96 1.08 
5S 
  
>50 
 
1.93 0.13 5.27 0.71 
6S 
  
>50 
 
12.1 0.6 4.16 0.41 
7S 
  
>50 
 
11.9 1.1 14.4 2.6 
8S 
  
>50 
 
5.17 0.43 5.07 0.91 
9S 
  
>50 
 
1.29 0.11 0.28 0.89 
11S 
  
>50 
 
1.97 0.10 0.71 0.09 
12S 
  
>50 
 
5.74 0.53 10.7 0.9 
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Table S9 Primers used during this study. 
NO NAME SEQUENCE USE 
1 NWMN_0144_F TTTTCCTGATCCTGATTCAC Sanger Sequencing 
2 NWMN_0144_R ATGATGCTTCCATGTTTGTT Sanger Sequencing 
3 NWMN_0306_F AATACACCGGGTAACACAAC Sanger Sequencing 
4 NWMN_0306_R CGTTTTGTTGAGCTAATTCC Sanger Sequencing 
5 NWMN_0309_F ACCATGCTTAAAGGGATTTT Sanger Sequencing 
6 NWMN_0309_R TGTCACCTAAGTCAACACCA Sanger Sequencing 
7 NWMN_0407 (lpl4nm) _F CCGTTGGAGATAGGAAGTTA Sanger Sequencing 
8 NWMN_0407 (lpl4nm) _R TTTGTGCTTCTTTTGAACCT Sanger Sequencing 
9 NWMN_0654_F GAAAATGGAAGACTGATTGC Sanger Sequencing 
10 NWMN_0654_R TAATGCATCTGACAAAGTCG Sanger Sequencing 
11 NWMN_0762_F GGTGAAGTTTTGGACGATAA Sanger Sequencing 
12 NWMN_0762_R TTTTCATCTGTCCGACTTTT Sanger Sequencing 
13 NWMN_1101_F TCCACCTATTGGAATTATCG Sanger Sequencing 
14 NWMN_1101_R AGACGTTCAATTTCAGTGCT Sanger Sequencing 
15 NWMN_1192 (pgsA) _F TGGGACGAAGTAATTACAGTT Sanger Sequencing 
16 NWMN_1192 (pgsA) _R ATATCCCCCTTGTATCGTTT Sanger Sequencing 
17 NWMN_1308 (dapD) _F TCTATTCGTGGAGGTACGAT Sanger Sequencing 
18 NWMN_1308 (dapD) _R ATCGTATGTGAGCCATTACC Sanger Sequencing 
19 NWMN_1410_F CGATAAACCTAAACCACTCG Sanger Sequencing 
20 NWMN_1410_R ATAAACAATGCTTGCCAAAT Sanger Sequencing 
21 NWMN_1505_F TGAAGGTGAATTAAGCGATG Sanger Sequencing 
22 NWMN_1505_R TGCTATTCCCAATTTGTTCA Sanger Sequencing 
23 NWMN_1655_F GAATTGTTGCAATTTAATGGT Sanger Sequencing 
24 NWMN_1655_R AACGTAATCATGCTCCATTC Sanger Sequencing 
25 NWMN_1679_F CCATGGGAAAAATTAGACAA Sanger Sequencing 
26 NWMN_1679_R AAATATCGCCTCACCTTTTT Sanger Sequencing 
27 NWMN_1723 (hemY) _F GCCGAATACACATCCATTAT Sanger Sequencing 
28 NWMN_1723 (hemY) _R AACCTTTGTCTCTGCTTCAA Sanger Sequencing 
29 NWMN_1851 (nadC) _F AGCCATTTTAGCACCATAAA Sanger Sequencing 
30 NWMN_1851 (nadC)_R TAGAATCCTGTCCTCCTGAA Sanger Sequencing 
31 NWMN_2057 (mtlF)_F TGTACAACGGTGTTGTTTTG Sanger Sequencing 
32 NWMN_2057 (mtlF)_R CGGTGAATAGTACGAGAGGA Sanger Sequencing 
33 NWMN_2528_F ACTGATGCTTTACCAGAAAC Sanger Sequencing 
34 NWMN_2528_R TCAGCGGTAGTAATAAAGGT Sanger Sequencing 
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Table S10 Accession numbers for the isolates used in WhatsGNU analysis. 
Isolate Bioproject Biosample WGS SRA 
AD_3_179 PRJNA512846 SAMN10689346 VYMI00000000 SRR8389007 
AD_11_548 PRJNA512846 SAMN10689354 VYMN00000000 SRR8389002 
AD_14_565 PRJNA512846 SAMN10689355 VYMO00000000 SRR8389003 
AD_16_660 PRJNA512846 SAMN10689358 SJAX00000000 SRR8389044 
AD_61_868 PRJNA512846 SAMN10689401 VYNS00000000  SRR11016776 
AD_85_830 PRJNA512846 SAMN10689428 VYOK00000000 SRR8389056 
AD_96_471 PRJNA512846 SAMN10689447 VYOW00000000 SRR8389016 
AD_103_347 PRJNA512846 SAMN10689453 VYPC00000000 SRR8389035 
AD_113_782 PRJNA512846 SAMN10689463 VYPL00000000  SRR8389099 
SSTI_227_44 PRJNA563582 SAMN12642230 VUGB00000000 SRR11016228 
SSTI_228_42 PRJNA563582 SAMN12642226 VUGF00000000 SRR11016232 
SSTI_231_2 PRJNA563582 SAMN12642218 VUGN00000000 SRR11016241 
SSTI_233_51 PRJNA563582 SAMN12642215 VUGQ00000000 SRR11016244 
SSTI_235 PRJNA563582 SAMN12642210 VUGV00000000 SRR11016250 
SSTI_241_9 PRJNA563582 SAMN12642203 VUHC00000000 SRR11016198 
SSTI_247_75 PRJNA563582 SAMN12642193 VUHM00000000 SRR11016209 
SSTI_258_57 PRJNA563582 SAMN12642177 VUIB00000000 SRR11016226 
SSTI_290 PRJNA563582 SAMN12642174 VUIE00000000 SRR11016283 
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Chapter 5: Conclusion 
197 
 
5.1 Summary 
As the prevalence of multidrug-resistant bacteria and parasites continues to grow, there is an 
urgent need to develop novel antimicrobials with new targets. One underdeveloped therapeutic 
strategy is targeting microbial metabolism. Metabolic inhibitors are simple to design as substrate 
mimics and have multiple druggable options in each organism (1–4). Unfortunately, metabolic 
based inhibitors often rely on phosphate or phosphonate residues which are cell impermeable (5–
11). In this work, we add to a growing body of literature supporting the claim that lipophilic 
prodrugging strategies can increase the potency and cellular penetrability of phosphonate 
antibiotics (6, Chapter 2). However, current lipophilic prodrugging strategies are readily cleaved 
by host enzymes, greatly limiting the efficacy of these strategies in the clinic. For the first time, 
we have described how lipophilic prodrugs are activated intracellularly by microbial cells (12, 
Chapter 3). This key finding allowed us to launch a structure-activity relationship campaign on 
the two staphylococcal esterases responsible for prodrug activation, FrmB and GloB (Chapter 4). 
In addition to characterizing GloB (Chapter 4) and FrmB (Chapter 4, Appendix A), we also 
characterize the substrate specificity of human and mouse sera, demonstrating that simple 
modifications to ester prodrugs not only have an impact on rates of in vivo activation, but also 
can confer specificity to the location of prodrug activation (Chapter 4). This finding is also 
briefly examined for the unicellular parasite, Plasmodium falciparum (Appendix B). Together 
these studies lay an important groundwork for the development of targeted prodrug therapies. 
Finally, in work parallel to the primary focus of this thesis, we work to understand the origin of 
P. falciparum volatile compounds such as the mosquito attractive terpene, α-pinene (Appendix C 
and D). 
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5.2 Lipophilic prodrug transit 
We find that addition of the lipophilic promoiety, pivaloyloxymethyl (POM), to the phosphonate 
residues of ERJ significantly increases potency against S. schleiferi and S. pseudintermedius (6). 
POM-dependent potency increases have similarly been observed for ERJ, ERJ analogues, and 
other phosphonate antibiotics against several other organisms. Presumably, the underlying 
mechanism of POM-prodrug increases in potency stems from increased cellular permeability of 
phosphonate antibiotics, however it is also feasible that lipophilic prodrugging increases transit 
via a yet unknown transporter or siderophore. Supporting the first hypothesis, we find that while 
ERJ requires the glycerol-3-phosphate transporter, GlpT, for cellular entry, POM-ERJ can 
bypass GlpT mediated transport (Chapter 2). This finding has also been demonstrated in the 
gram negative organism, Francisella novicida (7). The exact mechanism by which POM 
prodrugs enter cells remains unknown however defining this mechanism will be crucial for 
understanding the potential uses and limitations of lipophilic prodrugs. 
One exciting application of lipophilic prodrugs is the targeting of drugs to specific cell types. 
How lipophilic prodrugs enter cells, whether through passive permeability or through enzyme 
mediated transit, remains unknown. Understanding how prodrugs enter cells will determine how 
broadly lipophilic prodrugging strategies can be applied. For instance, if lipophilic prodrugs truly 
passively enter cells, any lipophilic environment could harbor a prodrug. This is especially 
relevant when applying lipophilic prodrugs to the clinic and would impact the dosing strategies 
depending on the lipid content of each individual patient. Simple experiments utilizing mass-
spectrometry to track prodrug localization in whole liposomes as opposed to washed and lysed 
liposomes would serve to address this question. Similarly, development of liposome transit 
assays will allow an understanding of how lipid composition impacts prodrug transit.  
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5.3 The (lack of) efficacy of lipophilic prodrugs on gram-
negative bacteria 
Consistently we and others have observed that POM-ERJ is ineffective against E. coli and other 
gram-negative organisms (K. pneumoniae, S. typhimurium, S. sonnei, S. marcescens, and B. 
tahilandensis) (6). Notably, the compound POM-ERJ is ineffective against E. coli despite the 
activated compound, ERJ, displaying potent activity both against whole-cell E. coli and ERJ’s 
target, EcDXR (6) (Chapter 2). POM-HEX is similarly ineffective against whole cell E. coli, 
though whether HEX has activity against EcENO remains unknown. Three hypotheses exist 
which explain this lack of activity (Figure 1). First, gram negative organisms may not maintain 
the enzymes responsible for prodrug activation resulting in no accumulation of activated drug in 
vivo. Second, POM-prodrugs may not effectively transit the double membrane of gram-negative 
bacteria. The final hypothesis is that POM-prodrugs are activated by gram-negative bacteria but 
are not activated in the correct cellular location to achieve target inhibition. In the following 
section we will discuss the cases for and against each of these hypotheses. Defining why POM-
prodrugs do not have efficacy on gram-negative organisms will ultimately determine how 
efficacious targeted lipophilic prodrugging strategies will be as antimicrobials. 
 
Hypothesis 1) POM-prodrugs are not activated in vivo by gram-negative organisms. We 
have shown that in the gram-positive organism, S. aureus, two carboxylesterases, FrmB and 
GloB, catalyze the removal of the first POM-moiety in di-POM prodrugs (Chapter 4). At least 
one additional enzyme is required for the final conversion from the mono-POM-prodrug to the 
fully deprotected version of this compound, though the identity of this protein is unknown. GloB 
and FrmB both have orthologs in E. coli, suggesting that at least the first step in prodrug 
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activation may be possible in E. coli. Low conservation of FrmB and GloB between E. coli and 
S. aureus raises the possibility that the substrate specificities of these two enzymes vary 
disallowing prodrug activation in E. coli (Chapter 4). We have expressed each SaFrmB and 
SaGloB individually in E. coli using classical IPTG inducible promoters and protein expression 
vectors and find that E. coli remains insensitive to POM-ERJ. It remains possible that the final 
enzyme(s) in POM-prodrug activation are not present in E. coli.  
 
Hypothesis 2) POM-prodrugs do not diffuse through the periplasm. POM-prodrugs are 
hypothesized to bypass active transit mechanisms and diffuse freely into cells. In part, this 
hypothesis is founded on the GlpT independent transit of POM-prodrugged fosmidomycin and 
fosmidomycin analogues (6, 7). This hypothesis is also grounded in chemistry, as POM-prodrugs 
of small metabolites often have cLogP values > 1.5, reflective of the lipophilic nature of POM-
prodrugs. As a result, one would imagine that in single membrane cellular environments, the 
POM-promoiety has a rate of transition between the being exposed extracellularly and 
intracellularly, while similarly transitioning between the aqueous environment and the lipophilic 
environment. Rapid hydrolysis of intracellular POM-prodrugs would thus result in an 
accumulation of activated drug inside the cell.  
In gram-negative organisms which have two membranes separated by periplasmic space, pure 
diffusion of lipophilic compounds may result in no activation (Figure 1). An extracellular 
lipophilic prodrug entering a cell must first enter the extracellular membrane, subsequently 
diffuse into and across the periplasm before imbedding into the intracellular membrane, flipping 
from the periplasmic side of the intracellular membrane to the intracellular side of the 
201 
 
membrane, and finally dissociate into the cytoplasm for cleavage. For extremely lipophilic 
groups, the equilibrium between the extracellular membrane and periplasmic space would 
heavily favor the compound staying imbedded in the membrane. Any compound reaching the 
intracellular membrane would also heavily favor staying in that membrane. Given an infinite 
time, eventually the concentrations of POM-prodrug in each membrane would equilibrate, 
however this equilibration may not occur on a biologically relevant timescale.  
Perhaps the strongest evidence against this hypothesis is the potent anti-E. coli activity of a 
lipophilic prodrug of FR900098 (13). The designed FR900098 prodrug is similarly lipophilic to 
POM-ERJ (cLogP 2.14 and 1.44 respectively), however the promoieties are highly divergent. 
This suggests that compound lipophobicity alone does not prevent drug penetrance across the 
gram-negative double membrane. 
Hypothesis 3) POM-prodrugs are activated in periplasmic space and cannot cross the inner 
membrane. Several enzymes localize to the gram-negative periplasm, including at least three 
hydrolases (14). This raises the possibility that these hydrolases can activate, either fully or 
partially, POM-compounds. As even partially deprotected phosphonate molecules are membrane 
impermeable, any compound partially activated would be stuck in the periplasmic space (Figure 
1) (15). Perhaps the strongest evidence against this hypothesis is that in E. coli the glycerol-3-
phosphate transporter (GlpT) is localized to the inner membrane of E. coli (16, 17). This would 
suggest that in the case of POM-ERJ, conversion to ERJ in the periplasm would still result in 
inhibition of E. coli. One potential explanation remedying this disagreement is that partial 
conversion of POM-ERJ, for example to hemi-POM-ERJ, would likely be sufficient to prevent 
GlpT mediated transport while simultaneously leaving the molecule membrane impermeable. 
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With all three hypotheses addressed, POM-prodrug activation by two additional organisms needs 
to be considered. Mycobacterium tuberculosis, a gram intermediate, and Francisella novicida, a 
lightly stained gram-negative, are both killed by POM-prodrugs (7, 18). The cell wall of M. 
tuberculosis most closely resembles that of gram-positive organisms. However, the 
peptidoglycan layer of M. tuberculosis often accumulates a layer of lipids forming a 
pseudoperiplasm (19). This lipid layer is sufficient to retain gram-stain, though whether this 
layer recapitulates the typical gram-negative outer membrane for POM-prodrugs is not clear. 
Defining why POM-prodrugs do not inhibit gram-negative organisms will ultimately inform how 
widely lipophilic microbe specific prodrug targeting can be applied. If POM-prodrugs fail 
because they cannot cross the periplasm lipophilic prodrugging strategies targeting cytoplasmic 
esterases will never work for gram-negative organisms. If substrate specificity is the limiting 
factor then alternative promoieties, cleavable by gram-negative organisms, can be designed. 
Several experiments can be quickly performed to identify which of the above hypotheses is 
correct. Quantifying POM-prodrug activation in intact and lysed E. coli will directly answer 
whether E. coli has the capacity to activate POM-promoieties. Similarly, these experiments could 
be performed with pro-fluorescent substrates as in Chapter 4. Alternatively, the activity of POM-
prodrugs could be assayed in the presence of outer membrane pore formers such as polymyxin B 
as a means of decoupling prodrug transit and activity. 
5.4 The Cellular Roles of FrmB and GloB 
We have shown that carboxy ester prodrug activation in Staphylococcus spp. hijacks two 
esterases which are conserved throughout the tree of life, FrmB and GloB. Both enzymes have 
high GNU scores indicating they are well conserved within S. aureus and suggesting that their 
native function is important for cell survival and fitness. Somewhat surprisingly, deletion of 
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either FrmB or GloB results in no observable fitness defects in rich axenic culture. The native 
role(s) and physiological function(s) for FrmB and GloB remain unclear. 
GloB is annotated as a hydroxyacylglutathione hydrolase and is the second enzymatic step of the 
two-step glyoxalase pathway (comprised of GloA and GloB). This pathway is canonically 
viewed as a means of cellular protection from the toxic cellular metabolite, methylglyoxal. 
Methylglyoxal is spontaneously generated via nonenzymatic decomposition of glyceraldehyde-3-
phosphate (GAP) and dihydroxyacetone phosphate (DHAP) and is highly reactive impacting 
both protein function and glycating nucleic acids (20–22). Spontaneous coupling of 
methylglyoxal to glutathione, isomerization to D-lactoylglutathione, and subsequent hydrolysis 
to lactate and glutathione are catalyzed by GloA and GloB respectively. Despite endogenous 
methylglyoxal detoxification, addition of exogenous methylglyoxal kills S. schleiferi with a half-
maximal inhibitory concentration (IC50) in the low mM. Surprisingly, mutations in GloB do not 
impact S. schleiferi sensitivity to methylglyoxal, despite GloB having traditional GloB activity 
(Chapters 3 and 4). Two hypotheses potentially explain these findings. First, Staphylococcus spp. 
have multiple means of detoxifying methylglyoxal. S. aureus has 6 enzymes with predicted 
GloA activity and 3 enzymes with predicted GloB activity (including the GloB characterized 
here). In addition to the genetic redundancy within the glyoxalase pathway, S. aureus has 
recently been described to have a glutathione independent methylglyoxal detoxification 
mechanism (23). Beyond these two pathways, it is feasible that alternative oxidoreductases may 
play a role in methylglyoxal detoxification (24–26). Secondly, it is possible that while GloB 
mutations are tolerated in the short term, long term mutations in GloB become lethal. Protein 
glycation has only been demonstrated to slightly reduce the activity of glycolytic proteins 
suggesting some glycation may be tolerable (20). DNA glycation, conversely, is likely to be fatal 
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as it results in strand breaks and interstrand cross-linking, though these errors may be slow to 
accumulate (21).  
Similar to GloB, FrmB is also annotated as a detoxification enzyme. Rather than detoxifying 
methylglyoxal, FrmB is reported as a formylglutathione hydrolase, responsible for protecting 
against free cellular formaldehyde. Formaldehyde detoxification mirrors the glyoxalase pathway. 
Free formaldehyde is coupled to glutathione, oxidized via a formaldehyde dehydrogenase, before 
subsequent hydrolysis to formate and glutathione by FrmB. FrmB and FrmB orthologs have been 
characterized in several eukaryotes and prokaryotes, however the conditions where FrmB is 
required remains unclear (27–32). In Paracoccus denitrificans, FrmB is required for growth on 
methanol, methylamine, and choline suggesting that the pathway is essential for growth on 
methylotrophic growth in some organisms. In humans, mutation of the analogous esterase, 
esterase D, have been linked to Wilson’s disease and retinoblastoma (33). 
Several intriguing questions remain regarding the native roles of FrmB and GloB. Are their 
conditions where these two genes are essential? How redundant are the two pathways that FrmB 
and GloB comprise respectively? Growing FrmB or GloB mutant strains in a variety of nutrient 
conditions and stressors may reveal growth phenotypes which can be traced to a native function. 
Performing these experiments in competition with WT S. aureus may improve the sensitivity of 
these assays. Additionally, generating reporter strains that fluoresce upon FrmB or GloB 
transcription should be a relatively easy process that stands to improve assay sensitivity enabling 
a secondary means of evaluating when the cell requires FrmB or GloB (34). The impact of GloB 
or FrmB loss on survival and virulence in in vivo settings remains another interesting avenue. 
Ultimately, understanding how essential GloB and FrmB are for S. aureus growth and virulence 
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is an important consideration given how quickly POM-prodrug resistance can arise due to 
mutations in these genes. 
 
5.5 Alternative resistance mechanisms to POM-prodrugs 
We have described here three independent screens of Staphylococcus spp. resulting in resistance 
to POM-prodrugs. Multiple SNPs were identified in two esterases, FrmB and GloB. We have 
demonstrated that mutations in FrmB and GloB disrupt protein functionality and lead to a lack of 
prodrug activation in these mutant cells. However, several strains (S. aureus 8/25, S. schleiferi 
9/16, S. pseudintermedius 4/18) have no identified mutations in FrmB or GloB. The genetic 
cause of prodrug resistance in these staphylococci remains unclear. In several of the S. aureus 
strains, there are no candidate SNPs following Sanger sequencing. Further, of the strains with 
SNPs remaining, none of the impacted genes have an obvious mechanism of resistance. 
To explore the possibility of SNPs that were missed by Whole Genome Sequencing, we 
performed Sanger Sequencing on GloB and FrmB for each unexplained mutant of S. aureus. In 
addition to sequencing the coding region, we also sequenced the 500 bp upstream of the FrmB 
start codon to find any potential promoter disruptions. No mutations were identified in the 
coding region of either gene, nor were SNPs discovered in the promoter region of FrmB. The 
promoter region of GloB was not sequenced as there is no clear 5’ promoter region as GloB may 
be a member of an operon. Barring promoter disruptions in GloB and sequencing errors that 
obfuscate any existing SNPs one possible means of resistance in these strains is silencing of 
RNA encoding either GloB, FrmB, or yet unknown prodrug activating enzymes. The evolution 
of RNAi to change gene expression in response to drug selection has been observed in the fungal 
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pathogen Mucor circinelloides (35). S. aureus maintains several sRNAs indicating that the basal 
machinery to produce sRNAs (36–38). Further, addition of exogenous siRNA to S. aureus has 
been demonstrated to decrease gene expression (39). While siRNA mediated drug resistance has 
not yet been observed in bacteria, it appears all the requisite tools are in place. Investigation into 
how our remaining staphylococci have become POM-prodrug resistance will either result in 
identification of a new resistance mechanism for bacteria or more information about POM-
prodrug activation. 
5.6 Barriers to metabolic prodrug resistance 
The work presented here focuses on the development of two anti-metabolites, POM-HEX and 
POM-ERJ. In the organisms where these inhibitors have been studied, very rarely does resistance 
arise due to mutations in the target of the inhibitor. In E. coli, resistance to the ERJ analogue, 
fosmidomycin, through mutation of the target, DXR, only occurs upon PCR-mediated generation 
of resistance (13, 40). Similarly, after repeated fosmidomycin selections in P. falciparum, only 
one mutation in DXR has been observed (data not shown). Instead of mutating metabolic 
enzymes, resistance tends to arise via other mechanisms for metabolic inhibitors. In S. schleiferi 
and F. novicida, fosmidomycin resistance arises by disrupting the transporter which allows 
fosmidomycin into the cell (6, 41). In P. falciparum, fosmidomycin resistance arises through 
manipulation of the metabolic flux through the isoprenoid biosynthetic pathway (42). In part, this 
is to be expected. The enzymes targeted by anti-metabolites are essential. Most anti-metabolites 
are competitive active site inhibitors. Most mutations that would prevent active site inhibitor 
binding also disrupt binding of the native substrate. While resistance can arise via other 
mechanisms, metabolic rerouting only confers a partial resistance to fosmidomycin in P. 
falciparum and results in decreased fitness in the absence of fosmidomycin (43). Fosmidomycin 
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resistance in S. schleiferi and F. novicida can be acquired through disruption of active transit 
mechanisms, but lipophilic prodrugging strategies circumvent this resistance mechanism.  
Providing microbially targeted lipophilic promoieties can be developed, metabolism as an 
antibiotic target appears to be a ripe and underdeveloped area. Inhibitors can be readily designed 
as substrate mimics, and mutations in target proteins appear difficult to acquire. Quantifying the 
barrier to resistance for metabolic inhibitors and their prodrugged forms, as well as the 
development of animal models to study resistance generation are useful avenues for 
understanding the clinical efficacy of metabolic prodrugs. It is feasible that in clinical settings 
pathogens will simultaneously face both the prodrugged and active form of metabolic inhibitors. 
For POM-ERJ, it seems unlikely that S. schleiferi would simultaneously mutate both GlpT and 
either FrmB or GloB. Quantifying the likelihood of resistance in dual treatment would be more 
reflective of a clinical setting. Further, understanding the causes of this resistance may reveal 
mechanisms of metabolic regulation. Finally, combination therapy approaches to prodrug 
administration- using independent esterases for prodrug activation- may be an interesting avenue 
to pursue. 
 
5.7 The Complete Prodrug Activation Pathway 
We have demonstrated that mutations in the carboxylesterases GloB or FrmB confer resistance 
to di-POM-prodrugs. NMR characterization of the products of GloB and FrmB with di-POM 
prodrugs suggests that both enzymes remove the first POM moiety but are unable to remove the 
second and fully deprotect the compound (Figure 2). This is not altogether unsurprising when 
considering the reaction mechanisms for each FrmB and GloB. GloB is hypothesized to 
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deprotonate a water molecule and utilize the hydroxide ion to initiate attack on carbonyl 
substrates (44). A negatively charged, mono-POM compound may be repelled from the 
hydroxide, thereby preventing further hydrolysis. Similarly, FrmB is hypothesized to undergo 
several charge rearrangements during substrate hydrolysis. These charge transfers presumably 
become unfavorable for a charged mono-POM molecule. How mono-POM phosphonates are 
converted to the fully deprotected compound remains unknown. Understanding how prodrugs are 
fully activated affords an additional layer of specificity that can be engineered into prodrug 
activation. This approach may be especially useful in attempting to develop anti-metabolites 
which are otherwise host toxic. 
One hypothesis is that a phosphodiesterase is required to terminate prodrug activation. We have 
performed three forward genetic and one reverse genetic screen in efforts to identify prodrug 
activating enzymes. Our reverse genetic screen purposefully included every non-essential 
phosphodiesterase of S. aureus. Unfortunately, we were unable to identify enzymes beyond 
GloB and FrmB that contribute to prodrug activation. Two hypotheses are likely to explain this 
finding. First, the final enzyme is required to S. aureus growth. Secondly, the final enzymatic 
step could be performed by multiple enzymes with each enzyme being supplied in excess. If this 
is the case, deletion of just one enzyme would have no impact on POM-prodrug survival as other 
cellular enzymes would compensate for the lost activity. Our screens are unable to differentiate 
between these two hypotheses. To identify the final enzyme(s) in the prodrug activation 
pathway, the most straightforward approach is likely to perform an activity-based-proteomics for 
enzymes hydrolyzing mono-POM substrates (45–48). 
Targeting multiple microbial esterases simultaneously for prodrug activation may be an optimal 
strategy. While POM-prodrugs have no activity against enzymes, single mutations in either GloB 
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or FrmB do not fully protect S. aureus from POM-HEX. Presumably, this is because both GloB 
and FrmB can partially activate POM-HEX. Along this reasoning, creation of a S. aureus strain 
with mutations in both FrmB and GloB would likely result in high levels of resistance to POM-
HEX. As the development of microbe targeted promoieties continues, promoieties that have 
redundant activation pathways in bacteria may be preferred. Promoieties taking advantage of 
multiple esterases increases the number of mutations required for full resistance to arise. Likely, 
redundant targeting of esterases also increases the rate of prodrug activation in vivo, thereby 
contributing to higher intracellular levels of active drug.  
5.8 Prodrug activation in P. falciparum 
In Appendix B we discuss prodrug activation by one of the malarial parasites, Plasmodium 
falciparum. Since 2000, rates of malaria cases and deaths have fallen, yet P. falciparum still 
causes an enormous disease burden annually. The increasing prevalence of artemisinin resistance 
threatens the progress made to date. New antimalarial inhibitors which are safe and effective, 
especially those capable of killing all parasites after administration as a single dose, are urgently 
needed. Prodrug targeted therapies, whether activated by the erythrocyte or by the parasite, 
present an intriguing opportunity to both increase antimalarial potency while simultaneously 
improving pharmacokinetic properties. Identification and characterization of erythrocyte and 
parasite esterases remains a high priority for the development of these inhibitors. 
We developed a unique screening approach to identify the malarial esterase responsible for 
activation of POM-ERJ. In using parasites with mutations in HAD1 as a parental strain, we 
removed one mechanism of resistance to the activated compound, ERJ. Regrettably, we were not 
able to generate stable mutants resistant to POM-ERJ, and thus unable to identify the 
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Plasmodium esterase responsible for POM-ERJ activation. While this is promising for POM-
ERJ, more attempts at raising resistance should be made before classifying POM-ERJ as 
“irresistible”. One attractive explanation for the lack of resistance to POM-ERJ is that 
erythrocyte esterases activate POM-ERJ and release ERJ for normal uptake. As the parasites 
already have mutations in HAD1, resistance to ERJ may be more difficult for parasites to 
achieve. While it should be noted that increased resistance to fosmidomycin, an analogue of ERJ, 
has already been observed in HAD1 backgrounds (data not shown), POM-prodrugs being 
activated by erythrocyte esterases is not unheard of. Acyclic immucillin phosphonates (AIPs) are 
potent inhibitors of hypoxanthine-guanine-xanthine phosphoribosyltransferase (HGXPRT) in 
vitro, yet are ineffective at killing whole-cell parasites despite the enzyme being essential (49). 
POM-prodrugging of AIPs resulted in compounds that were membrane permeable, but still 
ineffective against P. falciparum due to cleavage in the erythrocyte (49). Similarly, POM-HEX, 
a potent inhibitor of enolase, potently inhibits erythrocyte enolase, ultimately causing hemolysis 
(15).  
While on the surface, erythrocyte targeted prodrugs may appear to be undesirable, targeting 
erythrocytes for prodrug activation may be extremely beneficial. P. falciparum demonstrates a 
remarkable ability to become resistant to antimalarials, including prodrugs (50). Targeting 
erythrocytes for prodrug activation eliminates one potential resistance strategy for the parasite. 
Further, this targeting strategy has enormous pharmacokinetic potential. Inhibitors that are 
trapped inside erythrocytes (due to the exposed charge on phosphonate residues, for example) 
will not be subject to the same metabolic processing that free serum compounds would. 
Likewise, drugged erythrocytes are not generally cleared by the liver or kidney, thereby reducing 
the amount of drug eliminated from the system. Depending on the length of time drug-loaded 
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erythrocytes circulate, these compounds could be highly effective prophylactics and may enable 
a drug-based malaria elimination campaign. While the major benefit conferred by lipophilic 
prodrugging of phosphonates appears to be membrane permeability, some inhibitors, such as 
fosmidomycin, appear to be readily taken up by P. falciparum. Likely uptake of fosmidomycin 
requires an active transport mechanism, however resistance to fosmidomycin via transporter 
mutations has not been observed yet as it has in bacterial systems. Potentially other nutrients 
required for P. falciparum growth also transit through this channel.  
While erythrocyte targeted prodrug activation is okay for some compounds, others, such as the 
AIPs, require parasite specific targeting. We have demonstrated that medium chain lipophilic 
ester promoieties are already targeted for parasite specific activation. These promoieties are 
removed at rates fast enough to observe significant fluorescence accumulation (Appendix B). 
More work defining the relevant esterases for P. falciparum and human erythrocytes is needed. 
Promoieties that are preferentially activated by either the P. falciparum esterase(s) or the 
erythrocyte esterase(s), and not serum esterases, have enormous potential to both increase the 
druggable space for antimalarials as well as improve dosing regimens and patient efficacy. 
5.9 Clinical opportunities for microbially targeted prodrugs 
Some microbial infections are difficult to treat as the pathogen becomes sequestered in locations 
that receive poor drug penetrance. For example, antituberculosis treatment courses exceeding 6 
months are routinely prescribed to eliminate drug tolerant Mycobacterium tuberculosis (Mtb) 
(51). One of the hallmarks of Mtb infection is the formation of large aggregates of immune cells 
around replicating Mtb. These lesions are termed granulomas and serve to limit the spread and 
success of Mtb. Unfortunately, the formation of these lesions also restricts delivery of antibiotics 
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to replicating bacteria (52–55). Similarly, bacterial infections that result in biofilms, or infections 
that localize to the bone such as S. aureus osteomyelitis, can be recalcitrant to treatment due in 
part to poor drug penetrance (56–60). Development of lipophilic prodrugs targeting microbes 
may increase drug penetrance thereby facilitating the development of new antimicrobial agents 
while simultaneously improving treatment efficacy.  
Selectively targeting prodrugs for microbial activation as opposed to host activation is likely 
feasible. How broadly prodrugs are activated amongst the microbial populations, however, 
remains an open and intriguing question. It is feasible that prodrug therapies will be broadly 
hydrolysable by all microbial populations. In this case, microbially targeted protherapies serve to 
help all microbial infections as broad-spectrum antibiotics. However, it is likewise possible that 
targeted protherapies will result in narrow-spectrum antibiotics, possibly even at the level of 
genus or species. On first glance, narrow-spectrum antibiotics may seem less useful as clinicians 
need to identify the cause of infection prior to treatment. However, narrow-spectrum antibiotics 
are less likely to acquire resistance mechanisms from microbial community members thereby 
prolonging their clinical efficacy (61). Additionally, treatment with narrow, as opposed to broad-
spectrum, antibiotics is less likely to result in microbiome depletion and mitigates the risk of 
Clostridium difficile infection (62, 63). 
If pro-therapies are indeed narrow-spectrum, promoieties can also be utilized to develop novel 
diagnostic imaging techniques. One can imagine in vivo imaging agents similar to the fluorescent 
pro-substrates that are inactive prior to activation. Once activated, these pro-substrates would 
subsequently yield high signal in the imaging channel. This diagnostic technique would be 
especially useful in diagnosing microbial infections in body sites where samples are difficult to 
213 
 
acquire, or where the diagnostic itself is slow or unreliable. For example, culture based Mtb 
diagnostics are limited by the growth rate of Mtb, and diagnosis of S. aureus osteomyelitis often 
requires invasive bone biopsies (64, 65).  
5.10 Transitioning microbially targeted prodrugs to the 
clinic 
In chapter 4 we demonstrate that the microbial esterases FrmB and GloB from S. aureus exhibit 
catalytic specificity differences for simple ester substrates. Further, the catalytic specificities of 
FrmB and GloB are discriminatory from human and mouse serum esterases suggesting that ester 
promoieties may be tuned to activation by staphylococcal esterases. This finding has many 
potential clinical implications. Microbially targeted prodrugs open significant druggable space 
for development. Additionally, selective prodrug activation will increase the therapeutic index of 
many antimicrobials. Before these compounds can move into clinical development, several 
questions need to be addressed. 
In chapter 4 our analysis focuses on the catalytic specificity of microbial esterases and serum 
esterases using a fluorogenic reporter library. This analysis is likely an oversimplification of the 
true biological situation. We directly compare the activity of purified microbial esterases to the 
total protein in unpurified human sera. Additionally, when prodrugs are dosed in a clinical 
setting they circulate in the serum for an undefined period before eventually entering the target 
cells. We are unable to account for variable incubation time in our assays. Finally, the rate of 
prodrug activation required for each antimicrobial has the potential to vary. Some compounds 
will be exceptionally potent inhibitors only requiring a few molecules of inhibitor per cell, 
whereas others will require more. A slow rate of intracellular prodrug activation is tolerable for 
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exceptionally potent but will not suffice if large amounts of activated drug are required. While 
the fluorogenic substrate library facilitates high-throughput analysis, it is not capable of 
answering the question “how fast is fast enough?”. Several prodrugs should be synthesized using 
the same active compound but selecting varying promoieties. These varying promoieties should 
subsequently be evaluated for their ability to survive hydrolysis in sera and their ability to kill the 
target organism. In doing this, direct comparisons back to the rates of prodrug activation 
identified via the fluorogenic screen can be used to benchmark relevant rates of microbial 
prodrug activation, and meaningful stability in human sera. This strategy also allows for the 
expansion of the fluorogenic substrate library, enabling promoiety screening independent of the 
warhead. 
In addition to defining the relevance of prodrug activation rates, an important consideration prior 
to clinical deployment of these compounds is the toxicity of prodrug byproducts. POM-prodrug 
activation likely results in the release of formaldehyde and pivalic acid, however more chemical 
analysis of prodrug activation products is required (10). Both pivalic acid and formaldehyde raise 
concern for their release into humans. Long term exposure to pivalic acid in humans has 
associated with reduced levels of carnitine (66). For a full microbially targeted prodrug, toxic 
prodrug byproducts would be expected to remain microbially contained if the cell remained 
intact. Further research in understanding how prodrugs are activated, and what happens to 
prodrug byproducts following microbial activation, is necessary. 
Perhaps the final challenge for the development of microbially targeted prodrugs will be 
assessing the pharmacokinetics and dynamics (PK/PD) profiles and efficacy of these prodrugs. 
PK/PD studies are necessary to understand how a developing drug performs in a more complex 
215 
 
system such as host. These studies directly inform the dosing of novel drugs and serve as 
preliminary proof that the developing drug is safe. Typically, PK/PD models are first tested in a 
murine model and subsequently performed in additional animal models that more closely 
replicate humans. In chapter 4, we demonstrate a longstanding understanding that the esterases in 
mouse sera are different than those in human sera. The benefits of targeted prodrugs stem from 
the prodrug being delivered intact at the site of infection. Thus, if prodrug PK/PD models do not 
accurately reflect prodrug cleavage, the efficacy and dosing requirements of prodrugs will be 
incorrect. Several tools exist already to combat this barrier. First, esterase inhibitors have been 
developed in effort to reduce esterase activity in mice (67). Second, esterase 1 knockout mice 
have been developed in an effort to recapitulate human sera in mice (68). Finally, alternative 
animals which more closely mimic human sera exist as model systems including guinea pigs, 
rabbits, and rats. Unfortunately, each organism has discrete differences in carboxylesterase 
activity (69–78). Carboxy ester stability will likely need to be evaluated in a serum model for 
each animal to find activity profiles matching those of humans before efficacy and PK/PD 
studies can be performed. 
 
5.11 Closing thoughts 
Rising rates of antimicrobial resistance are an important concern for global health and we 
urgently need to develop new therapeutic strategies and incentivize antimicrobial research. The 
development of microbially targeted prodrugs not only increases the druggable space for 
antimicrobials but also serves to de-risk antimicrobial development by increasing drug 
specificity. In this work, we have described the benefits of lipophilic prodrugging strategies. 
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Additionally, we have uncovered the partial activation mechanism for these prodrugs in 
staphylococci. Finally, we have highlighted how knowledge of the activation pathway for 
lipophilic prodrugs can guide targeted prodrug design. We expect that these studies will enable 
the development of microbe-specific prodrugs and novel imaging based diagnostic mechanisms 
for microbial infections. 
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5.12 Figures 
 
 
Figure 1 Models for lack of POM-prodrug activity on gram negative organisms.  
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Figure 2 Proposed POM-HEX activation mechanism. GloB and FrmB accumulate mono-POM-HEX (circled in gray) when incubated 
individually or in combination with POM-HEX. Promoieties highlighted in green. 
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A.1 Introduction 
S. aureus is a highly successful human pathogen responsible for a wide variety of invasive and 
life-threatening infections. Widespread methicillin resistance in S. aureus (MRSA) is especially 
concerning and has been labeled a “serious threat” by the Centers for Disease Control and 
Prevention (CDC) (1). New antimicrobials are urgently needed to address this pressing threat. 
 
Recently, advancements in the understanding of prodrug activation in S. aureus have led to the 
possibility of S. aureus targeted prodrugs (Chapter 4). One of the identified proteins, FrmB, was 
found to have several mutations which resulted in resistance to pivaloyloxymethyl (POM) 
prodrugs. FrmB is a carboxylesterase with a suggested biological function of detoxifying 
formaldehyde (2). We previously hypothesized that mutations in FrmB prevent catalytic activity 
thereby conferring resistance to POM prodrugs. The structural rationale for FrmB mutations 
conferring POM-prodrug resistance, was not explored. Here, we examine how each of the 
previously identified mutations in FrmB impact catalytic activity. Further, we explore how FrmB 
dimerization impacts catalytic activity as well as the impact of mutations in the flexible capping 
domain.  
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A.2 Methods 
A.2.1 Cloning of mutant FrmB 
FrmB mutations (Table 1) were generated using QuikChange PCR mutagenesis (Agilent) using 
the previously cloned WT FrmB from S. aureus as a template and the primers listed in Table 2. 
Mutant FrmB constructs were cloned into the E. coli expression vector, pET28a, to introduce a 
hexa-histidine tag, and plasmids were maintained in TOP10 chemically competent E. coli 
(Thermofisher). All plasmids and mutations were verified using Sanger sequencing. 
 
A.2.2 Mutant FrmB purification 
FrmB mutant plasmids were introduced into chemically competent BL21 (DE3) E. coli cells 
(Thermofisher) and selected for using 50 μg/mL kanamycin. A single colony was used to 
inoculate a 5 mL overnight culture in LB media supplemented with 50 μg/mLkanamycin. The 
following day, 2 mL of the overnight culture was back diluted into 1 L terrific broth (24 g Yeast 
Extract, 12 g Tryptone, 9.4 g K2HPO4, 2.2 g KH2PO4, 0.04% glucose per liter) supplemented 
with 50 μg/mL kanamycin. Cultures were grown at 37 ºC until reaching an OD600 of 0.4-0.7 at 
which point the cultures were chilled to 16 ºC and protein expression was induced with 0.5 mM 
isopropyl β-D-1-thiogalactopyranoside. Following 16 hours of induction, cell cultures were 
harvested via centrifugation at 6000 x g for 15 min at 4 ºC. Cell pellets were resuspended in 45 
mL lysis buffer (25 mM Tris pH 7.5, 250 mM NaCl, 1 mM MgCl2, 10% glycerol, 1 mM PMSF, 
and 20 mM imidazole). Pellets were lysed via sonication and insoluble cell fractions were 
removed via centrifugation at 12,000 x g for 45 minutes at 4 ºC.  Hexa-histidine tagged FrmB 
mutants were purified via nickle agarose beads. Bound protein was washed with 50 mL lysis 
buffer, and washed protein was eluted with lysis buffer supplemented with 300 mM imidazole. 
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Eluted proteins were dialyzed in dialysis buffer containing 25 mM Tris pH 7.5, 100 mM NaCl, 
and 20% glycerol. Protein concentrations were determined using the Bradford assay. 
 
A.2.3 FrmB activity assay 
FrmB activity against the substrate 4-nitrophenyl acetate was determined in 100 μL assays in 96 
well clear flat bottom plates. Assays were performed in buffer consisting of 25 mM tris pH 7.5, 
250 mM NaCl, 1 mM MgCl2, 10% glycerol, and 5 μg purified protein. 4-nitrophenyl acetate 
concentrations were varied from 1 mM to 0.5 μM in 2-fold dilutions. Reactions were initiated 
through the addition of substrate and the formation of 4-nitrophenol was monitored 
spectrophotometrically at 405 nm using a Tecan platereader. Prior to assay initiation, assay 
plates were pre-warmed to a temperature of 37 ºC. Assays preformed without the addition of 
enzyme were used as a negative control for background substrate hydrolysis. Reactions were 
performed in triplicate with technical duplicates. The initial velocity for each reaction was fit to a 
line using Graphpad Prism. Initial rates of reaction were plotted versus the concentration of 
substrate to a standard Michaelis-Menten equation using Graphpad Prism to obtain estimates of 
the Vmax and Km for each mutant. For proteins where saturating conditions were not met, kcat/Km 
was estimated using the following derivation of Michaelis Menten- 
Equation (1)       
 
When Km>>[S] 
Equation (2)      
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Therefore 
Equation (3)      
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A.3 Results  
A.3.1 SNPs near FrmB active site disrupt catalytic activity 
Mutations in the formylglutathione hydrolase, FrmB, confer resistance to the carboxy ester 
prodrug POM-HEX in S. aureus. POM-HEX requires hydrolysis to inhibit the target enzyme, 
enolase. As, WT FrmB hydrolyzes POM-HEX, a natural conclusion of these two pieces of 
evidence is that mutations in FrmB disrupt catalytic activity, thereby conferring protection to 
POM-HEX. Three of the four observed mutations in FrmB rationally should disrupt protein 
function. M74X truncates a majority of FrmB including the active site. Two additional 
mutations, G119D and M122I, are located within the active site and conceivably disrupt protein 
function (Figure 1A).  
 
To test the hypothesis that FrmB mutations disrupt catalytic activity we substituted G119 and 
M122 with alanine mutations (Table 1). We utilized the chromogenic esterase substrate, 4-
nitrophenyl acetate, which results in a change of absorbance upon hydrolysis. Mutation of G119 
to alanine or M122 to alanine results in protein with no detectable activity (Figure 1B).  
 
A.3.2 SaFrmB dimerization may be critical to FrmB function 
The last observed mutation conferring resistance to POM-HEX, G14R, is puzzling as the G14 is 
located on a loop far from the active site (Figure 2A). Size exclusion chromatography indicates 
that FrmB is a dimer in solution, and the crystal structure of FrmB has two monomers in the 
asymmetric unit (Figure 2A). Thus, a natural hypothesis is that FrmB is only catalytically active 
as a dimer and disruption of the dimerization interface results in attenuated catalytic activity.  
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We next created a FrmB mutation with residue G14 mutated to an arginine. In addition to G14R, 
we generated two additional mutations in a different portion of the dimerization interface: S32A 
and V36L (Figure 2B). The resulting mutant proteins exhibit markedly reduced catalytic activity 
(Figure 2C, Table 3). Each of these mutations exhibits a >6-fold reduction in catalytic specificity 
which appears to be driven by a lack of enzyme turnover. Taken together, this structural and 
enzymatic data suggests that FrmB dimerization is important for substrate catalysis, but not 
substrate binding. Future studies should more rigorously assess the dimeric state of FrmB 
mutants as well as the binding affinity of FrmB mutants. 
  
A.3.3 The flexible capping domain of FrmB is essential for protein function. 
Previous studies on structurally similar esterases have suggested that the flexible cap domain of 
FrmB may be responsible for substrate specificity (Figure 3A) (3–5). Additionally, mutations in 
this region may impact the thermostability of the esterase (5). Unfortunately, the flexible cap 
domain is not entirely resolved in the crystal structure of SaFrmB due to poor electron density. 
We generated mutations in several residues of the flexible cap domain including I167P, L170D, 
and G175A (Figure 3A). Surprisingly, each of these mutations completely ablated catalytic 
activity (Figure 3B, Table 3). I167P likely severely reduces the flexibility of this loop. Likewise, 
G175A introduces steric hindrance and presumably reduces the flexibility of the capping 
domain. While L170D adds some steric bulk, likely the more problematic change is the addition 
of a charge which may alter normal loop movement. In summation, these data suggest that the 
flexibility of the cap domain is essential for FrmB function. How these mutations impact 
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substrate utilization and temperature sensitivity, as well as the affect of less drastic substitutions, 
remains unknown. 
xxxii 
 
A.4 Discussion 
FrmB has been identified as an activator of POM-prodrugs in S. aureus. Preliminary structure-
activity relationships have identified several substrates that are well-cleaved by FrmB but poorly 
cleaved by human sera, suggesting these substrates may be used to target FrmB for S. aureus-
specific prodrugs. Here we characterize several domains of FrmB using targeted mutagenesis. 
We find that mutations in the active site, dimerization interface, and the capping domain all 
severely attenuate FrmB activity. Notably, mutations to the dimeric interface appear to reduce 
substrate turnover irrespective of substrate binding. This suggests that dimerization is critical for 
the catalytic competency of FrmB.  
 
Previous studies have demonstrated esterases requiring dimerization for catalysis (6, 7). Other 
studies have demonstrated that mutation of the catalytic serine and histidine from other α/β 
hydrolases results in decreased substrate turnover and binding affinity. Conversely, mutagenesis 
of the catalytic aspartate only impacts substrate turnover (8). As a result, the prevailing model in 
the field suggests that esterase dimerization leads to movement of the catalytic aspartate into a 
catalytically competent orientation.   
 
Further analysis, especially regarding the ability of FrmB to change substrate specificities, are 
warranted to understand the possibility of FrmB mediated prodrug resistance. Beyond FrmB as a 
potential prodrug activator, esterases also play an important role in industrial conversion and 
production of chemicals. Utilizing FrmB as a scaffold for specific esterase activity may be 
possible.  
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A.5 Figures 
 
Figure 1 SNPs near the FrmB catalytic triad disrupt FrmB activity. (A) Crystal structure of SaFrmB. Indicated in gray is the catalytic triad, 
indicated in orange are the mutations observed to confer POM-HEX resistance. (B) Catalytic activity of WT and mutant FrmB. Values are the 
means of three independent experiments performed in technical duplicate. Error bars denote SD. 
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Figure 2 Mutations at the dimerization interface disrupt FrmB activity. (A) Locations of SNP G14R (orange sticks) in relation to catalytic 
triad (gray spheres). FrmB monomer A in green, monomer B in blue. (B) Location of mutations made at the dimerization interface. (C) Activity 
of mutant FrmB proteins. Displayed are the means of three independent experiments with technical duplicates. Error bars denote SD. 
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Figure 3. Mutations in the flexible cap of FrmB ablate catalytic activity. A) Locations of mutations made at in the flexible capping domain. 
Residues 168-175 are not observable in the electron density due to flexibility. Catalytic triad represented in gray spheres. (B) Activity of mutant 
FrmB proteins. Displayed are the means of three independent experiments with technical duplicates. Error bars denote SD. 
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A.6 Tables 
Table 1. FrmB mutants generated and verified by Biol 4522. 
Position 
Natural Amino 
Acid Substitutions Made 
Kinetics 
Tested 
14 Gly Arg Arg 
32 Ser Ala Ala 
36 Val Ala, Leu Leu 
71 Ala Asp, Trp Trp 
119 Gly Ala, Cys Ala 
122 Met Ala, Ser Ala 
167 Ile Pro Pro 
170 Leu Ala, Asp Asp 
175 Gly Ala Ala 
221 Ile Ala, Glu Glu 
245 Arg Leu 
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Table 2. Primers used during this study 
Primer Name Sequence 
S32A Forward CCGGAAGATCAAAGCTTCTTTAATGCGGATACAACTG 
S32A Reverse CAGTTGTATCCGCATTAAAGAAGCTTTGATCTTCGCG 
S32R Forward CCGGAAGATCAAAGCTTCTTTAATCGGGATACAACTG 
S32R Reverse CAGTTGTATCCCCATTAAAGAAGCTTTGATCTTCGCG 
V36A Forward ACGGATACAACTGCTAAACCATTAAAAACT 
V36A Reverse AGTTTTTAATGGTTTAGCAGTTGTATCGCT 
V36L Forward ACGGATACAACTCTTAAACCATTAAAAACT 
V36L Reverse AGTTTTTAATGGTTTAAGAGTTGTATCGCT 
A71D Forward GCGAATGAACACAAATTAGATGTGATTATGCCCAATGTGG 
A71D Reverse CCACATTGGGCATAATCACATCTAATTTGTGTTCATTCGC 
A71W Forward GCGAATGAACACAAATTATGGGTGATTATGCCCAATGTGG 
A71W Reverse CCACATTGGGCATAATCACCCATAATTTGTGTTCATTCGC 
G119C Forward GACAATTTTATAGCATGTCACTCTATGGGAGGATATGGC 
G119C Reverse GCCATATCCTCCCATAGAGTGACATGCTATAAAATTGTC 
G119A Froward GACAATTTTATAGCAGCTCACTCTATGGGAGGATATGGC 
G119A Reverse GCCATATCCTCCCATAGAGTGAGCTGCTATAAAATTGTC 
M122A Forward CAGGTCACTCTGCGGGAGGATATGGCAC 
M122A Reverse GTGCCATATCCTCCCGCAGAGTGACCTG 
M122S Forward GCAGGTCACTCTTCGGGAGGATATGGCAC 
M122S Reverse GTGCCATATCCTCCCGAAGAGTGACCTGC 
I167A Forward TCAAAAGAGGCCATAGCTGGCAATCTTTCAAGT 
I167A Reverse ACTTGAAAGATTGCCAGCTATGGCCTCTTTTGA 
I167P Forward TCAAAAGAGGCCATACCTGGCAATCTTTCAAGTG 
I167P Reverse CACTTGAAAGATTGCCAGGTATGGCCTCTTTTGA 
L170D Forward GAGGCCATAATTGGCAATGATTCAAGTGTTAAAGGAAC 
L170D Reverse GTTCCTTTAACACTTGAATCATTGCCAATTATGGCCTC 
L170P Forward GACGCCATAATTGGCAATGCTTCAAGTGTTAAAGGA 
L170P Reverse TCCTTTAACACTTGAAGCATTGCCAATTATGGCCTC 
G175A Forward GGCAATCTTTCAAGTGTTAAAGCTACTGAACATGATCCG 
G175A Reverse CGGATCATGTTCAGTAGCTTTAACACTTGAAAGATTGCC 
G175H Forward GGCAATCTTTCAAGTGTTAAACACACTGAACATGATCCG 
G175H Reverse CGGATCATGTTCAGTGTGTTTAACACTTGAAAGATTGCC 
I221A Forward ATTTATCACGCGCAAATGTTCCTTATCAATTTGAAGATGGACC 
I221A Reverse GGTCCATCTTCAAATTGATAAGGAACATTTGCGCGTGATAAAT 
I221E Forward ATTTATCACGCGAAAATGTTCCTTATCAATTTGAAGATGGACC 
I221E Reverse GGTCCATCTTCAAATTGATAAGGAACATTTTCGCGTGATAAAT 
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Table 3. Michaelis-Menten parameters for mutant FrmB. All values are the results of three independent experiments performed in technical 
duplicate. N/A indicates that no appreciable activity was detected using 5 μg protein. 
Mutant Kcat/Km (min-1μM-1) Kcat/Km*kuncat (μM-1) 
  Mean SE Mean SD 
WT 8.31E+02 2.4E+01 4.04E+09 2.50E+09 
G14R 1.22E+02 7E+00 5.91E+08 6.70E+08 
S32A 1.34E+02 9.7E+00 6.54E+08 9.97E+08 
V36L 7.16E+01 6.3E+00 3.48E+08 6.5E+08 
A71W N/A N/A N/A N/A 
G119A N/A N/A N/A N/A 
M122A N/A N/A N/A N/A 
I167P N/A N/A N/A N/A 
L170D N/A N/A N/A N/A 
G175A N/A N/A N/A N/A 
I221E 2.88E+01 4.5E+00 1.40E+08 4.61E+08 
     
     
kuncat (1/min) 2.06E-07 9.7E-09   
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B.1 Introduction 
Antimalarial drug resistance threatens an already fraught global health issue of enormous scale. 
In 2018, over 210 million individuals suffered a malaria infection (1). Further, resistance to the 
current frontline therapy, artemisinin, has become increasingly common and is detected at a 
significant prevalence (>5%) in south-east Asia, Guyana, Papua New Guinea, and Rwanda (2). 
New antimalarials are urgently needed to combat this looming crisis. 
 
One approach to drug development which has attracted recent attention is prodrugging. A 
prodrug is a compound which has been chemically modified to be inactive until converted 
(chemically or enzymatically) back into the active compound. Prodrugging affords chemists a 
means of altering the drug-like properties of a drug (e.g. solubility, oral absorption), without 
modifying the underlying active drug. This is especially attractive when the goal is to develop 
inhibitors, such as phosphonates, which are otherwise cellularly impermeable as lipophilic 
promoieties may be attached to confer increased cellular penetrance.  
 
We have previously deployed the lipophilic promoiety, pivaloyloxymethyl (POM) to improve 
the potency of the isoprenoid biosynthesis inhibitor, fosmidomycin, and several structural 
analogues (3). Unfortunately, the POM-promoiety is rapidly cleaved by serum esterases 
returning the less potent phosphonate warhead in any treatment setting (3). Identification of the 
POM-prodrug activating enzyme(s) of P. falciparum will allow for the structure-guided 
development of promoieties which are specifically activated by P. falciparum. 
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One P. falciparum esterase, PfPARE, has recently garnered attention as a prodrug activatior for 
unbranched or minimally branched C6 esters (4–6). We have previously found that PfPARE 
mutations do not confer resistance to our prodrugged analogue of fosmidomycin, POM-ERJ 
(Figure 1). This finding suggests that additional esterases, either parasite or erythrocyte resident, 
must be responsible for POM-ERJ activation. Here, we attempt to identify the esterase 
responsible for POM-prodrug activation in P. falciparum. We also demonstrate the localization 
of simple ester prosubstrates in P. falciparum, laying the groundwork for future exploration in P. 
falciparum targeted prodrug development. 
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B.2 Methods 
B.2.1 P. falciparum maintenance and culturing 
The P. falciparum strain used for POM-ERJ selection was the had-1 strain, AM1-G3 (7). For 
imaging experiments, the P. falciparum strain used was 3D7 (8). Strains were cultured at 37 °C 
in a suspension of 2% human erythrocytes in RPMI-1640 medium (Sigma-Aldrich, SKU R4130) 
supplemented with 27 mM sodium bicarbonate, 11 mM glucose, 5 mM HEPES, 1 mM sodium 
pyruvate, 0.37 mM hypoxanthine, 0.01 mM thymidine, 10 μg ml-1 gentamycin, and 0.5% 
albumax (Life Technologies) under an atmosphere of 5% O2/ 5%CO2 / 90% N2 as previously 
described (9). Culture growth was monitored by microscopic analysis of Giemsa-stained blood 
smears. 
 
B.2.2 Selection of POM-ERJ resistant P. falciparum 
The had-1 strain, AM1-G3 was used as the parental strain for resistant mutant selection. The 
parental strain was seeded at 0.5 % parasitemia in 4 mL cultures at the initiation of POM-ERJ 
selection. Parasites were cultured in media containing 60, 120, or 300 nM POM-ERJ (1, 2, and 
5x the 3-day half maximal growth inhibitory concentration), and continuously maintained at or 
below a parasitemia of 4 %. In some cases, drug was removed from the media once parasites 
were no longer visible in culture wells.  
 
B.2.3 Quantification of POM-ERJ resistance 
Asynchronous P. falciparum cultures were counted microscopically via Giemsa-stained blood 
smears and diluted to a parasitemia of 0.5%, prior to being cultured in POM-ERJ concentrations 
ranging from 3 μM to 5.9 nM. After 3 days, parasite growth was quantified by measuring DNA 
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content using PicoGreen (Life Technologies) on a FLUOstar Omega platereader (BMG Labtech) 
at 485 excitation and 528 emission (10). The half maximal inhibitory concentration (IC50) was 
calculated by nonlinear regression in GraphPad Prism.  
 
B.2.4 P. falciparum microscopic analysis of prodrug activation 
Asynchronous cultures of P. falciparum 3D7 were enriched for infected erythrocytes using a 
magnetic cell fractionation system (MACS, Mitenyi Biotec). Parasite cultures were loaded onto a 
MACS column pre-equilibrated with culture medium and placed within a magnetic field. 
Parasites were subsequently washed with culture medium until unbound erythrocytes no longer 
eluted from the column, at which point the column was removed from the magnetic field and 
infected erythrocytes were recovered in culture media. Immediately prior to cell loading, P. 
falciparum cultures were diluted to a concentration of 5x106 cells/mL and transferred into sterile 
filtered Dulbecco’s phosphate-buffered saline (DPBS) supplemented with 20 mM glucose. Cells 
were immediately loaded on a bacterial CellASIC Onix microfluidic plate (Millipore Sigma 
B04A-03) prewarmed to 37 °C and pre-equilibrated with DPBS + 20 mM glucose. Prior to plate 
loading, CellASIC Onix microfluidic lines were flushed with DPBS + 20 mM glucose or 10 µM 
fluorescent prosubstrate in DPBS + 1% DMSO + 20 mM glucose. 
 
The microfluidics plate was loaded onto a Nikon Ti-E inverted microscope (Nikon Instruments, 
Inc) equipped with a 100x Plan N (N.A. = 1.45) Ph3 objective, X-cite 120 LED light source 
(Lumen Dynamics), and an OrcaERG CCD camera (Hammamatsu Photonics, Bridgewater, N.J), 
which was used to obtain both phase contrast and fluorescent images. Filter sets were purchased 
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from Chroma Technology Corporation. Cells were loaded until a single field of view contained 
20-50 cells. Following cell loading, PBS was flown through the flow cell (t = 0) and cells were 
observed in both phase and fluorescent channels for 10 minutes before the flow media was 
switched to PBS containing 1% DMSO and 10 µM fluorescent pro-substrate. Images were 
captured every two minutes for a total of 44 minutes, and all experiments were undertaken at 37 
°C. The phase contrast exposure time was kept constant at: 200 ms, and the fluorescent channel 
exposure time was kept constant at 500 ms. For fluorescent images, the gain remained constant 
across all experiments. Image capture and analysis was performed using Nikon Elements 
Advanced Research software. 
 
xlvii 
 
B.3 Results  
B.3.1 Generation of POM-ERJ resistant P. falciparum 
We attempted to generate POM-ERJ resistant P. falciparum by culturing the had1 strain, AM1-
G3 in the presence of 1x, 2x, or 5x the half maximal inhibitory concentration (IC50) of POM-
ERJ. We selected AM1-G3 as the parental strain as we were interested in identifying the prodrug 
activating enzymes responsible for POM-ERJ activation, and HAD1 loss appears to be a rapid 
and easy means of generating resistance to isoprenoid biosynthesis inhibitors. Within 3-5 days of 
drug application no parasites were visibly replicating in the 2x and 5x IC50 conditions. Parasites 
were cultured continuously in the presence of POM-ERJ, and following 3 weeks of culturing, the 
1xIC50 condition had robust levels of parasites present. The IC50 of these strains against POM-
ERJ was determined and found to be insignificantly different than the wild-type parental strain 
(Figure 2A). 
 
We next attempted an alternative selection method wherein drug is kept in the culture media 
until parasites are no longer visible and then is removed to allow an expansion of any surviving 
parasite populations. 2x or 5x the IC50 of POM-ERJ was applied to AM1-G3 until parasites were 
no longer visible via thick smear. Once parasites had recovered, the IC50 of these strains against 
POM-ERJ was again determined and found to be insignificantly different than the parental strain 
(Figure 2B).  
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B.3.2 P. falciparum carboxyester activation 
We next sought to understand where whole-cell P. falciparum activates prodrugs. We enriched 
for late-stage parasites (trophozoites and schizonts) via magnetic bead sorting and transferred 
parasites into a microfluidics device placed under a fluorescence microscope. This microfluidics 
device allows for individual cells to be held in place while the surrounding media is rapidly 
exchanged. We acquired a 32-compound pro-fluorescent carboxy ester substrate library which 
fluoresces upon ester cleavage (11). We selected 2 compounds, 3C and 1O, which display 
moderate and high catalytic specificity respectively, for the Staphylococcus aureus esterases, 
FrmB and GloB, and tracked pro-substrate activation by P. falciparum (Figure 3A).  
 
As observed for wild-type S. aureus, compound 1O is rapidly activated and the fluorescent signal 
reaches saturation within the first frame of the experiment. Conversely, pro-substrate 3C is 
slowly activated and the fluorescent signal increases steadily through the course of the 
experiment (Figure 3B). As observed in our experiments with S. aureus, compound 1O has a 
significant amount of background fluorescence, suggesting that the probe has slowly activated 
ahead of introduction to the microfluidics device. 
 
One attractive advantage of prodrugs is targeted activation to specific tissues or cellular 
compartments. P. falciparum has several compartments where prodrug activation could be 
targeted, including the parasite cytoplasm, food vacuole, and the surrounding erythrocyte 
cytoplasm. Again, using our microfluidics setup we use compound 3C to visualize where the 
substrate is activated in P. falciparum. Fluorescence predominantly accumulates in the parasite 
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cytoplasm and appears to be excluded from the parasite food vacuole and the erythrocyte 
cytoplasm (Figure 4). 
 
While our imaging field was dominated by trophozoites, we were fortunately able to capture 
some cells infected with early stage schizonts, and one instance of schizonts egressing. We find 
that trophozoites and early schizonts activate compound 3C to similar levels (Figure 4 middle, 
bottom). While egressed schizonts still accumulate fluorescence, it is attenuated in comparison to 
intact schizonts (Figure 4 bottom). 
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B.4 Discussion 
Targeted prodrug delivery to P. falciparum is an exciting possibility with potential to 
fundamentally change drug design for antimalarials. Identifying the malarial enzymes 
responsible for prodrug activation will allow a structure-guided approach to prodrug 
development. While one esterase, PfPARE, is responsible for the activation of hexylester 
prodrugs, it is not responsible for the activation of POM-ERJ (4). This finding is unsurprising as 
PfPARE does not act on the tertiary carbamate, MMV030666, whose prodrug motif is highly 
similar to the POM moiety. Unfortunately, the activation mechanism for POM- prodrug motifs 
by P. falciparum remains an intriguing question. Here, we have attempted to identify the P. 
falciparum esterase responsible for POM-prodrug activation, by raising resistance to the prodrug, 
POM-ERJ.  
 
Unfortunately, we were unsuccessful in generating long-lasting resistance to POM-ERJ.  
Parasites grew in the presence of inhibitory concentrations of POM-ERJ but were not shown to 
be resistant to POM-ERJ via a 3-day IC50. Additional studies in this area remain a valuable 
endeavor and future studies should employ a varied approach in resistance generation, such as 
the step-up approach where parasites are cultured in low levels of drug and the concentration of 
drug is slowly increased in response to parasite tolerance. Alternatively, multiple rounds of drug-
pulsing may be an appropriate route forward. It is interesting to hypothesize that POM-ERJ may 
be an “irresistible” drug, however multiple rounds of attempted resistance selection with large 
pools of parasites being screened before this claim is made. All resistance attempts in this 
manuscript were carried out using the had1 null strain, AM1-G3, to reduce the potential number 
of non-esterase mutations acquired. Resistance should still be achievable in these strains, 
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however, as P. falciparum can become more resistant to the POM-ERJ non-prodrugged analog, 
fosmidomycin, through loss of HAD2 among other genes (12). 
 
Erythrocyte esterases are a second candidate for antimalarial prodrug activation. While 
erythrocyte esterase mediated activation does not protect host cells from potential antimalarial 
toxicity, it still has several appealing benefits. Resistance to hexyl ester prodrugs is rapidly 
achieved by P. falciparum through mutation of PfPARE, however, parasite modification of host 
esterases would be a substantial feat and is unlikely to occur. Additionally, erythrocyte targeted 
prodrugs may have an extensive lifetime within the host as the converted drug would be 
sequestered inside erythrocytes and thus safe from host metabolism and excretion. One major 
potential drawback to erythrocyte targeted prodrugs is that activated drugs may not transit from 
the erythrocyte cytoplasm to the parasite cytoplasm. This appears to be the case with the POM-
prodrug of the hypoxanthine-guanine-xanthine-phosphoribosyltransferase (HGXPRT) inhibitor, 
Immucillin-H 5’phosphate (ImmHP) (13). While ImmHP is a potent inhibitor of HGXPRT in 
vitro, it has no activity against whole cell P. falciparum. Further investigation has revealed that 
the POM-prodrug of ImmHP effectively enters the erythrocyte but is rapidly converted back to 
ImmHP and is unable to enter the parasite cytoplasm to exert its activity.  
 
Ultimately, the localization and timing of prodrug activation across P. falciparum lifecycles is an 
important consideration in antimalarial prodrug development. Here, we have shown that simple 
lipophilic esters 1O and 3C are activated primarily in the cytoplasm of P. falciparum though at 
different speeds. Expanding the understanding of how prodrugs are activated in P. falciparum, 
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specifically how different ester promoieties act, is an important next step for P. falciparum 
prodrug development. Finally, how fast a prodrug needs to activate in vivo remains an open 
question which will dictate prodrug efficacy.  
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B.5 Figures 
 
 
 
Figure 1 ERJ and POM-ERJ sensitivity of WT and PfPARE mutant P. falciparum. Black- wild-type P. falciparum, red- PfPARE mutant parasites. 
IC50 determined by Rachel Edwards, points represent the mean of a single biological replicate in technical duplicate (A) ERJ (B) POM-ERJ. 
 
 
Figure 1 ERJ and POM-ERJ sensitivity of WT and PfPARE mutant P. falciparum. Black- wild-type P. falciparum, red- PfPARE mutant parasites. 
IC50 determined by Rachel Edwards, points represent the mean of a single biological replicate in technical duplicate (A) ERJ (B) POM-ERJ. 
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Figure 2 Quantification of POM-ERJ resistance for parasites growing in media containing POM-ERJ. Black- parental strain, 
AM1-G3, red- parasites grown in POM-ERJ. (A) Parasites grown for 3 weeks in media containing 1xIC50 POM-ERJ. (B) Parasites 
pulsed with POM-ERJ until parasites were no longer visible by microscopy. Points represent the mean of a single experiment in 
technical duplicate. 
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Figure 3 Time-dependent pro-substrate activation by P. falciparum. (A) Activation mechanism and structure of pro-fluorescent substrates tested. (B) 
Time-lapse imaging of single cell P. falciparum. Pro-fluorescent substrate was rapidly added to media 10 minutes into the experiment. Images 
representative of experiments performed in technical duplicate. 
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Figure 4 Pro-fluorescent substrate 3C activation by P. falciparum. Parasites were incubated with pro-fluorescent substrate for 30 
minutes and subsequently imaged. Images representative of experiments performed in technical duplicate. 
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Abstract 
Plasmodium falciparum, the primary cause of deadly human malaria, remains a critical global 
health concern, particularly for young infants and children who are uniquely susceptible to 
severe disease and death. Unfortunately, the most widespread rapid diagnostics tests for malaria 
have high false positive rates and are increasingly at risk due to the spread of parasite strains that 
avoid detection. There is an urgent need for new malaria diagnostics, and the World Health 
Organization has declared this a key global health priority. Multiple studies indicate that 
Plasmodium-infected hosts are more attractive to Anopheles mosquitoes than uninfected and 
gametocyte negative controls. This altered behavioral preference is likely due to changes in the 
infected host’s odor profile, as reflected in the skin and breath. In this chapter, we examine the 
changes that Plasmodium spp. infection imparts on host odors and the resulting influences on 
vector behavior. We also review recent studies on human malaria, which have investigated the 
malaria-induced changes in skin and breath odors in asymptomatic and symptomatic malaria 
patients. 
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C.1 Overview of malaria 
In 2017, an estimated 219 million cases of malaria occurred worldwide, resulting in an estimated 
435,000 deaths. Aggressive global efforts to control malaria over the last fifteen years have been 
highly successful, with 20 million fewer cases in 2017 than in 2010. However, progress has 
stalled alarmingly over the last several years 1. Among the more pressing current challenges to 
malaria control is the need for additional effective diagnostic tools to detect both symptomatic 
and asymptomatic infections.   
Malaria is caused by infection by protozoan parasites in the genus Plasmodium. While several 
Plasmodium spp. infect humans, the majority of severe and life-threatening malaria is due to P. 
falciparum infection. Transmitted person-to-person by Anopheles mosquitoes, symptomatic P. 
falciparum malaria is characterized by repeated cycles of asexual replication within mature 
human erythrocytes. A small proportion of asexual bloodstream parasites undergo sexual 
differentiation. Ongoing malaria transmission requires consumption of these sexual-stage 
parasites, termed gametocytes, during blood meals by female Anopheles. Malaria diagnostics 
used for point-of-care clinical diagnostic testing of symptomatic individuals in malaria-endemic 
areas must be highly sensitive to the presence of asexual bloodstream Plasmodium infection. In 
contrast, a diagnostic test that reflects gametocytemia would impact public health strategies to 
identify individuals at risk of malaria transmission.   
For more than a century, microscopic evaluation of capillary blood samples has been used to 
identify bloodstream malaria parasites 2. Highly sensitive and specific nucleic acid-based tests 
have been also developed 3, 4, but are not readily available in low- and middle-income countries 
(LMIC) where malaria is endemic. Conversely, lateral-flow-based rapid diagnostic tests (RDTs) 
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are sensitive and require little training, making them overwhelmingly the method of choice to 
evaluate for point-of-care diagnosis in malaria-endemic areas. In 2017, 276 million RDTs were 
sold, and an estimated 75% of diagnostic testing in sub-Saharan Africa was performed by RDT1. 
The current generation of RDTs largely relies on detection of a distinct P. falciparum-specific 
protein, HRP2. Unfortunately, HRP2-based RDTs possess critical weaknesses. False positive 
RDTs are common as HRP2 can be detected up to one month after malaria clearance, making it 
impossible to distinguish acute from recent infections 5. More importantly, HRP2-based RDTs 
are at risk due to the recent emergence and spread of P. falciparum strains that lack HRP2. Hrp2 
null parasites were first reported in 2010 in South America 6, but deletions have subsequently 
been found in several locations in Africa 7-10. In a recent study in Eritrea, up to 80% of all 
patients were infected with hrp2- parasites 7. Computational modeling projects a dramatic rise in 
RDT-undetectable parasites, as widespread use of RDTs has maintained ongoing selective 
pressure against parasites that still express HRP2 11. 
Other challenges in the diagnosis of malaria include addressing the large asymptomatic reservoir, 
as nearly 75% of individuals infected with Plasmodium spp. are asymptomatic. Asymptomatic 
individuals constitute a major source of ongoing transmission, because they are more likely to be 
bitten by mosquitoes than parasite-free individuals, they do not present for care (and are 
therefore not diagnosed or treated), and are often mobile, increasing their potential for malaria 
transmission and geographic spread 12.  
Growing evidence suggests that vector mosquito species can differentiate between malaria-
infected and uninfected individuals based on odor. This finding has inspired recent work to 
address the possibility of diagnosing malaria via volatile biomarkers emitted by breath and/or 
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skin. In this chapter, we examine the changes that Plasmodium spp. infection imparts on host 
odors and the resulting impacts on vector behavior. We also review recent studies on human 
malaria that have evaluated volatiles from the skin and breath of Plasmodium-infected 
individuals.  
 
C.2  Mosquito attraction to malaria-infected hosts 
Female Anopheles mosquitoes require mammalian blood meals to mature eggs; however, 
mosquito biting behavior is highly complex and context-dependent. Mosquitoes detect human 
hosts using a combination of cues, with olfactory cues being undoubtedly the most important 
group of external stimuli affecting mosquito behavior 13. From a distance, female mosquitoes 
sense CO2 and preferentially migrate to areas of higher CO2. As they move closer to the target 
blood meal, they sense host heat, skin odors, and potentially the breath volatiles of the target host 
14. Increasing evidence, reviewed below, indicates that host volatiles—and, as a result, mosquito 
behavior—are exploited by mammalian Plasmodium spp. parasites, including P. falciparum, to 
increase likelihood of transmission (Figure 1). 
Humans infected with P. falciparum may be more mosquito-attractive than uninfected humans. 
For example, investigators evaluated the attraction of Anopheles gambiae to 5-12 year old 
Kenyan children of variable infection status and their uninfected classmates, using a dual-choice 
olfactometer (a setup which allows testing preference of one odor against another) 15. 
Plasmodium-infected children were treated with antimalarials and, following parasite clearance, 
the attraction of mosquitoes to these children was reassessed. Investigators found that A. 
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gambiae mosquitoes were nearly twice as attracted to children carrying high burdens of 
gametocytes (microscopically visible) than parasite-free individuals, individuals infected with 
only asexual stages, or individuals carrying sub-microscopic levels of gametocytes 15. As 
expected, treatment with antimalarials reduced asexual and sexual-stage parasite levels below the 
limits of molecular detection. Importantly, following antimalarial treatment, Plasmodium-
infected children were no longer preferentially attractive to A. gambiae mosquitoes. This is in 
agreement with a previous study by Lacroix et al 16 in which mosquito attractiveness was seen to 
be approximately double in gametocyte-positive children, relative to uninfected children or those 
with asexual-stage parasitemia.  
While there is increasing evidence that P. falciparum infection alters A. gambiae host-seeking 
behavior, it is not clear which volatile compounds may be responsible. To address this question, 
Robinson et al 17 assessed the behavioral response of A. gambiae to the foot odors of 5-12 year 
old Kenyan school children, before and after antimalarial treatment. Foot odors of asymptomatic 
P. falciparum-infected and -uninfected children were collected on socks over 20 h and extracted 
for mass-spectrometry analysis. For infected individuals, odors were collected after 
administration of the first dose of treatment with the antimalarial. Following confirmed parasite 
clearance (21 days later), odor samples were collected in the same manner from the same 
children. A. gambiae mosquitoes were offered the choice of either Day 1 or Day 21 odor samples 
from the same child, in a dual-choice cage assay. Investigators found that mosquitoes did not 
differentiate between Day 1 and Day 21 odor samples from uninfected children but were more 
attracted to the Day 1 samples from children harboring asexual or gametocyte-stage Plasmodium 
parasites. Somewhat unexpectedly, researchers did not observe the gametocyte-specific effect 
that was previously described 15, 16. The authors suggest that imperfect detection of low densities 
lxv 
 
of gametocytes could play a role in this discrepancy. Alternatively, gametocyte-specific 
attraction may be communicated through a distinct mechanism.  
Non-human animal studies also provide evidence for increased mosquito attractiveness of 
Plasmodium-infected individuals. For example, De Moraes et al 18 evaluated whole-body 
volatiles from healthy and P. chabaudi-infected mice throughout the course of infection. 
Investigators found that A. stephensi were preferentially attracted to infected mice, relative to 
control mice, during the time period in which mice harbored relatively high levels of 
gametocytes. The investigators also observed increased attraction to gametocyte-positive vs. 
gametocyte-negative individuals during this period. Alongside these behavioral studies, the 
investigators observed distinct body odor profiles between healthy and Plasmodium-infected 
individuals, during both acute and chronic stages of infection. The characteristic components of 
Plasmodium-infected odor profiles were identified by mass spectrometry and subsequently 
confirmed to increase mosquito attraction individually, when added to the odor of healthy mice. 
Specifically, hexanoic acid, 2- and 3-methyl butanoic acid, and tridecane were increased in 
abundance in the odor profiles of malaria-infected animals and displayed a direct relationship 
with mosquito attractiveness. Conversely, benzothiazole, present in reduced amounts in 
chronically infected mice, was inversely related with mosquito attraction. 
While several studies have focused on identifying the changes in odor profiles resulting from 
Plasmodium infection, fewer studies have focused on the origin of these changes. Three 
hypotheses currently exist for the basis of Plasmodium-dependent odor changes: 1) Plasmodium 
infection leads to changes in the skin microbiome that indirectly change the host odor profile; 2) 
Plasmodium infection stimulates endogenous host changes that alter the host odor profile; and 3) 
Plasmodium spp. directly generate and release malaria-associated volatile compounds.  
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The direct production of Plasmodium-volatile compounds by Plasmodium garnered early 
attention as Kelly et al 19 identified the plant-like terpenes α-pinene and limonene as arising from 
cultured P. falciparum-erythrocytes. Apicomplexan parasites, including Plasmodium species, 
contain an apicoplast, an organelle with a similar endosymbiotic evolutionary origin to plant 
chloroplasts, which synthesizes isoprenoids (such as α-pinene and limonene) via the 
methylerythritol phosphate (MEP) pathway. This pathway is not present in animals, though a 
parallel metabolic route, the mevalonate pathway, does exist. Kelly et al 19 hypothesized that P. 
falciparum parasites might utilize the MEP pathway to produce terpenes and indeed saw that 
inhibition of the pathway via the MEP-pathway specific inhibitor (fosmidomycin) ablated 
accumulation of α-pinene and limonene. Interestingly, Emami et al20 found that, even in the 
absence of P. falciparum parasites, introduction of the isoprenoid precursor (E)-4-hydroxy-3-
methyl-but-2-enyl pyrophosphate (HMBPP) altered erythrocyte headspace volatile profiles and 
increased mosquito attractiveness. Specifically, HMBPP-treated erythrocytes produced higher 
headspace levels of aldehydes (octanal, nonanal, and decanal) and monoterpenes (α-pinene, ß-
pinene, and limonene). This result remains surprising, as there is no clear biosynthetic route to 
monoterpenes in human erythrocytes and the metabolic origin of these compounds in 
erythrocytes is enigmatic. There is some overlap in the types of compounds (terpenes and 
aldehydes) found in P. falciparum-infected and HMBPP-treated erythrocytes. Indeed, as noted 
below, several of these compounds have been also detected in the odor profiles of malaria-
infected human subjects 21-24. 
Given the important role of host odor profiles on Anopheles spp. mosquito attraction, the finding 
that Plasmodium spp. infection consistently alters mosquito attraction provides an important 
proof-of-concept that malaria parasites reproducibly alter host volatile profiles. Below we review 
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the current literature on breath and skin odor changes during asymptomatic and symptomatic 
Plasmodium spp. infection in humans.   
C.3  Breath odor profiles in asymptomatic malaria 
While acute, uncomplicated P. falciparum infection in children is most often characterized by 
fever, a large proportion of P. falciparum infections in semi-immune individuals in highly 
endemic regions will be asymptomatic. As individuals with asymptomatic infections do not 
present for care, asymptomatic infections are an important public health concern as they 
represent a hidden reservoir that contributes to persistent malaria transmission. Detecting sub-
microscopic infections requires sensitive molecular diagnostic methods, such as polymerase 
chain reaction (PCR) or loop-attenuated isothermal amplification (LAMP). These molecular 
diagnostic tests have shown that even in regions of low endemicity, asymptomatic Plasmodium 
spp. infection is common, representing up to 75% of positive individuals in community surveys 
25.  
To identify biomarkers of asymptomatic malaria, odor profiles of breath and skin have been 
characterized both under natural field conditions in malaria-endemic regions and during 
controlled human malaria infection (CHMI). During CHMI, volunteers receive a direct 
intravenous inoculation of Plasmodium-infected erythrocytes, followed by close monitoring and 
treatment. CHMI trials are increasingly being used to aid vaccine and drug development.  
The first study on breath biomarkers of P. falciparum CHMI volunteers was published by Berna 
et al 26. One liter of breath was collected from each volunteer as malaria infection progressed and 
additional samples were taken following antimalarial administration. Exhaled breath was 
collected using sampling bags, and volatiles were then transferred from the bags to sorbent tubes 
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(Tenax/ Unicarb) via a pump. The authors identified nine compounds whose concentrations 
varied significantly over the course of malaria infection: carbon dioxide, isoprene, acetone, 
benzene, cyclohexanone, and 4 thioethers (allyl methyl sulfide, 1-methylthio-propane, (Z)-1-
methylthio-1-propene, and (E)-1-methylthio-1-propene) (Table 26.1). The malaria-associated 
thioethers were of particular interest as a potential disease biomarker, because they have not 
previously been associated with any pathological condition, and because their concentrations 
changed during infection for all individuals. Machine learning methods were further applied, 
which accurately classified all samples into “active infection” and baseline/post-P. falciparum 
clearance on the basis of thioester levels. Of note, due to the nature of CHMI, parasite counts 
were quite low and gametocytes, which take approximately two weeks to develop, were never 
detected. Berna et al 26 attempted to detect thioethers in in vitro cultures of P. falciparum, but did 
not find any appreciable levels. While the metabolic origin of breath thioethers found during 
CHMI is not known, these results suggest that interplay between host and parasite metabolic 
pathways may be required. In a follow-up study, these same researchers 21 found that thioether 
concentrations in breath exhibit a diurnal cyclical pattern and, in general, thioether levels are 
significantly higher in P. falciparum CHMI volunteers compared to healthy control individuals. 
Moreover, the authors demonstrated that breath volatiles have a time-of-day variation that 
impacts the ability to predict P. falciparum infection using the thioethers. Additionally, this study 
found that terpenes (α-terpinene, m-cymene, limonene, and terpinolene) were elevated in the 
breath of P. falciparum-infected individuals. Of these terpenes, limonene had been previously 
reported to be associated with cultured asexual P. falciparum19. The top two compounds with the 
highest classification accuracies (healthy vs P. facliparum) were terpinolene (87.7% correct 
classification), followed by m-cymene (92.7% correct classification). 
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Malaria-associated volatile biomarkers have also been investigated in skin samples. De Boer et al 
23 collected skin odor samples from two cohorts of P. falciparum CHMI volunteers. Skin odors 
were collected by placing one foot of the volunteer into a clean bag, and volatiles from the bag 
were then pumped into Tenax filter and Porapak filters.  Skin odor samples were collected two 
days prior to parasite challenge, during Plasmodium infection, and post-treatment. Foot odor 
profiles were distinct in P. falciparum-challenged individuals. In Table 26.1, we report those vo-
latile compounds that showed significant differences “before treatment” versus “during malaria 
infection” (qPCR-positive for P. falciparum). Several compounds (e.g., sesquiterpene, 1-
dodecene, 2-methyl butanal, and dodecanal) increased significantly upon infection. Aldehydes 
have been previously found in mammalian skin odors and are well recognized as host attractants 
for hematophagous insects. The authors hypothesize that the increased aldehyde levels found in 
malarious samples originate from lipid peroxidation, caused by oxidative stress induced by P. 
falciparum. Alternatively, the authors postulate that the aldehydes might be produced directly by 
Plasmodium parasites, as aldehydes are emitted by HMBPP-treated erythrocyte cultures 20. In 
parallel with compound identification, researchers performed dual-choice olfactometer 
experiments to determine whether changes in body odor during P. falciparum infection affect 
mosquito behavior. Unexpectedly, they found reduced attractiveness of parasite positive 
participants in one cohort and no significant effect of P. falciparum infection in a second group. 
They attributed this discrepancy to the use of different parasite strains in both cohorts. Mature 
gametocytes were not detected in any of the participants during any portion of this study. 
A more recent study also aimed to identify malaria-associated skin odor biomarkers, through 
evaluation of more than 400 primary school children (aged ≤12 y) in western Kenya 24. In this 
study, investigators profiled arm and foot volatiles from each individual, using a portable volatile 
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collection system. Collection from both sites occurred in parallel, prior to treatment of malaria-
positive individuals, and odors were stored on HayeSep adsorbant polymer prior to gas 
chromatography-mass spectrometry (GC-MS). Machine learning was employed to identify 
volatile patterns that predicted malaria infection (Table 26.1). Of these, only 2-ethylhexan-1-ol 
and ethylbenzene were found in both foot and arm samples. Critically, predictive models 
successfully identified asymptomatic infections with 100% sensitivity in foot samples and 75% 
sensitivity in arm samples. The majority of the identified foot volatiles increased in concentration 
during infection, whereas the direction of the change was not specified for the majority of skin 
volatiles. The authors indicate that all identified compounds have either previously been reported 
from human volatile collections or have known mechanisms of natural production from humans 
or potentially human-associated microbes. Interestingly, none of the volatiles reported in this 
study were also reported from skin volatile profiling from asymptomatic CHMI volunteers 23.   
To explore the molecular basis of odor manipulation by malaria, Robinson et al 17 both 
quantitatively and qualitatively compared the volatile compounds emitted from the feet of 
asymptomatic infected children in Western Kenya. This work was done in parallel with the 
mosquito attraction work mentioned earlier in this chapter. Of note is that the study site was the 
same as De Moraes 24 and Busula 15. For each child, one foot was placed in a plastic bag, and 
volatiles were collected in Porapak filters (similar to De Boer et al. 23) and sampled for 100 min 
(at 500 mL/min). Detailed infection status (uninfected, infected with low parasitemia, high 
parasitemia, or infected with gametocytes) was collected using an 18S-based qPCR for P. 
falciparum asexual stages and QT-NASBA qPCR for quantifying gametocytes. (E)-2-decenal 
was the only compound that showed significant differences if individuals were categorized 
simply as Plasmodium-positive or parasite-free (Table 26.1). The analysis also revealed higher 
lxxi 
 
abundance in the levels of the aldehydes heptanal, octanal, nonanal, (E)-2-octenal, and (E)-2-
decenal by infected asymptomatic individuals compared to control (solvent) or empty bag. A 
positive trend on the levels of these VOCs was also observed when associated to the parasite 
densities (low and high). Additionally, the ketone 2-octanone was found to be associated with the 
presence of microscopic gametocytes. Although similar VOC collection technique was used by 
De Boer et al 23 (from the same research group), none of the compounds identified by De Boer et 
al were reported in this work. Inconsistencies could be due to the low parasitemia present in De 
Boer et al 23 as well as the absence of gametocytes. 
Taken together, the results from this collection of recent studies on volatiles emitted from skin 
and breath clearly establish that malaria infection is associated with changes in volatile profiles. 
Of the malaria-associated VOCs reported (Table 26.1), only nonanal was detected in two 
independent studies of individuals with asymptomatic parasitemia. However, the two studies 
problematically disagree about the direction of change with infection: in one study, nonanal 
levels increase with malaria infection 17; in the other, nonanal levels decrease24. A possible 
source of this discrepancy may be the variability in volatile collection methods, absorbent 
materials, and/or analytical techniques employed. While diet is thought to influence breath and 
skin volatile profiles, both studies in question recruited from the same locality in western Kenya. 
More broadly, the use of malaria-naïve individuals (as in CHMI) versus naturally infected 
individuals (in endemic areas) also presents challenges for comparison purposes, as study 
participants in field studies are likely to have had previous malaria exposure.  
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C.4 Breath odor profiles of symptomatic Plasmodium 
infection 
The first report of candidate diagnostic biomarkers in the breath of symptomatic P. falciparum–
infected children from a typical malaria-endemic clinical setting was published recently by 
Schaber et al. 22 Samples were collected in Malawi from children 3–15 years old presenting for 
care for fever. In the study, 1 L of exhaled breath was collected in a sample bag and transferred 
to stainless-steel sorbent tube (Tenax/Carbograph/Carboxen). Investigators found global 
differences in breath VOC composition based on infection status. In addition, six breath volatiles 
were highly correlated with infection status, and together yielded a classification accuracy of 
83%: methyl undecane, dimethyl decane, trimethyl hexane, nonanal, isoprene, and tridecane 
(Table 26.2). Of these six VOCs, methyl undecane and dimethyl decane levels increased with 
malaria infection. The only compound that had previously been associated with Plasmodium 
infection was nonanal. Plasmodium-infected individuals have decreased levels of skin-emitted 
nonanal, when arm volatiles were sampled 24. In contrast, skin-emitted nonanal from the feet of 
Plasmodium-infected individuals was elevated compared to controls 17.   
Schaber et al. 22 also found significantly increased breath levels of two terpenes, α-pinene (p = 
0.04, with 20% higher mean) and 3-carene (p = 0.01, with a 28% higher mean). α-Pinene has 
been observed reproducibly to arise during P. falciparum asexual infection of erythrocytes in 
culture 19. In addition, this terpene is a direct, potent, and specific activator of A. gambiae 
odorant receptors 19. Both α-pinene and the related 3-carene are among the volatiles produced by 
mosquito-preferred nectar-providing plant species 27. The investigators postulate that because 
malaria-induced volatiles are chemically identical to those produced by mosquito-preferred 
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plants, parasites might produce or induce production of these volatiles in order to hijack 
mosquito behavior and increase transmission.  
Of note, the results of this research group were somewhat distinct from the previous breath 
metabolite findings reported by Berna et al 26, from a population of naïve healthy adults 
undergoing CHMI P. falciparum infection. Thioethers were not detected, suggesting that parasite 
densities, parasite stage, or age of host might induce a range of physiological changes in the 
human body that manifest in the breath and body odor. Alternatively, P. falciparum may produce 
volatiles in a density- or stage-specific manner. Prior parasite exposure may also be required for 
host-generated volatiles produced during P. falciparum infection. The different sorbent material 
and storage conditions used in both studies, may also contribute to an absence of thioethers in the 
work of Schaber et al. 22  
De Moraes et al 24 also examined symptomatic Plasmodium-infected children at a primary school 
located in western Kenya. In this work, researchers collected foot and arm volatiles and 
employed machine learning algorithms to develop predictive models for infection status. The 
following volatiles were found to be key predictors of malaria: 4-hydroxy-4-methylpentan-2-one, 
toluene, ethylcyclohexane, and ethylbenzene (Table 26.2). Toluene is notable in that it has 
previously been reported to be produced by P. falciparum in vitro 19 and has also been found to 
be associated with human skin. De Moraes et al 24 suggest that toluene could be produced by 
Clostridium spp. residing in the human microbiome 28. Most of the volatiles found by De Moraes 
et al 24 in arm and foot samples were in lower abundance in Plasmodium-infected individuals. 
Importantly seven of the volatiles reported in symptomatic malaria cases were also detected in 
samples from asymptomatic Plasmodium-infected individuals (VOCs in boldface text - Tables 
26.1 and 26.2). Predictive models using foot volatiles exhibited greater sensitivity (91%) than 
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using arm volatiles (89%). It is important to note that these sensitivities were achieved using 
samples that were collected over 3 years across 41 schools in western Kenya. Additionally, some 
subjects were co-infected with multiple Plasmodium species, and, in some cases, were co-
infected with other organisms including HIV and intestinal helminths.  
No volatiles were found in common among studies with symptomatic patients, possibly due to 
variations in collection methods and/or materials. 
C.5 Summary 
Despite substantial global investment, malaria remains a serious global health problem. Young 
infants and children are particularly at risk, with more than 400,000 deaths each year. Over the 
past decade, rapid diagnostic tests (RDTs) have transformed malaria diagnosis and have been 
instrumental to malaria control efforts. However, there is an urgent need to develop new malaria 
diagnostics. Because parasite proteins can persist in the bloodstream long after treatment, “false 
positive” tests are common in children who do not have malaria, meaning that non-malaria 
infections can be missed and untreated. Even more ominously, variant parasite strains have 
emerged, such that in some parts of the world, 80% of parasites are no longer detected by current 
tests. There is a pressing need for highly sensitive and specific malaria diagnostics that are also 
simple and affordable. For public health campaigns, noninvasive testing would also represent a 
major advance, since all current malaria tests require blood samples. 
There is mounting evidence that malaria parasites affect the behavior of Anopheles mosquito 
vectors and hosts in ways that increase the contacts between them to favor parasite transmission. 
Such changes in attractiveness have been demonstrated in both animal and human malaria 
systems, as well as in other vector-borne disease systems. Body odor, comprising the volatile 
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compounds emitted from the skin and breath of vertebrates, is the most important cue used by 
Anopheles for host location. While increased attractiveness of Plasmodium-infected individuals 
has been demonstrated in a malaria-endemic setting, remarkably, very few studies have 
investigated the chemical ecology underlying this phenomenon. Volatiles emitted from human 
skin, breath, and from cultured human red blood cells are all altered in the presence of 
Plasmodium spp. infection. Of note, the identified volatile biomarkers have been highly variable 
from study-to-study. These differences may reflect variability in volatile collection methods, 
absorbent materials, and/or analytical techniques employed. In addition, study populations were 
distinct with respect to prior exposure to malaria and duration of infection, which may influence 
the volatile profiles due to presence/absence of gametocytes and parasite densities. However, the 
reproducible finding that malaria induces volatile changes provides compelling hope for a future 
malaria diagnostic that identifies both asexual parasitemia and the presence of gametocytes. 
Future work should include research in different geographical regions using collection methods 
and analytical techniques similar to those used in previous studies. In addition, a compelling 
question is how diet, age of host, genetic, and environmental factors affect the volatile 
fingerprint of malaria-infected individuals. The biological origin of those volatile compounds 
induced by malaria are yet unknown, and remains an outstanding question of importance in 
understanding the specificity of these volatiles as biomarkers to be used in a noninvasive 
diagnostic for malaria.  
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C.6  Figures 
 
Figure 1 Life cycle of P. falciparum and volatile attraction schematic. (A) Life cycle of Plasmodium 
falciparum. (B) Human body odor is altered upon malaria infection and attracts Anopheles spp. 
mosquitoes. 
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C.7 Tables 
Table 1 Summary of studies on individuals with asymptomatic Plasmodium spp. Infection.  
Sample 
type 
Compounds Study population Ref 
Breath (E)-1-methylthio-1-propene  
(Z)-1-methylthio-1-propene  
1-methylthio-propane  
allyl methyl sulfide  
α-terpinene  
m-cymene  
limonene  
terpinolene  
Controlled human malaria 
infection (malaria-naïve 
adults) 
Berna et al 21, 
26 
Skin sesquiterpene  
1-dodecene  
2-methyl butanal  
dodecanal  
Controlled human malaria 
infection (malaria-naïve 
adults); foot odors 
De Boer  
et al 23 
Foot Naturally infected school-
children; foot/arm odors 
De Moraes et 
al 24 nonanal  
2-ethylhexan-1-ol  
benzaldehyde  
1-ethyl-3-methylbenzene  
toluene  
4-hydroxy-4-methylpentan-2-
one  
ethylbenzene  
hexanal   
Arm 
2-ethylhexan-1-ol  
ethylbenzene  
toluene  
dodecane  
octanal  
octane  
2,4-dimethylhept-1-ene  
(E)-2-decenal 
 
Naturally infected school-
children; foot/arm odors 
*Robinson et 
al 17 
In bold, volatiles were also found in subjects with symptomatic Plasmodium infection (Table 26.2). In 
blue, levels of volatile increased with infection. In coral, volatile levels decreased with infection. In black, 
direction of change was not provided. *Volatiles reported in this table are based on comparisons relative 
to parasite-free individuals vs. all individuals with detectable Plasmodium spp. parasitemia. 
lxxviii 
 
Table 2 Summary of studies on individuals with symptomatic Plasmodium spp. infection.  
Sample 
type 
Compounds  Patients/volunteers Ref 
Breath dimethyl decane 
isoprene  
methyl undecane 
nonanal  
tridecane  
trimethyl hexane   
3-carene 
α-pinene 
  
Naturally infected 
children (age 3-15) 
Schaber et al 22 
Skin  Foot Naturally infected 
school-aged 
children; foot/arm 
odors 
De Moraes et al 24 
hexanal  
4-hydroxy-4-methylpentan-2-one  
toluene  
ethylcyclohexane  
ethylbenzene  
1-ethyl-3-methylbenzene   
Arm 
octanal  
2-ethylhexan-1-ol  
m-xylene (or p-xylene)  
4-hydroxy-4-methylpentan-2-one  
toluene  
ethylcyclohexane 
ethylbenzene  
2,4-dimethylhept-1-ene  
In boldface, volatiles were also found in subjects with asymptomatic Plasmodium infection 
(Table 26.1). In blue, levels of volatile increased with infection. In coral, volatile levels decreased 
with infection. In black, direction of change was not provided. 
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Appendix D: The malaria metabolite 
HMBPP does not trigger erythrocyte terpene 
release  
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D.1 Abstract 
Infection with malarial parasites renders hosts more mosquito attractive than their uninfected, 
healthy, counterparts. One volatile organic compound, α-pinene, is associated with Plasmodium 
spp. infection in multiple studies and is a known mosquito attractant. However, how malarial 
infection results in elevated levels of host-associated α-pinene remains unclear. One study 
suggests that erythrocyte exposure to the malarial metabolite, (E)-4-hydroxy-3-methyl-but-2-
enyl pyrophosphate (HMBPP), results in increased levels of α-pinene. Here, we establish that 
endogenous levels of α-pinene are present in human erythrocytes, that these levels vary widely 
by erythrocyte donor, and that α-pinene levels are not altered by HMBPP treatment.  
 
lxxxiv 
 
D.2 Introduction 
Plasmodium falciparum, the primary causative agent of lethal malaria infections, has a two-host 
life cycle between humans and mosquitoes. Transit between the two hosts is a critical 
requirement for the parasite lifecycle and represents a substantial population bottleneck(1). 
Mosquitoes are more attracted to humans(2–5), mice(6), and birds(7) infected with malaria 
parasites in comparison to uninfected, healthy hosts. This observation has led to the hypothesis 
that Plasmodium species actively manipulate host odor profiles to coordinate transmission to the 
mosquito. Indeed, changes in the composition of host odor profiles have been observed in 
humans(8–13) and mice(6) infected with malaria; however the molecular basis for infection-
induced changes in volatile organic compound (VOC) production or release remains unknown. 
 
Of particular interest has been the mosquito semiochemical, α-pinene, which is found in higher 
concentrations in the breath of humans with symptomatic Plasmodium infection(8) vs healthy 
controls. Additionally,  α-pinene has been identified in the headspace above Plasmodium 
falciparum infected erythrocytes(14). The VOC α-pinene is a member of the large and bioactive 
class of molecules termed terpenes. Terpenes are biosynthesized by a variety of plants, soil and 
environmental organisms, mammalian commensal and pathogenic microbes, and some 
insects(15–22). α-pinene is a known component of plant-derived odorant blends that are 
attractive to the Anopheles spp. mosquitoes that transmit malaria(23, 24). As for other terpenes, 
biosynthesis of α-pinene begins with the 5-carbon isoprenoid precursor, isopentyl pyrophosphate 
(IPP), which is enzymatically condensed with a second molecule of IPP by geranyl 
pyrophosphate synthase (GPPS) to form the 10-carbon metabolite, geranyl pyrophosphate (GPP). 
lxxxv 
 
Subsequent rearrangement and cyclization are catalyzed by a monoterpene synthase (pinene 
synthase) to yield α-pinene (Figure 1A).  
 
Recently, it was reported that incubation of the microbial metabolite (E)-4-hydroxy-3-methyl-
but-2-enyl pyrophosphate (HMBPP) with uninfected human erythrocytes results in increased 
attraction and feeding behavior of anopheline mosquitoes. Concordantly, an increase in the 
headspace concentration of α-pinene above HMBPP-treated erythrocytes was also reported(25). 
HMBPP is a late intermediate in the 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway for 
synthesis of IPP and downstream isoprenoids (Figure 1A). While eubacteria and apicomplexan 
parasites, such as Plasmodium spp., utilize the MEP pathway for isoprenoid biosynthesis(26), 
humans utilize a distinct and evolutionarily divergent biosynthetic pathway (mevalonate 
pathway) to synthesize IPP(27).  
 
The mechanism by which HMBPP exposure of erythrocytes may lead to α-pinene production or 
release is unclear, but two possibilities may explain these findings. First, HMBPP may serve as 
an exogenous signal that triggers erythrocytes to release stores of α-pinene which may have 
accumulated via metabolic, environmental, or dietary routes. A potent activator of human 
Vγ9Vδ2-T cells(28), HMBPP is recognized as a pathogen-associated molecular pattern (PAMP) 
through its interaction with butyrophilin receptors(29), suggesting that HMBPP may serve a 
signaling role to mediate erythrocyte α-pinene release. Alternatively, because HMBPP is itself a 
precursor to isoprenoids and terpenes in bacteria and plants, this metabolite may be directly 
incorporated into α-pinene in erythrocytes via the pathway illustrated in Figure 1A, or via an as-
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yet-undescribed alternative enzymatic route. However, human erythrocytes do not express the 
known biosynthetic machinery for synthesis of α-pinene from HMBPP; mammals lack the MEP 
pathway and specifically do not express the final enzyme in the pathway, IspH, which converts 
HMBPP to the immediate α-pinene precursor, IPP. Finally, no erythrocyte monoterpene 
synthases, nor any proteins with the terpene synthase fold, have yet been described that might 
mediate the final biocatalysis of GPP to α-pinene. In contrast, humans do express other prenyl 
diphosphate synthase orthologs, and these enzymes have been reported to moonlight as terpene 
synthases(20–22). For this reason, we sought to interrogate the possibility of HMBPP-triggered, 
erythrocyte-produced α-pinene. 
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D.3 Methods 
D.3.1 Materials and reagents 
(E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate, HMBPP, was purchased from both Sigma 
Aldrich and Echelon Biosciences Incorporated (Salt Lake City, Utah, USA), resuspended at 4 
mM in highly purified water, and stored at -80 ºC. Human erythrocytes (types A, B, and O, 
leukocyte reduced and irradiated) were obtained from the St. Louis Children’s Hospital Blood 
Bank (St. Louis, Missouri, USA). 
 
D.3.2 Volatile collection and GC-MS analysis 
Erythrocytes were washed 3 times with an equal volume of RPMI-1640 media (Sigma-Aldrich, 
SKU R4130) supplemented with: 27 mM sodium bicarbonate, 11 mM glucose, 5 mM HEPES, 1 
mM sodium pyruvate, 0.37 mM hypoxanthine, 0.01 mM thymidine, 10 µg/mL gentamycin, and 
0.5% albumax (Thermo Fisher Scientific, 11020039) and stored at 50% hematocrit at 4 ºC. When 
testing responses of erythrocytes to HMBPP and water, erythrocytes were stored as 1.4 mL 
aliquots in individual 1.5 mL microfuge tubes (Thermo Fisher Scientific, 05-408-129), wrapped 
in parafilm (Sigma-Aldrick, SKU P7793) and stored at 4 ºC. Prior to sampling, 1 mL 50% 
erythrocytes were transferred to 4 mL glass autosampler tubes (Thermo Fisher Scientific, 03-
391-19), closed with screw caps with septa (Thermo Fisher Scientific 03-391-21), and 
equilibrated at 38 ºC for 15 minutes. Following equilibration, 2.5 µL of 4 mM HMBPP (final 
concentration 10 µM) or purified water were added to the erythrocytes, caps were closed, and 
parafilm was used to seal the vial. Volatiles were immediately collected from the headspace 
using solid phase micro-extraction (n=5, randomized order for each sample). Directly before 
sampling, the Divinylbenzene/Caboxen/Polydimethylsiloxane fiber (Sigma-Aldrich, SKU 
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57348) was conditioned for 30 minutes at 225 ºC in the inlet of an Agilent 7890A gas 
chromatographer. Headspace sampling occurred over 30 minutes with temperatures maintained 
at 38 ºC. Following sampling, the collected volatiles were desorbed onto the injector of the 
Agilent 7890A gas chromatographer with an Agilent HP-5MS column (30m, 0.25-mm inner 
diameter, 0.25-µm film thickness) and interfaced with an Agilent 5975C mass spectrometer. 
Throughout the run, the inlet temperature was held constant at 225 ºC. Injection was performed 
in the splitless mode for one minute before split vent opening. The oven program followed a 
linear temperature gradient, with an initial temperature of 60 ºC (held for 2 minutes), a ramp of 
10 ºC/min until 225 ºC, and a final hold for 5 minutes at 225 ºC. Helium was used as the carrier 
gas with a constant flow of 1 mL/min (25.6 cm/sec). The transfer line temperature was held 
constant at 300 ºC. Ionization was performed using electron ionization, with an ion source 
temperature, electron energy, and emission current set at 230 ºC, 70 eV, and 300 µA respectively. 
Mass spectra were acquired in scan mode between 40.0 and 170.0 m/z. α-pinene was identified 
based on retention time of an analytical standard (Sigma-Aldrich, SKU 80605), and abundance 
was quantified using the area under the curve of extracted ion 93. Integration was performed in 
Agilent MassHunter (Version B.05.00 Build 5.0.519.0) using the Agile integrator. To measure 
the background contamination of HMBPP with α-pinene 2.5 µL of 4 mM HMBPP (final 
concentration 10 µM) was added to 1 mL of erythrocyte storage media.  
An α-pinene standard curve was generated through the addition of 2.5 µL of commercial α-
pinene diluted in hexanes to autosampler tubes containing 1 mL pure water and sampled as with 
erythrocyte treatments. Tested concentrations of α-pinene were 500 ng, 250 ng, 100 ng, 75 ng, 
50 ng, 25 ng, 10 ng, and 0 ng (hexanes spiked into water). Standard curve generated by 
measuring samples in three independent experiments. The limit of detection was defined as 3 
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times the area under the curve (ion 93) at the retention time for commercial α-pinene in negative 
controls containing only water and sampled as with erythrocytes. 
 
D.3.3 Measuring α-pinene time-dependent concentration 
To measure α-pinene loss over time, 14 mL of washed erythrocytes were placed in a 15 mL 
conical (Sigma-Aldrich, SKU CLS430791) and stored at 4oC. For some experiments, analytical 
α-pinene, diluted in water, was added to a final concentration of 10 ng/mL in erythrocytes at the 
time of aliquoting. During the experiment, erythrocytes were stored, capped, on ice and 
iteratively sampled from. Volatile collection and GC-MS analysis proceeded as above. 
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D.4 Results 
D.4.1 Erythrocytes do not release α-pinene upon HMBPP exposure 
We established a working method for sampling the volatile organic compounds associated with 
cultured erythrocytes. Similar to Emami et al., we sealed donated human erythrocytes within a 
closed, airtight chromatography vial, prewarmed to 38 ºC, and performed headspace sampling 
using solid phase microextraction (SPME) (Figure 1B) (25). Headspace composition was 
determined using gas chromatography-mass spectrometry. Using a pure commercial α-pinene 
standard, we established the sensitivity and dynamic range of this assay (Figure 1C), yielding a 
signal-to-noise ratio of 3 and a limit-of-detection of 0.3 ng α-pinene (area under the curve for ion 
93, 2.36 x 103) . Accommodating volumes up to 1 mL of blood, we can detect α-pinene blood 
concentrations as low as 2.2 nmol/L. We next sought to determine whether α-pinene was present 
in the headspace above untreated erythrocytes. Indeed, we confirmed that α-pinene can be 
detected in the headspace from donor erythrocytes, and both the retention time and mass spectra 
match that of the pure α-pinene standard (Figure 1D,E). 
 
A previous study had indicated that treatment of human erythrocytes with the microbial 
metabolite HMBPP leads to substantial release of α-pinene. To control for batch-to-batch 
variability in low-level contaminants present in purified HMBPP, we acquired HMBPP from two 
independent chemical suppliers. Headspace sampling from both pure preparations of HMBPP 
confirmed that neither had contaminating levels of α-pinene above our limit-of-detection (Figure 
2A). We next treated erythrocytes with either HMBPP or water (vehicle control) and quantified 
headspace α-pinene. Because monoterpenes such as α-pinene can diffuse into the ambient air, we 
pre-aliquoted all blood samples into sealed individual-use aliquots. Treatment of erythrocytes 
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with HMBPP did not result in increased levels of α-pinene (Figure 2B), and this finding was not 
donor-dependent. A previous study also indicated that levels of other monoterpenes (β-pinene 
and limonene), as well as several aldehydes (octanal, nonanal, and decanal), were increased in 
response to HMBPP treatment. While we searched for the presence of these additional VOCs 
they were not detected in our assay. Our studies thus indicate that if erythrocytes can sense 
HMBPP, this signal is not accompanied by a substantial release of α-pinene within the thirty 
minutes our experiment proceeded. Alternatively, if erythrocytes do incorporate HMBPP for the 
direct de novo synthesis of α-pinene, it does not occur during the thirty minutes our experiment 
proceeded.  
 
D.4.2 Erythrocyte α-pinene levels are donor-dependent 
In the course of the above experiments, we noted substantial donor-to-donor variability in the 
endogenous levels of α-pinene present in a given erythrocyte culture. We therefore secured 
erythrocytes from an additional 3 independent, unrelated donors and quantified α-pinene levels 
as before. We find that α-pinene levels are strongly dependent on donor identity and range 
widely among our 6 donors (Figure 3). We find that blood α-pinene concentrations range from 
0.37 ng/mL - 2.57 ng/mL (mean and standard deviation, 0.91 +/- 0.84 ng/mL). While 
biosynthesis of α-pinene has not been documented in humans, α-pinene is a volatile component 
of several common dietary plants, suggesting that one explanation for the variability in α-pinene 
levels is due to the variability in diet of individual donors. Alternatively, α-pinene may be 
synthesized by members of the human microbiome that may contribute to endogenous α-pinene 
levels. Unfortunately, blood samples were provided anonymously with no dietary recall or 
additional sampling available, prohibiting additional analysis. 
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D.4.3 α-pinene levels deplete with repeated sampling 
To reconcile our findings with previous studies that had reported HMBPP-induced α-pinene 
release we hypothesized that loss of volatile α-pinene through diffusion, following repeated 
sampling of the same sample over time, may be a possible explanation for the results observed 
by the previous study. To test this hypothesis, we filled a single air-tight sample tube with 
erythrocytes from a single donor. At t=0, we removed 1 mL of erythrocytes from the conical tube 
and measured the headspace concentration of α-pinene according to our previous assay. We left 
the remainder of the sample sealed (Figure 4A). We repeated this process for a total of 10 
iterations, allowing the tube of erythrocytes to reequilibrate for one hour between sampling. We 
find that α-pinene levels decrease by 25-60% (100 * first run / final run) as a result of repeated 
sampling (Figure 4B). As expected given its vapor pressure (4.75 mm Hg at 25 °C), α-pinene is 
in a vapor-liquid equilibrium(30). Each time our pooled erythrocytes are uncapped and sampled, 
vaporous α-pinene diffuses away, and a new vapor-liquid equilibrium is established. The total 
concentration of liquid α-pinene is thus depleted over time, thereby resulting in a reduced pool of 
α-pinene in each subsequent sampling. To confirm that this is not unique to α-pinene naturally 
absorbed within erythrocytes, we supplemented erythrocytes with 10 ng/mL (73.4 nM) α-pinene 
and found that α-pinene levels drop by 66-80% over the course of repeated sampling (Figure 
4C). 
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D.5 Discussion 
While run-to-run variability and the run-order effect is a commonly observed problem for mass 
spectrometry, our results highlight an additional precaution that needs to be taken when sampling 
biologically generated volatiles. All samples should be aliquoted and sealed in an air-tight 
container prior to the start of the experiment, as repeated sampling from the same container will 
result in artificially decreased volatile concentration over time. Investigators should continue to 
control for run-order effects by randomizing the order in which samples are run.  
 
While mounting evidence suggests that Plasmodium infection alters host odor profiles and 
results in increased mosquito attraction, the mechanism by which this occurs remains unclear. 
One class of molecules, terpenes, notably α-pinene, has been repeatedly highlighted for being 
both mosquito attractive and enriched during Plasmodium infection. The metabolic origin of 
terpenes during Plasmodium infection remains unclear as mammals do not express orthologs of 
the terpene synthases required for terpene production. Here, we establish that endogenous levels 
of α-pinene are present in human erythrocytes. While α-pinene levels from erythrocytes from a 
single donor sample are highly reproducible, α-pinene levels vary widely by erythrocyte donor. 
While the source of erythrocyte α-pinene remains enigmatic, it is possible that α-pinene may be 
dietary in origin, explaining the donor-to-donor variability that we observe.  
 
While HMBPP-mediated α-pinene release has been previously reported(25), we do not find 
evidence that the headspace of HMBPP-treated erythrocytes contains increased levels of α-
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pinene. HMBPP-treated erythrocytes also appear more mosquito attractive than untreated 
erythrocytes(25). Human erythrocytes bind several chemokines(31, 32) and human Vγ9Vδ2-T 
cells actively respond to HMBPP(28), raising the possibility that HMBPP exposure of 
erythrocytes may result in other properties that increase mosquito attraction, independent of α-
pinene release. CO2 emission from erythrocytes has also been reported to be elevated upon 
HMBPP exposure. As CO2 is also a mosquito semiochemical(33, 34), elevated CO2 levels could 
be responsible for mosquito attraction to HMBPP-treated erythrocytes. However, 
supplementation of 5 ppm CO2 to untreated erythrocytes was not sufficient to sway mosquitoes 
from HMBPP-treated erythrocytes.  
 
Subsequent experiments are needed to identify the origin of Plasmodium infection-associated 
volatiles. Infection of germ-free animal models may be valuable in discerning volatiles that arise 
from microbiome vs. host or Plasmodium parasite metabolism.  Identification of either human or 
malarial terpene synthases or metabolic labeling studies are required to understand the origin of 
Plasmodium infection-associated terpenes. Carefully controlled dietary recall studies are 
necessary to understand whether erythrocyte endogenous α-pinene is biosynthesized by humans 
or human microbiome members.  
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D.6 Figures 
 
Figure 1. α-pinene biosynthesis and detection. (A) Metabolic pathways leading to α-pinene. Enzymes highlighted with salmon boxes. 
HMBPP- E-4-hydroxy-3-methyl-but-2-enyl pyrophosphate, MPP- mevalonate pyrophosphate, IPP- isopentenyl pyrophosphate, GPP- geranyl 
pyrophosphate. (B) Schematic of α-pinene detection assay. (C) α-pinene standard curve generated using commercial α-pinene over a range of 
500 ng/mL to 0 ng/mL. Displayed are the means of standards measured in triplicate, error bars denote SD. (D) gas chromatography-mass 
spectroscopy trace of commercial α-pinene (bottom) and erythrocyte headspace (top) for α-pinene parent ion, 93. (E) Mass spectra from 
retention time 4.77 min, the elution time for commercial α-pinene, for erythrocyte headspace (top) and commercial α-pinene (bottom). 
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Figure 2. Erythrocytes do not release α-pinene following HMBPP exposure. (A) α-pinene abundance in HMBPP from Echelon 
Biosciences, Sigma Aldrich, or vehicle control (water). (B) Erythrocyte α-pinene abundance following treatment with HMBPP or vehicle 
control (water). Values are not significantly different by Mann-Whitney U test (Donor 1: p = 0.841, Donor 2: p = 0.548, Donor 3: p = 0.420). 
All assays performed with n = 5. Line indicates the mean of each sample, with error bars indicating standard error of the mean. 
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Figure 3 α-pinene abundance in the headspace of untreated human erythrocytes, n = 5. 
xcviii 
 
 
Figure 4. α-pinene levels decrease with repeated sampling. (A) Schematic of repeated sampling mechanism. Time between each sampling 
is one hour. At each sampling, one mL erythrocytes are removed and the headspace composition of the removed cells is assessed. (B, C) 
Headspace concentration of α-pinene over untreated human erythrocytes (B) or erythrocytes (C) supplemented with 10 ng/mL commercial α-
pinene as a function of GC-MS run (and accordingly number of tube openings). Displayed are the values of experiments performed in 
duplicate, with connecting lines indicating an individual replicate. 
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